Document:

Warrant Agreement, dated as of November 29, 2012

 Exhibit 4.1 

 
  

 
 WARRANT AGREEMENT 

Dated as of 

November 29, 2012 
 between 
 ZIONS BANCORPORATION 

and 
 ZIONS FIRST
NATIONAL BANK 
 as Warrant Agent 
  

 
 Warrants for

 Common Stock 
  

 
  

 
  

 Table of Contents 

 

							
	 	  	 	  	Page	 
			
		  	ARTICLE I	  			
			
		  	DEFINITIONS	  			
			
	Section 1.01.	  	Definitions	  	 	1	  
	Section 1.02.	  	Other Definitions	  	 	3	  
	Section 1.03.	  	Rules of Construction	  	 	3	  
			
		  	ARTICLE II	  			
			
		  	WARRANTS	  			
			
	Section 2.01.	  	Form	  	 	3	  
	Section 2.02.	  	Execution and Countersignature	  	 	4	  
	Section 2.03.	  	Registry	  	 	5	  
	Section 2.04.	  	Transfer and Exchange	  	 	5	  
	Section 2.05.	  	Definitive Warrants	  	 	7	  
	Section 2.06.	  	Replacement Certificates	  	 	9	  
	Section 2.07.	  	Outstanding Warrants	  	 	9	  
	Section 2.08.	  	Cancellation	  	 	9	  
	Section 2.09.	  	CUSIP Numbers	  	 	9	  
			
		  	ARTICLE III	  			
			
		  	EXERCISE TERMS	  			
			
	Section 3.01.	  	Exercise	  	 	10	  
	Section 3.02.	  	Manner of Exercise and Issuance of Shares	  	 	10	  
	Section 3.03.	  	Covenant to Make Stock Certificates Available	  	 	10	  
			
		  	ARTICLE IV	  			
			
		  	ANTIDILUTION PROVISIONS	  			
			
	Section 4.01.	  	Antidilution Adjustments; Notice of Adjustment	  	 	11	  
	Section 4.02.	  	Adjustment to Warrant Certificate	  	 	11	  
			
		  	ARTICLE V	  			
			
		  	WARRANT AGENT	  			
			
	Section 5.01.	  	Appointment of Warrant Agent	  	 	11	  
	Section 5.02.	  	Rights and Duties of Warrant Agent	  	 	11	  
	Section 5.03.	  	Individual Rights of Warrant Agent	  	 	12	  
	Section 5.04.	  	Warrant Agent’s Disclaimer	  	 	13	  
	Section 5.05.	  	Compensation and Indemnity	  	 	13	  
	Section 5.06.	  	Successor Warrant Agent	  	 	13	  

  
 i 

							
		  	ARTICLE VI	  			
			
		  	MISCELLANEOUS	  			
			
	Section 6.01.	  	Persons Benefitting	  	 	15	  
	Section 6.02.	  	Amendment	  	 	16	  
	Section 6.03.	  	Notices	  	 	16	  
	Section 6.04.	  	Governing Law	  	 	17	  
	Section 6.05.	  	Successors	  	 	17	  
	Section 6.06.	  	Multiple Originals	  	 	18	  
	Section 6.07.	  	Inspection of Agreement	  	 	18	  
	Section 6.08.	  	Table of Contents	  	 	18	  
	Section 6.09.	  	Severability	  	 	18	  
			
	EXHIBIT A	  	Form of Warrant	  			

  
 ii 

 Exhibit 4.1 
 WARRANT AGREEMENT dated as of November 29, 2012 (this “Agreement”), between Zions Bancorporation, a Utah corporation (the “Company”) and Zions First National Bank as
Warrant Agent (the “Warrant Agent”). 
 The Company has issued the warrants described herein (each, a
“Warrant” and collectively, the “Warrants”) to the U.S. Department of the Treasury (“Treasury”) in connection with Treasury’s Capital Purchase Program pursuant to the Letter Agreement dated
November 14, 2008 between the Company and Treasury, which agreement incorporates by reference the Securities Purchase Agreement—Standard Terms attached thereto as Exhibit A. Treasury desires to sell all or a portion of the Warrants at any
time or from time to time. 
 Each Warrant entitles the registered holder thereof (the “Holder”) to purchase
one share of Common Stock, subject to the provisions of this Agreement and the relevant Warrant Certificate. Each Warrant Certificate (including any Global Warrant) shall evidence such number of Warrants as is set forth therein, subject to
adjustment pursuant to the provisions of the Warrant Certificate. 
 The Warrants and the shares of Common Stock issuable upon
exercise of the Warrants will be freely transferable by Holders that are not Affiliates of the Company. The Company desires the Warrant Agent to act on behalf of the Company in connection with the registration, transfer, exchange, redemption,
exercise and cancellation of the Warrants as provided herein and the Warrant Agent is willing to so act. 
 Each party agrees as
follows for the benefit of the other party and for the equal and ratable benefit of the Holders of Warrants: 
 ARTICLE I

 DEFINITIONS 
 Section 1.01. Definitions. 
 “Affiliate” means, with respect
to any Person, any Person directly or indirectly controlling, controlled by or under common control with, such other Person. For purposes of this definition, “control” (including, with correlative meanings, the terms “controlled
by” and “under common control with”) when used with respect to any Person, means the possession, directly or indirectly, of the power to cause the direction of management and/or policies of such Person, whether through the ownership
of voting securities by contract or otherwise. 
 “Agent Members” means the securities brokers and dealers,
banks and trust companies, clearing organizations and certain other organizations that are participants in the Depositary’s system. 
 “business day” means any day except Saturday, Sunday and (i) at any time when the Warrants are listed on the Nasdaq Global Select Market, any day on which the Nasdaq Global Select
Market is authorized or required by law or other governmental actions to close or (ii) at any time when the Warrants are not listed on the Nasdaq Global Select Market, any day on which banking institutions in the State of New York are
authorized or required by law or other governmental actions to close. 

  
 1 

 “Common Stock” means the common stock of the Company. 

“Definitive Warrant” means a Warrant Certificate in definitive form that is not deposited with the Depositary or with
the Warrant Agent as custodian for the Depositary. 
 “Depositary” means The Depository Trust Company, its
nominees and their respective successors. 
 “Exchange Act” means the U.S. Securities Exchange Act of 1934, as
amended, or any successor statute, and the rules and regulations promulgated thereunder. 
 “Exercise Price”
has the meaning set forth in the form of Warrant Certificate attached as Exhibit A hereto. 
 “Expiration Time”
has the meaning set forth in the form of Warrant Certificate attached as Exhibit A hereto. 
 “Officer” means
the Chief Executive Officer, the President, the Chief Financial Officer, any Vice President, the Treasurer, any Assistant Treasurer, the Secretary or any Assistant Secretary of the Company. 

“Officers’ Certificate” means a certificate signed by two Officers. 

“Opinion of Counsel” means a written opinion from legal counsel who is reasonably acceptable to the Warrant Agent. Such
counsel may be an employee of or counsel to the Company or the Warrant Agent. 
 “Person” means an individual,
corporation, partnership, joint venture, association, joint-stock company, limited liability company, limited liability partnership, trust, unincorporated organization, or government or any agency or political subdivision thereof or any other
entity. 
 “Shares” has the meaning set forth in the form of Warrant Certificate attached as Exhibit A hereto.

 “Transfer Agent” has the meaning set forth in the form of Warrant Certificate attached as Exhibit A hereto.

 “Warrant Certificate” means any fully registered certificate (including a Global Warrant) issued by the
Company and authenticated by the Warrant Agent under this Agreement evidencing Warrants, in the form attached as Exhibit A hereto. 
 “Warrant Share Number” has the meaning set forth in the form of Warrant Certificate attached as Exhibit A hereto. 

  
 2 

 Section 1.02. Other Definitions. 

 

			
	 Term
	  	 Defined in Section

	 “Agreement”
	  	Recitals
	 “Company”
	  	Recitals
	 “Global Warrant”
	  	2.01(a)
	 “Holders”
	  	Recitals
	 “Registry”
	  	2.03
	 “Warrant”
	  	Recitals
	 “Warrant Agent”
	  	Recitals

 Section 1.03. Rules of Construction. 

Unless the text otherwise requires: 
 (i) a defined term has the meaning assigned to it; 
 (ii) an
accounting term not otherwise defined has the meaning assigned to it in accordance with generally accepted accounting principles as in effect on the date hereof; 

(iii) “or” is not exclusive; 

(iv) “including” means including, without limitation; and 

(v) words in the singular include the plural and words in the plural include the singular. 

ARTICLE II 

WARRANTS 

Section 2.01. Form. 
 (a) Global Warrants. Except as provided in Section 2.04 or 2.05, Warrants issued upon any transfer or exchange thereof shall be issued in the form of one or more permanent global Warrants in
fully registered form with the global securities legend set forth in Exhibit A hereto (each, a “Global Warrant”), which shall be deposited on behalf of the Company with the Warrant Agent, as custodian for the Depositary (or with such other
custodian as the Depositary may direct), and registered in the name of the Depositary or a nominee of the Depositary, duly executed by the Company and countersigned by the Warrant Agent as hereinafter provided. 

  
 3 

 (b) Book-Entry Provisions. This Section 2.01(b) shall apply only to a Global
Warrant deposited with or on behalf of the Depositary. 
 (i) The Company shall execute and the Warrant Agent
shall, in accordance with Section 2.02, countersign, by either manual or facsimile signature, and deliver one or more Global Warrants that (A) shall be registered in the name of the Depositary or the nominee of the Depositary and
(B) shall be delivered by the Warrant Agent to the Depositary or pursuant to the Depositary’s instructions or held by the Warrant Agent as custodian for the Depositary. Each Global Warrant shall be dated the date of its countersignature by
the Warrant Agent. 
 (ii) Agent Members shall have no rights under this Agreement with respect to any Global
Warrant held on their behalf by the Depositary or by the Warrant Agent as the custodian of the Depositary or under such Global Warrant except to the extent set forth herein or in a Warrant Certificate, and the Depositary may be treated by the
Company, the Warrant Agent and any agent of the Company or the Warrant Agent as the absolute owner of such Global Warrant for all purposes whatsoever. Notwithstanding the foregoing, nothing herein shall (A) prevent the Company, the Warrant
Agent or any agent of the Company or the Warrant Agent from giving effect to any written certification, proxy or other authorization furnished by the Depositary or (B) impair, as between the Depositary and the Agent Members, the operation of
customary practices of the Depositary governing the exercise of the rights of a holder of a beneficial interest in any Warrant. The rights of beneficial owners in a Global Warrant shall be exercised through the Depositary subject to the applicable
procedures of the Depositary except to the extent set forth herein or in a Warrant Certificate. 
 (c) Definitive
Securities. Except as provided in Section 2.04 or 2.05, owners of beneficial interests in Global Warrants will not be entitled to receive physical delivery of Definitive Warrants. 

(d) Warrant Certificates. Warrant Certificates shall be in substantially the form attached as Exhibit A hereto and shall be typed,
printed, lithographed or engraved or produced by any combination of such methods or produced in any other manner permitted by the rules of any securities exchange on which the Warrants may be listed, all as determined by the Officer or Officers
executing such Warrant Certificates, as evidenced by their execution thereof. Any Warrant Certificate shall have such insertions as are appropriate or required or permitted by this Agreement and may have such letters, numbers or other marks of
identification and such legends and endorsements, stamped, printed, lithographed or engraved thereon, (i) as the Company may deem appropriate and as are not inconsistent with the provisions of this Agreement, (ii) such as may be required
to comply with this Agreement, any law or any rule of any securities exchange on which the Warrants may be listed, and (iii) such as may be necessary to conform to customary usage. 

Section 2.02. Execution and Countersignature. 
 At least one Officer shall sign the Warrant Certificates for the Company by manual or facsimile signature. 

  
 4 

 If an Officer whose signature is on a Warrant Certificate no longer holds that office at the
time the Warrant Agent countersigns the Warrant Certificate, the Warrants evidenced by such Warrant Certificate shall be valid nevertheless. 
 The Warrant Agent shall initially countersign, by either manual or facsimile signature, and deliver Warrant Certificates entitling the Holders thereof to purchase in the aggregate not more than 5,789,909
shares of Common Stock (subject to adjustment as provided in such Warrant Certificates) upon a written order of the Company signed by one Officer of the Company. Each Warrant Certificate shall be dated the date of its countersignature by the Warrant
Agent. 
 At any time and from time to time after the execution of this Agreement, the Warrant Agent shall upon receipt of a
written order of the Company signed by an Officer of the Company countersign, by either manual or facsimile signature, for issue a Warrant Certificate evidencing the number of Warrants specified in such order; provided, however, that
the Warrant Agent shall be entitled to receive an Officers’ Certificate and an Opinion of Counsel of the Company that it may reasonably request in connection with such countersignature of Warrants. Such order shall specify the number of
Warrants to be evidenced on the Warrant Certificate to be countersigned, the date on which such Warrant Certificate is to be countersigned and the number of Warrants then authorized. 

The Warrants evidenced by a Warrant Certificate shall not be valid until an authorized signatory of the Warrant Agent countersigns the
Warrant Certificate either manually or by facsimile signature. Such signature shall be solely for the purpose of authenticating the Warrant Certificate and shall be conclusive evidence that the Warrant Certificate so countersigned has been duly
authenticated and issued under this Agreement. 
 Section 2.03. Registry. 

The Warrants shall be issued in registered form only. The Warrant Agent shall keep a registry (the “Registry”) of the Warrant
Certificates and of their transfer and exchange. The Registry shall show the names and addresses of the respective Holders and the date and number of Warrants evidenced on the face of each of the Warrant Certificates. The Holder of any Global
Warrant will be the Depositary or a nominee of the Depositary in whose name the Global Warrant is registered. The Warrant holdings of Agent Members will be recorded on the books of the Depositary. The beneficial interests in the Global Warrant held
by customers of Agent Members will be reflected on the books and records of such Agent Members and will not be known to the Warrant Agent, the Company or to the Depositary. 
 Except as otherwise provided herein or in the Warrant Certificate, the Company and the Warrant Agent may deem and treat any Person in whose name a Warrant Certificate is registered in the Registry as the
absolute owner of such Warrant Certificate for all purposes whatsoever and neither the Company nor the Warrant Agent shall be affected by notice to the contrary. 
 Section 2.04. Transfer and Exchange. 
 (a) Transfer and Exchange of Global
Warrants. 

  
 5 

 (i) Registration of the transfer and exchange of Global Warrants or
beneficial interests therein shall be effected through the book-entry system maintained by the Depositary, in accordance with this Agreement and the Warrant Certificates and the procedures of the Depositary therefor. A transferor of a beneficial
interest in a Global Warrant (or the relevant Agent Member on behalf of such transferor) shall deliver to the Warrant Agent (x) a written order given in accordance with the Depositary’s procedures containing information regarding the
account of the Agent Member to be credited with a beneficial interest in the Global Warrant and (y) a written instruction of transfer in form satisfactory to the Warrant Agent, duly executed by the Holder thereof or by his attorney, duly
authorized in writing. Additionally, prior to the Holder registering the transfer or making the exchange as requested, the requirements for such transfer or exchange to be issued in a name other than the registered Holder shall be met. Such
requirements include, inter alia, a signature guarantee from an eligible guarantor institution participating in a signature guarantee program approved by the Securities Transfer Association, and any other reasonable evidence of authority that may be
required by the Warrant Agent. Upon satisfaction of the conditions in this Clause (i), the Warrant Agent shall, in accordance with such instructions, instruct the Depositary to credit to the account of the Agent Member specified in such instructions
a beneficial interest in the Global Warrant and to debit the account of the Agent Member making the transfer of the beneficial interest in the Warrant being transferred. 

(ii) Notwithstanding any other provisions of this Agreement (other than the provisions set forth in Section 2.05), a
Global Warrant may only be transferred as a whole, and not in part, and only by (i) the Depositary, to a nominee of the Depositary, (ii) a nominee of the Depositary, to the Depositary or another nominee of the Depositary, or (iii) the
Depositary or any such nominee to a successor Depositary or its nominee. 
 (iii) In the event that a Global
Warrant is exchanged and transferred for Definitive Warrants pursuant to Section 2.05, such Warrants may be exchanged only in accordance with such procedures as are substantially consistent with the provisions of this Section 2.04 and the
requirements of any Warrant Certificate and such other procedures as may from time to time be adopted by the Company that are not inconsistent with the terms of this Agreement or of any Warrant Certificate. 

(b) Cancellation or Adjustment of Global Warrant. At such time as all beneficial interests in a Global Warrant have been exchanged
for Definitive Warrants, redeemed, repurchased or canceled, such Global Warrant shall be returned to the Depositary for cancellation or retained and canceled by the Warrant Agent. At any time prior to such cancellation, if any beneficial interest in
a Global Warrant is transferred or exchanged for Definitive Warrants, redeemed, repurchased or canceled, the number of Warrants represented by such Global Warrant shall be reduced and an adjustment shall be made on the books and records of the
Warrant Agent to reflect such reduction. 
 (c) Obligations with Respect to Transfers and Exchanges of Warrants.

  
 6 

 (i) To permit registrations of transfers and exchanges, the Company shall
execute and the Warrant Agent shall countersign, by either manual or facsimile signature, Global Warrants and Definitive Warrants as required pursuant to the provisions of Section 2.02 and this Section 2.04. 

(ii) No service charge shall be made to a Holder for any registration of transfer or exchange, but the Company may require
payment of a sum sufficient to cover any transfer tax, assessments, or similar governmental charge payable in connection therewith. 
 (iii) All Warrants issued upon any registration of transfer or exchange pursuant to the terms of this Agreement shall be the valid obligations of the Company, entitled to the same benefits under this
Agreement as the Warrants surrendered upon such registration for transfer or exchange. 
 (d) No Obligation of the Warrant
Agent. 
 (i) The Warrant Agent shall have no responsibility or obligation to any beneficial owner of a
Global Warrant, any Agent Member or other Person with respect to the accuracy of the records of the Depositary or its nominee or of any participant or member thereof, with respect to any ownership interest in the Warrants or with respect to the
delivery to any Agent Member, beneficial owner or other Person (other than the Depositary) of any notice or the payment of any amount, under or with respect to such Warrants. All notices and communications to be given to the Holders and all payments
to be made to Holders under the Warrants shall be given or made only to or upon the order of the registered Holders (which shall be the Depositary or its nominee in the case of a Global Warrant). The rights of beneficial owners in any Global Warrant
shall be exercised only through the Depositary subject to the applicable rules and procedures of the Depositary. The Warrant Agent may rely and shall be fully protected in relying upon information furnished by the Depositary with respect to its
members, participants and any beneficial owners. 
 (ii) The Warrant Agent shall have no obligation or duty to
monitor, determine or inquire as to compliance with any restrictions on transfer imposed under this Agreement or under applicable law with respect to any transfer of any interest in any Warrant (including any transfer between or among the Agent
Members or beneficial owners in any Global Warrant) other than to require delivery of such certificates and other documentation or evidence as are expressly required by, and to do so if and when expressly required by, the terms of this Agreement,
and to examine the same to determine substantial compliance as to form with the express requirements hereof. 

Section 2.05. Definitive Warrants. 
 (a) Beneficial interests in a Global Warrant deposited with the Depositary or with the Warrant Agent as custodian for the Depositary pursuant to Section 2.01 shall be transferred to each beneficial
owner thereof in the form of Definitive Warrants evidencing a number of Warrants equivalent to such owner’s beneficial interest in such Global Warrant, in exchange for 

  
 7 

 
such Global Warrant, only if such transfer complies with Section 2.04 and (i) the Depositary notifies the Company that it is unwilling or unable to continue as Depositary for such
Global Warrant or if at any time the Depositary ceases to be a “clearing agency” registered under the Exchange Act and, in each such case, a successor Depositary is not appointed by the Company within 90 days of such notice, (ii) the
Company, in its sole discretion, notifies the Warrant Agent in writing that it elects to cause the issuance of Definitive Warrants under this Agreement, or (iii) the Company shall be adjudged a bankrupt or insolvent or makes an assignment for
the benefit of its creditors or institutes proceedings to be adjudicated a bankrupt or shall consent to the filing of a bankruptcy proceeding against it, or shall file a petition or answer or consent seeking reorganization under Federal bankruptcy
laws or any other similar applicable Federal or State law, or shall consent to the filing of any such petition, or shall consent to the appointment of a receiver or custodian of all or any substantial part of its property, or shall admit in writing
its inability to pay or meet its debts as they mature, or if a receiver or custodian of it or all or any substantial part of its property shall be appointed, or if a public officer shall have taken charge or control of the Company or of its property
or affairs, for the purpose of rehabilitation, conservation or liquidation. 
 (b) Any Global Warrant that is transferable to
the beneficial owners thereof in the form of Definitive Warrants pursuant to this Section 2.05 shall be surrendered by the Depositary to the Warrant Agent, to be so transferred, in whole or from time to time in part, without charge, and the
Warrant Agent shall countersign, by either manual or facsimile signature, and deliver to each beneficial owner in the name of such beneficial owner, upon such transfer of each portion of such Global Warrant, Definitive Warrants evidencing a number
of Warrants equivalent to such beneficial owner’s beneficial interest in the Global Warrant. The Warrant Agent shall register such transfer in the Registry, and upon such transfer the surrendered Global Warrant shall be cancelled by the Warrant
Agent. 
 (c) All Definitive Warrants issued upon registration of transfer pursuant to this Section 2.05 shall be the valid
obligations of the Company, evidencing the same obligations of the Company and entitled to the same benefits under this Agreement and the Global Warrant surrendered for registration of such transfer. 

(d) Subject to the provisions of Section 2.05(b), the registered Holder of a Global Warrant may grant proxies and otherwise
authorize any Person, including Agent Members and Persons that may hold interests through Agent Members, to take any action that a Holder is entitled to take under this Agreement or the Warrants. 

(e) In the event of the occurrence of any of the events specified in Section 2.05(a), the Company will promptly make available to
the Warrant Agent a reasonable supply of Definitive Warrants in definitive, fully registered form. 
 (f) Neither the Company
nor the Warrant Agent will be liable or responsible for any registration or transfer of any Warrants that are registered or to be registered in the name of a fiduciary or the nominee of a fiduciary. 

  
 8 

 Section 2.06. Replacement Certificates. 

If a mutilated Warrant Certificate is surrendered to the Warrant Agent or if the Holder of a Warrant Certificate provides proof
reasonably satisfactory to the Company and the Warrant Agent that the Warrant Certificate has been lost, destroyed or wrongfully taken, the Company shall issue and the Warrant Agent shall countersign, by either manual or facsimile signature, a
replacement Warrant Certificate of like tenor and representing an equivalent number of Warrants, if the reasonable requirements of the Warrant Agent and of Section 8-405 of the Uniform Commercial Code as in effect in the State of New York are
met. If required by the Warrant Agent or the Company, such Holder shall furnish an indemnity bond sufficient in the reasonable judgment of the Company and the Warrant Agent to protect the Company and the Warrant Agent from any loss that either of
them may suffer if a Warrant Certificate is replaced. The Company and the Warrant Agent may charge the Holder for their expenses in replacing a Warrant Certificate. Every replacement Warrant Certificate evidences an additional obligation of the
Company. 
 Section 2.07. Outstanding Warrants. 
 The Warrants outstanding at any time are all Warrants evidenced on all Warrant Certificates authenticated by the Warrant Agent except for those canceled by it and those delivered to it for cancellation. A
Warrant ceases to be outstanding if the Company or an Affiliate of the Company holds the Warrant. 
 If a Warrant Certificate is
replaced pursuant to Section 2.06, the Warrants evidenced thereby cease to be outstanding unless the Warrant Agent and the Company receive proof satisfactory to them that the replaced Warrant Certificate is held by a bona fide purchaser.

 Section 2.08. Cancellation. 
 In the event the Company shall purchase or otherwise acquire Definitive Warrants, the same shall thereupon be delivered to the Warrant Agent for cancellation. 

The Warrant Agent and no one else shall cancel and destroy all Warrant Certificates surrendered for registration of transfer, exchange,
replacement, exercise or cancellation and deliver a certificate of such destruction to the Company unless the Company directs the Warrant Agent to deliver canceled Warrant Certificates to the Company. The Company may not issue new Warrant
Certificates to replace Warrant Certificates to the extent they evidence Warrants that have been exercised or Warrants that the Company has purchased or otherwise acquired. 
 Section 2.09. CUSIP Numbers. 
 The Company in issuing the Warrants may use
“CUSIP” numbers (if then generally in use) and, if so, the Warrant Agent shall use “CUSIP” numbers in notices as a convenience to Holders; provided, however, that any such notice may state that no representation is
made as to the correctness of such numbers either as printed on the Warrant Certificates or as contained in any notice and that reliance may be placed only on the other identification numbers printed on the Warrant Certificates. 

  
 9 

 ARTICLE III 
 EXERCISE TERMS 
 Section 3.01. Exercise. 

The Exercise Price of each Warrant, the Warrant Share Number, the number of Warrants evidenced by any Warrant Certificate and the
Expiration Time of each Warrant shall be set forth in the related Warrant Certificate. The Exercise Price of each Warrant and the Warrant Share Number are subject to adjustment pursuant to the terms set forth in the Warrant Certificate. 

Section 3.02. Manner of Exercise and Issuance of Shares. 
 Warrants may be exercised in the manner set forth in Section 3 of the Warrant Certificate, and upon any such exercise, Shares shall be issued in the manner set forth in Section 4 of the Warrant
Certificate. 
 Section 3.03. Covenant to Make Stock Certificates Available. 

(a) The Warrant Agent is hereby authorized to requisition from time to time from any stock transfer agents of the Company stock
certificates required to honor outstanding Warrants upon exercise thereof in accordance with the terms of this Agreement, and the Company agrees to authorize and direct such transfer agents to comply with all such requests of the Warrant Agent. The
Company shall supply such transfer agents with duly executed stock certificates for such purposes and shall provide or otherwise make available any cash or scrip that may be payable upon exercise of Warrants as provided herein and in each Warrant
Certificate. 
 (b) The Warrant Agent is hereby authorized to create a special account for the reserve of shares of Common Stock
to be issued upon exercise of the Warrants. 
 (c) In connection with the shares of Common Stock to be issued upon exercise, the
Company shall, if so required by the Warrant Agent, provide an Opinion of Counsel, stating that all such shares, when issued, will be: 
 (i) registered, or subject to a valid exemption from registration, under the Securities Act of 1933, as amended, and all material and necessary State securities law filings will have been made with
respect to such shares; and 
 (ii) validly issued, fully paid and non-assessable. 

  
 10 

 ARTICLE IV 
 ANTIDILUTION PROVISIONS 
 Section 4.01. Antidilution Adjustments;
Notice of Adjustment. 
 The Exercise Price and the Warrant Share Number shall be subject to adjustment from time to time as
provided in Section 12 of the Warrant Certificate. Whenever the Exercise Price or the Warrant Share Number is so adjusted or is proposed to be adjusted as provided in Section 12 of the Warrant Certificate, the Company shall deliver to the
Warrant Agent the notices or statements, and shall cause a copy of such notices or statements to be sent or communicated to each Holder pursuant to Section 6.03, as provided in Sections 12(H) and (I) of the Warrant Certificate. 

Section 4.02. Adjustment to Warrant Certificate. 
 The form of Warrant Certificate need not be changed because of any adjustment made pursuant to the Warrant Certificate, and Warrant Certificates issued after such adjustment may state the same Exercise
Price and the same Warrant Share Number as are stated in the Warrant Certificates initially issued pursuant to this Agreement. The Company, however, may at any time in its sole discretion make any change in the form of Warrant Certificate that it
may deem appropriate to give effect to such adjustments and that does not affect the substance of the Warrant Certificate, and any Warrant Certificate thereafter issued or countersigned, whether in exchange or substitution for an outstanding Warrant
Certificate or otherwise, may be in the form as so changed. 
 ARTICLE V 

WARRANT AGENT 
 Section 5.01. Appointment of Warrant Agent. 
 The Company hereby appoints the
Warrant Agent to act as agent for the Company in accordance with the provisions of this Agreement and the Warrant Agent hereby accepts such appointment. The Warrant Agent shall not be liable for anything that it may do or refrain from doing in
connection with this Agreement, except for its own gross negligence, willful misconduct or bad faith. 
 Section 5.02.
Rights and Duties of Warrant Agent. 
 (a) Agent for the Company. In acting under this Warrant Agreement and in
connection with the Warrant Certificates, the Warrant Agent is acting solely as agent of the Company and does not assume any obligation or relationship of agency or trust for or with any of the Holders of Warrant Certificates or beneficial owners of
Warrants. 
 (b) Counsel. The Warrant Agent may consult with counsel satisfactory to it (who may be counsel to the
Company), and the advice of such counsel shall be full and complete authorization and protection in respect of any action taken, suffered or omitted by it hereunder in good faith and in accordance with the advice of such counsel. 

(c) Documents. The Warrant Agent shall be protected and shall incur no liability for or in respect of any action taken or thing
suffered by it in reliance upon any Warrant Certificate, notice, direction, consent, certificate, affidavit, statement or other paper or document reasonably believed by it to be genuine and to have been presented or signed by the proper parties.

  
 11 

 (d) No Implied Obligations. The Warrant Agent shall be obligated to perform only such
duties as are specifically set forth herein and in the Warrant Certificates, and no implied duties or obligations of the Warrant Agent shall be read into this Agreement or the Warrant Certificates against the Warrant Agent. The Warrant Agent shall
not be under any obligation to take any action hereunder that may involve it in any expense or liability for which it does not receive indemnity if such indemnity is reasonably requested. The Warrant Agent shall not be accountable or under any duty
or responsibility for the use by the Company of any of the Warrant Certificates countersigned by the Warrant Agent and delivered by it to the Holders or on behalf of the Holders pursuant to this Agreement or for the application by the Company of the
proceeds of the Warrants. The Warrant Agent shall have no duty or responsibility in case of any default by the Company in the performance of its covenants or agreements contained herein or in the Warrant Certificates or in the case of the receipt of
any written demand from a Holder with respect to such default, including any duty or responsibility to initiate or attempt to initiate any proceedings at law or otherwise. 
 (e) Not Responsible for Adjustments or Validity of Stock. The Warrant Agent shall not at any time be under any duty or responsibility to any Holder to determine whether any facts exist that may
require an adjustment of the Warrant Share Number or the Exercise Price, or with respect to the nature or extent of any adjustment when made, or with respect to the method employed, or herein or in any supplemental agreement provided to be employed,
in making the same. The Warrant Agent shall not be accountable with respect to the validity or value of any Shares or of any securities or property that may at any time be issued or delivered upon the exercise of any Warrant or upon any adjustment
pursuant to Section 12 of the Warrant Certificate, and it makes no representation with respect thereto. The Warrant Agent shall not be responsible for any failure of the Company to make any cash payment or to issue, transfer or deliver any
Shares or stock certificates upon the surrender of any Warrant Certificate for the purpose of exercise or upon any adjustment pursuant to Section 12 of the Warrant Certificate, or to comply with any of the covenants of the Company contained in
the Warrant Certificate. 
 (f) Notices or Demands Addressed to the Company. If the Warrant Agent shall receive any
notice or demand (other than Notice of Exercise of Warrants) addressed to the Company by the Holder of a Warrant, the Warrant Agent shall promptly forward such notice or demand to the Company. 

Section 5.03. Individual Rights of Warrant Agent. 
 The Warrant Agent and any stockholder, director, officer or employee of the Warrant Agent may buy, sell or deal in any of the Warrants or other securities of the Company or its Affiliates or become
pecuniarily interested in transactions in which the Company or its Affiliates may be interested, or contract with or lend money to the Company or its Affiliates or otherwise act as fully and freely as though it were not the Warrant Agent under this
Agreement. Nothing herein shall preclude the Warrant Agent from acting in any other capacity for the Company or for any other legal entity. 

  
 12 

 Section 5.04. Warrant Agent’s Disclaimer. 

The Warrant Agent shall not be responsible for, and makes no representation as to the validity or adequacy of, this Agreement (except the
due and valid authorized execution and delivery of this Agreement by the Warrant Agent) or the Warrant Certificates (except the due countersignature of the Warrant Certificate(s) by the Warrant Agent) and it shall not be responsible for any
statement in this Agreement or the Warrant Certificates other than its countersignature thereon. 
 Section 5.05.
Compensation and Indemnity. 
 (a) The Company agrees to pay the Warrant Agent from time to time reasonable compensation for its
services as agreed and to reimburse the Warrant Agent upon request for all reasonable out-of-pocket expenses incurred by it, including the reasonable compensation and expenses of the Warrant Agent’s agents and counsel as agreed. The Company
shall indemnify the Warrant Agent, its officers, directors, agents and counsel against any loss, liability or expense (including reasonable agents’ and attorneys’ fees and expenses) incurred by it without gross negligence, willful
misconduct or bad faith on its part arising out of or in connection with the acceptance or performance of its duties under this Agreement. The Warrant Agent shall notify the Company promptly of any claim for which it may seek indemnity. The Company
need not reimburse any expense or indemnify against any loss or liability incurred by the Warrant Agent through willful misconduct, gross negligence or bad faith. The Company’s payment obligations pursuant to this Section shall survive the
termination of this Agreement. 
 (b) The Warrant Agent shall be responsible for and shall indemnify and hold the Company
harmless from and against any and all losses, damages, costs, charges, counsel fees, payments, expenses and liability arising out of or attributable to the Warrant Agent’s refusal or failure to comply with the terms of this Agreement, or which
arise out of Warrant Agent’s gross negligence, bad faith or willful misconduct or which arise out of the breach of any representation or warranty of the Warrant Agent hereunder, for which the Warrant Agent is not entitled to indemnification
under this Agreement; provided, however, the Warrant Agent’s aggregate liability hereunder during any term of this Agreement with respect to, arising from, or arising in connection with this Agreement, whether in contract, or in tort, or
otherwise, is limited to, and shall not exceed, the amounts paid hereunder by the Company to the Warrant Agent as fees and charges, but not including reimbursable expenses. 
 To secure the Company’s payment obligations under this Agreement, the Warrant Agent shall have a lien prior to the Holders on all money or property held or collected by the Warrant Agent. 

Section 5.06. Successor Warrant Agent. 
 (a) Company to Provide and Maintain Warrant Agent. The Company agrees for the benefit of the Holders that there shall at all times be a Warrant Agent hereunder until all the Warrants have been
exercised or cancelled or are no longer exercisable. 

  
 13 

 (b) Resignation and Removal. The Warrant Agent may at any time resign by giving
written notice to the Company of such intention on its part, specifying the date on which its desired resignation shall become effective; provided, however, that such date shall not be less than 60 days after the date on which such
notice is given unless the Company otherwise agrees. The Warrant Agent hereunder may be removed at any time by the filing with it of an instrument in writing signed by or on behalf of the Company and specifying such removal and the date when it
shall become effective, which date shall not be less than 60 days after such notice is given unless the Warrant Agent otherwise agrees. Any removal under this Section shall take effect upon the appointment by the Company as hereinafter provided of a
successor Warrant Agent (which shall be (i) a bank or trust company, (ii) organized under the laws of the United States of America or one of the states thereof, (iii) authorized under the laws of the jurisdiction of its organization
to exercise corporate trust powers, (iv) having a combined capital and surplus of at least $50,000,000 (as set forth in its most recent reports of condition published pursuant to law or to the requirements of any United States federal or state
regulatory or supervisory authority) and (v) having an office in the Borough of Manhattan, The City of New York) and the acceptance of such appointment by such successor Warrant Agent. The obligations of the Company under Section 5.05
shall continue to the extent set forth herein notwithstanding the resignation or removal of the Warrant Agent. 
 (c) Company
to Appoint Successor. In the event that at any time the Warrant Agent shall resign, or shall be removed, or shall become incapable of acting, or shall be adjudged bankrupt or insolvent, or shall commence a voluntary case under the Federal
bankruptcy laws, as now or hereafter constituted, or under any other applicable Federal or State bankruptcy, insolvency or similar law or shall consent to the appointment of or taking possession by a receiver, custodian, liquidator, assignee,
trustee, sequestrator (or other similar official) of the Warrant Agent or its property or affairs, or shall make an assignment for the benefit of creditors, or shall admit in writing its inability to pay its debts generally as they become due, or
shall take corporate action in furtherance of any such action, or a decree or order for relief by a court having jurisdiction in the premises shall have been entered in respect of the Warrant Agent in an involuntary case under the Federal bankruptcy
laws, as now or hereafter constituted, or any other applicable Federal or State bankruptcy, insolvency or similar law, or a decree or order by a court having jurisdiction in the premises shall have been entered for the appointment of a receiver,
custodian, liquidator, assignee, trustee, sequestrator (or similar official) of the Warrant Agent or of its property or affairs, or any public officer shall take charge or control of the Warrant Agent or of its property or affairs for the purpose of
rehabilitation, conservation, winding up or liquidation, a successor Warrant Agent, qualified as aforesaid, shall be appointed by the Company by an instrument in writing, filed with the successor Warrant Agent. In the event that a successor Warrant
Agent is not appointed by the Company, a successor Warrant Agent, qualified as aforesaid, may be appointed by the Warrant Agent or the Warrant Agent may petition a court to appoint a successor Warrant Agent. Upon the appointment as aforesaid of a
successor Warrant Agent and acceptance by the successor Warrant Agent of such appointment, the Warrant Agent shall cease to be Warrant Agent hereunder; provided, however, that in the event of the resignation of the Warrant Agent under
this subsection (c), such resignation shall be effective on the earlier of (i) the date specified in the Warrant Agent’s notice of resignation and (ii) the appointment and acceptance of a successor Warrant Agent hereunder. 

(d) Successor to Expressly Assume Duties. Any successor Warrant Agent appointed hereunder shall execute, acknowledge and deliver
to its predecessor and to the Company an instrument accepting such appointment hereunder, and thereupon such successor 

  
 14 

 
Warrant Agent, without any further act, deed or conveyance, shall become vested with all the rights and obligations of such predecessor with like effect as if originally named as Warrant Agent
hereunder, and such predecessor, upon payment of its charges and disbursements then unpaid, shall thereupon become obligated to transfer, deliver and pay over, and such successor Warrant Agent shall be entitled to receive, all monies, securities and
other property on deposit with or held by such predecessor, as Warrant Agent hereunder. 
 (e) Successor by Merger. Any
entity into which the Warrant Agent hereunder may be merged or consolidated, or any entity resulting from any merger or consolidation to which the Warrant Agent shall be a party, or any entity to which the Warrant Agent shall sell or otherwise
transfer all or substantially all of its assets and business, shall be the successor Warrant Agent under this Agreement without the execution or filing of any paper or any further act on the part of any of the parties hereto; provided,
however, that it shall be qualified as aforesaid. 
 Section 5.07. Representations of the Company. The Company
represents and warrants to the Warrant Agent that: 
 (a) the Company has been duly organized and is validly existing under the
laws of the jurisdiction of its incorporation; 
 (b) this Agreement has been duly authorized, executed and delivered by the
Company and is enforceable against the Company in accordance with its terms, except as may be limited by bankruptcy, insolvency, moratorium, reorganization and other similar laws affecting the enforcement of creditors’ rights generally; and

 (c) the execution and delivery of this Agreement does not, and the issuance of the Warrants in accordance with the terms of
this Agreement and the Warrant Certificate will not, (i) violate the Company’s certificate of incorporation or by-laws, (ii) violate any law or regulation applicable to the Company or order or decree of any court or public authority
having jurisdiction over the Company, or (iii) result in a breach of any mortgage, indenture, contract, agreement or undertaking to which the Company is a party or by which it is bound, except in the case of (ii) and (iii) for any
violations or breaches that could not reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. 
 ARTICLE VI 
 MISCELLANEOUS 

Section 6.01. Persons Benefitting. 
 Nothing in this Agreement is intended or shall be construed to confer upon any Person other than the Company, the Warrant Agent and the Holders any right, remedy or claim under or by reason of this
Agreement or any part hereof. 

  
 15 

 Section 6.02. Amendment. 

This Agreement and the Warrants may be amended by the parties hereto without the consent of any Holder for the purpose of curing any
ambiguity, or of curing, correcting or supplementing any defective provision contained herein or therein or adding or changing any other provisions with respect to matters or questions arising under this Agreement or the Warrants as the Company and
the Warrant Agent may deem necessary or desirable; provided, however, that such action shall not adversely affect the rights of any of the Holders in any material respect. Any amendment or supplement to this Agreement or the Warrants
that has a material adverse effect on the interests of any of the Holders or owners of a beneficial interest in a Global Warrant shall require the written consent of the Holders of a majority of the then outstanding Warrants; provided that
the consent of each Holder affected thereby shall be required for any amendment pursuant to which (i) the Exercise Price would be increased or the Warrant Share Number would be decreased (in each case, other than pursuant to adjustments
provided for in Section 12 of the Warrant Certificate), (ii) the time period during which the Warrants are exercisable would be shortened or (iii) any change adverse to the Holder would be made to the anti-dilution provisions set
forth in Article IV of this Agreement or Section 12 of the Warrant Certificate. In determining whether the Holders of the required number of Warrants have concurred in any direction, waiver or consent, Warrants owned by the Company or by any
Affiliate of the Company shall be disregarded and deemed not to be outstanding, except that, for the purpose of determining whether the Warrant Agent shall be protected in relying on any such direction, waiver or consent, only Warrants that the
Warrant Agent knows are so owned shall be so disregarded. Also, subject to the foregoing, only Warrants outstanding at the time shall be considered in any such determination. The Warrant Agent shall have no duty to determine whether any such
amendment would have an effect on the rights or interests of the Holders of the Warrants. Upon receipt by the Warrant Agent of an Officer’s Certificate and an Opinion of Counsel, each stating that all conditions precedent to the execution of
the amendment have been complied with and such execution is permitted by this Agreement and the Warrant Certificate, the Warrant Agent shall join in the execution of such amendment; provided, that the Warrant Agent may, but shall not be obligated
to, execute any amendment or supplement which affects the rights or changes or increases the duties or obligations of the Warrant Agent. 
 Section 6.03. Notices. 
 Any notice or communication shall be in writing and
delivered in person or mailed by first-class mail addressed as follows: 
 if to the Company: 

Zions Bancorporation 
 One South Main Street, 15th Floor 
 Salt Lake City, Utah 84133-1109 

Telephone: (801) 844-7637 
 Facsimile: (801) 524-2119 
 Attention: James Abbott 

  
 16 

 with a copy to: 
 Zions Bancorporation 
 One South Main Street, 15th Floor 

Salt Lake City, Utah 84133-1109 
 Telephone: (801) 844-7671 
 Facsimile: (801) 524-2129 

Attention: Alexander J. Hume 
 if to the Warrant Agent: 
 Zions First National Bank 

One South Main Street, 12th Floor 
 Salt Lake City, Utah 84133-1109 
 Telephone: (801) 844-7561 

Facsimile: (855) 547-5637 
 Attention: Shelene Brown 
 The Company or the Warrant Agent by notice to the other
may designate additional or different addresses for subsequent notices or communications. 
 Unless the Warrant is a Global
Warrant, any notice or communication mailed to a Holder shall be mailed to the Holder at the Holder’s address as it appears on the Registry and shall be sufficiently given if so mailed within the time prescribed. Any notice to the owners of a
beneficial interest in a Global Warrant shall be distributed through the Depositary in accordance with the procedures of the Depositary. Communications to such Holder shall be deemed to be effective at the time of dispatch to the Depositary.

 Failure to provide a notice or communication to a Holder or any defect in it shall not affect its sufficiency with respect to
other Holders. If a notice or communication is provided in the manner provided above, it is duly given, whether or not the intended recipient actually receives it. 
 Section 6.04. Governing Law. 
 This Agreement will be governed by and
construed in accordance with the laws of the State of New York applicable to contracts made and to be performed entirely within such State. 
 Section 6.05. Successors. 
 All agreements of the Company in this Agreement
and the Warrants shall bind its successors. All agreements of the Warrant Agent in this Agreement shall bind its successors. 

  
 17 

 Section 6.06. Multiple Originals. 

The parties may sign any number of copies of this Agreement. Each signed copy shall be an original, but all of them together represent
the same agreement. One signed copy is enough to prove this Agreement. 
 Section 6.07. Inspection of Agreement.

 A copy of this Agreement shall be made available at all reasonable times for inspection by any registered Holder or owner of
a beneficial interest in a Global Warrant at the principal office of the Warrant Agent (or successor warrant agent). 

Section 6.08. Table of Contents. 
 The table of contents and headings of the Articles and Sections of this Agreement have been inserted for convenience of reference only, are not intended to be considered a part hereof and shall not modify
or restrict any of the terms or provisions hereof. 
 Section 6.09. Severability. 

The provisions of this Agreement are severable, and if any clause or provision shall be held invalid, illegal or unenforceable in whole
or in part in any jurisdiction, then such invalidity or unenforceability shall affect in that jurisdiction only such clause or provision, or part thereof, and shall not in any manner affect such clause or provision in any other jurisdiction or any
other clause or provision of this Agreement in any jurisdiction. 

  
 18 

 IN WITNESS WHEREOF, the parties have caused this Warrant Agreement to be duly executed as of
the date first written above. 
  

			
	ZIONS BANCORPORATION
		
	by	 	/s/ Alexander J. Hume
		 	 Name: Alexander J. Hume

Title: SVP and Controller

	
	ZIONS FIRST NATIONAL BANK,
as Warrant Agent,
		
	by	 	/s/ Shelene Brown
		 	 Name: Shelene Brown
 Title:
Vice President

  
 19 

 EXHIBIT A 
 FORM OF WARRANT 
 [Global Securities Legend] 

UNLESS THIS GLOBAL WARRANT IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION
(“DTC”), NEW YORK, NEW YORK, TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY WARRANT CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS IS REQUESTED BY AN
AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS
WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN. 
 TRANSFERS OF THIS
GLOBAL WARRANT SHALL BE LIMITED TO TRANSFERS IN WHOLE, BUT NOT IN PART, TO NOMINEES OF DTC OR TO A SUCCESSOR THEREOF OR SUCH SUCCESSOR’S NOMINEE AND TRANSFERS OF PORTIONS OF THIS GLOBAL WARRANT SHALL BE LIMITED TO TRANSFERS MADE IN ACCORDANCE
WITH THE RESTRICTIONS SET FORTH IN THE WARRANT AGREEMENT REFERRED TO ON THE REVERSE HEREOF. 

  
 1 

 GLOBAL WARRANT 
 representing 
 WARRANTS 

to purchase 

Shares of 

Common Stock 

of 

ZIONS BANCORPORATION 
  

			
	No. [        ]	  	CUSIP No: 989701 131

 1. Definitions. 
 Unless the context otherwise requires, when used herein the following terms shall have the meanings indicated. Any capitalized terms used but not defined herein that are defined in the Warrant Agreement
shall have the meanings set forth in the Warrant Agreement. 
 “Affiliate” means, with respect to any Person,
any Person directly or indirectly controlling, controlled by or under common control with, such other Person. For purposes of this definition, “control” (including, with correlative meanings, the terms “controlled by” and
“under common control with”) when used with respect to any Person, means the possession, directly or indirectly, of the power to cause the direction of management and/or policies of such Person, whether through the ownership of voting
securities by contract or otherwise. 
 “Agent Members” means the securities brokers and dealers, banks and
trust companies, clearing organizations and certain other organizations that are participants in the Depositary’s system. 

“Board of Directors” means the board of directors of the Company, including any duly authorized committee thereof.

 “Business Combination” means a merger, consolidation, statutory share exchange or similar transaction that
requires the approval of the Company’s stockholders. 
 “business day” means any day except Saturday,
Sunday and (i) at any time when the Warrants are listed on the Nasdaq Global Select Market, any day on which the Nasdaq Global Select Market is authorized or required by law or other governmental actions to close or (ii) at any time when
the Warrants are not listed on the Nasdaq Global Select Market, any day on which banking institutions in the State of New York are authorized or required by law or other governmental actions to close. 

“Capital Stock” means (A) with respect to any Person that is a corporation or company, any and all shares,
interests, participations or other equivalents (however designated) of capital or capital stock of such Person and (B) with respect to any Person that is not a corporation or company, any and all partnership or other equity interests of such
Person. 

  
 2 

 “Charter” means, with respect to any Person, its certificate or articles of
incorporation, articles of association, or similar organizational document. 
 “Common Stock” means the common
stock of the Company. 
 “Company” means Zions Bancorporation, a corporation duly organized and existing under
the laws of Utah. 
 “Definitive Warrant” means a Warrant Certificate in definitive form that is not deposited
with the Depositary or with the Warrant Agent as custodian for the Depositary. 
 “Depositary” means The
Depository Trust Company, its nominees and their respective successors. 
 “Exchange Act” means the Securities
Exchange Act of 1934, as amended, or any successor statute, and the rules and regulations promulgated thereunder. 

“Exercise Price” means $36.27, subject to adjustment as set forth herein. 

“Expiration Time” has the meaning set forth in Section 3. 

“Fair Market Value” means, with respect to any security or other property, the fair market value of such security or
other property as determined by the Board of Directors, acting in good faith. 
 “Global Warrant” means a
Warrant Certificate in global form that is deposited with the Depositary or with the Warrant Agent as custodian for the Depositary. 
 “Governmental Entities” means, collectively, all United States and other governmental, regulatory or judicial authorities. 

“Issue Date” means November 14, 2008. 
 “Market Price” means, with respect to a particular security, on any given day, the last reported sale price regular way or, in case no such reported sale takes place on such day, the
average of the last closing bid and ask prices regular way, in either case on the principal national securities exchange on which the applicable securities are listed or admitted to trading, or if not listed or admitted to trading on any national
securities exchange, the average of the closing bid and ask prices as furnished by two members of the Financial Industry Regulatory Authority, Inc. selected from time to time by the Company for that purpose. “Market Price” shall be
determined without reference to after hours or extended hours trading. If such security is not listed and traded in a manner that the quotations referred to above are available for the period required hereunder, the Market Price per share of Common
Stock shall be deemed to be the fair market value per share of such security as determined in good faith by the Board of Directors in reliance on an opinion of a nationally recognized independent investment banking corporation retained by

  
 3 

 the Company for this purpose; provided that if any such security is listed or traded on a non-U.S.
market, such fair market value shall be determined by reference to the closing price of such security as of the end of the most recently ended business day in such market prior to the date of determination; and provided further that if making
such determination requires the conversion of any currency other than U.S. dollars into U.S. dollars, such conversion shall be done in accordance with customary procedures based on the rate for conversion of such currency into U.S. dollars displayed
on the relevant page by Bloomberg L.P. (or any successor or replacement service) on or by 4:00 p.m., New York City time, on such exercise date. For the purposes of determining the Market Price of the Common Stock on the “trading day”
preceding, on or following the occurrence of an event, (i) that trading day shall be deemed to commence immediately after the regular scheduled closing time of trading on the Nasdaq Global Select Market or, if trading is closed at an earlier
time, such earlier time and (ii) that trading day shall end at the next regular scheduled closing time, or if trading is closed at an earlier time, such earlier time (for the avoidance of doubt, and as an example, if the Market Price is to be
determined as of the last trading day preceding a specified event and the closing time of trading on a particular day is 4:00 p.m. and the specified event occurs at 5:00 p.m. on that day, the Market Price would be determined by reference to such
4:00 p.m. closing price). 
 “Ordinary Cash Dividends” means a regular quarterly cash
dividend on shares of Common Stock out of surplus or net profits legally available therefor (determined in accordance with U.S. GAAP in effect from time to time), provided that Ordinary Cash Dividends shall not include any cash dividends paid
subsequent to the Issue Date to the extent the aggregate per share dividends paid on the outstanding Common Stock in any quarter exceed $0.32, as adjusted for any stock split, stock dividend, reverse stock split, reclassification or similar
transaction. 
 “Person” has the meaning given to it in Section 3(a)(9) of the Exchange Act and as
used in Sections 13(d)(3) and 14(d)(2) of the Exchange Act. 
 “Per Share Fair Market Value” has the meaning
set forth in Section 12(B). 
 “Pro Rata Repurchases” means any purchase of shares of Common Stock by the
Company or any Affiliate thereof pursuant to (A) any tender offer or exchange offer subject to Section 13(e) or 14(e) of the Exchange Act or Regulation 14E promulgated thereunder or (B) any other offer available to substantially all
holders of Common Stock, in the case of both (A) and (B), whether for cash, shares of Capital Stock of the Company, other securities of the Company, evidences of indebtedness of the Company or any other Person or any other property (including,
without limitation, shares of Capital Stock, other securities or evidences of indebtedness of a subsidiary), or any combination thereof, effected while this Warrant Certificate is outstanding. The “Effective Date” of a Pro Rata
Repurchase shall mean the date of acceptance of shares for purchase or exchange by the Company under any tender or exchange offer which is a Pro Rata Repurchase or the date of purchase with respect to any Pro Rata Repurchase that is not a tender or
exchange offer. 
 “SEC” means the U.S. Securities and Exchange Commission. 

“Securities Act” means the Securities Act of 1933, as amended, or any successor statute, and the rules and regulations
promulgated thereunder. 

  
 4 

 “Shares” has the meaning set forth in Section 2. 

“trading day” means (A) if the shares of Common Stock are not traded on any national or regional securities
exchange or association or over-the-counter market, a business day or (B) if the shares of Common Stock are traded on any national or regional securities exchange or association or over-the-counter market, a business day on which such relevant
exchange or quotation system is scheduled to be open for business and on which the shares of Common Stock (i) are not suspended from trading on any national or regional securities exchange or association or over-the-counter market for any
period or periods aggregating one half hour or longer; and (ii) have traded at least once on the national or regional securities exchange or association or over-the-counter market that is the primary market for the trading of the shares of
Common Stock. The term “trading day” with respect to any security other than the Common Stock shall have a correlative meaning based on the primary exchange or quotation system on which such security is listed or traded. 

“Transfer Agent” means Zions First National Bank, as transfer agent of the Company, and any successor transfer agent.

 “U.S. GAAP” means United States generally accepted accounting principles. 

“Warrant” means a right to purchase a number of shares of the Company’s Common Stock equal to the Warrant Share
Number as provided herein. References herein to “Warrant” shall include the Global Warrant where the context requires. 
 “Warrant Agent” has the meaning set forth in Section 16. 

“Warrant Agreement” has the meaning set forth in Section 16. 

“Warrant Certificate” means a fully registered certificate evidencing Warrants. 

“Warrantholder” means a registered owner of Warrants as set forth in the Registry. 

“Warrant Share Number” means one share of Common Stock, as subsequently adjusted pursuant to the terms of this Warrant
and the Warrant Agreement. 
 2. Number of Shares; Exercise Price. 

This certifies that, for value received, Cede & Co., and any of its registered assigns, is the registered owner of the number of
Warrants set forth on Schedule A hereto, each of which entitles the Warrantholder to purchase from the Company, upon the terms and subject to the conditions hereinafter set forth, a number of fully paid and nonassessable shares of Common Stock (each
a “Share” and collectively the “Shares”) equal to the Warrant Share Number at a purchase price per share equal to the Exercise Price. The Warrant Share Number and the Exercise Price are subject to adjustment as
provided herein, and all references to “Warrant Share Number” and “Exercise Price” herein shall be deemed to include any such adjustment or series of adjustments. 

  
 5 

 3. Exercise of Warrant; Term. 

Subject to Section 2, to the extent permitted by applicable laws and regulations, all or a portion of the Warrants evidenced by this
Warrant Certificate are exercisable by the Warrantholder, at any time or from time to time after the execution and delivery of this Warrant Certificate by the Company on the date hereof, but in no event later than 5:00 p.m., New York City time on
the tenth anniversary of the Issue Date (the “Expiration Time”), by (A) delivery to the Warrant Agent of a Notice of Exercise in the form annexed hereto, duly completed and executed (or to the Company or to such other
office or agency of the Company in the United States as the Company may designate by notice in writing to the Warrantholders pursuant to Section 18), and (B) payment of the Exercise Price for the Shares thereby purchased by having the
Company withhold, from the shares of Common Stock that would otherwise be delivered to such Warrantholder upon such exercise, Shares issuable upon exercise of the Warrants so exercised equal in value to the aggregate Exercise Price as to such
Shares, based on the Market Price of the Common Stock on the trading day on which such Warrants are exercised and the Notice of Exercise is delivered to the Warrant Agent pursuant to this Section 3. For the avoidance of doubt, if Warrants are
exercised such that the Exercise Price would exceed the value of the Shares issuable upon exercise, no amount shall be due and payable by the Warrantholder to the Company. In the case of a Global Warrant, any person with a beneficial interest in
such Global Warrant shall effect compliance with the requirements in clauses (A) and (B) above through the relevant Agent Member in accordance with procedures of the Depositary. 

In the case of a Global Warrant, whenever some but not all of the Warrants represented by such Global Warrant are exercised in accordance
with the terms thereof and of the Warrant Agreement, such Global Warrant shall be surrendered by the Warrantholder to the Warrant Agent, which shall cause an adjustment to be made to Schedule A to such Global Warrant so that the number of Warrants
represented thereby will be equal to the number of Warrants theretofor represented by such Global Warrant less the number of Warrants then exercised. The Warrant Agent shall thereafter promptly return such Global Warrant to the Warrantholder or its
nominee or custodian. In the case of a Definitive Warrant, whenever some but not all of the Warrants represented by such Definitive Warrant are exercised in accordance with the terms thereof and of the Warrant Agreement, the Warrantholder shall be
entitled, at the request of such Warrantholder, to receive from the Company within a reasonable time, not to exceed three business days, a new Definitive Warrant in substantially identical form for the number of Warrants equal to the number of
Warrants theretofor represented by such Definitive Warrant less the number of Warrants then exercised. 
 If this Warrant
Certificate shall have been exercised in full, the Warrant Agent shall promptly cancel such certificate following its receipt from the Warrantholder or the Depositary, as applicable. 

Notwithstanding anything in this Warrant Certificate to the contrary, in the case of Warrants evidenced by a Global Warrant, any Agent
Member may, without the consent of the Warrant Agent or any other person, on its own behalf and on behalf of any beneficial owner for which it is acting, enforce, and may institute and maintain, any suit, action or proceeding against the Company
suitable to enforce, or otherwise in respect of, its right to exercise, and to receive Shares for, its Warrants as provided in the Global Warrant, and to enforce the Warrant Agreement. 

  
 6 

 4. Issuance of Shares; Authorization; Listing. 

Shares issued upon exercise of Warrants evidenced by this Warrant Certificate shall be (i) issued in such name or names as the
exercising Warrantholder may designate and (ii) delivered by the Transfer Agent to such Warrantholder or its nominee or nominees (A) via book-entry transfer crediting the account of such Warrantholder (or the relevant Agent Member for the
benefit of such Warrantholder) through the Depositary’s DWAC system (if the Transfer Agent participates in such system), or (B) otherwise in certificated form by physical delivery to the address specified by the Warrantholder in the Notice
of Exercise. The Company shall use its commercially reasonable efforts to cause its Transfer Agent to be a participant in the Depositary’s DWAC system. The Company shall cause the number of full Shares to which such Warrantholder shall be
entitled to be so delivered by the Transfer Agent within a reasonable time, not to exceed three business days after the date on which Warrants evidenced by this Warrant Certificate have been duly exercised in accordance with the terms hereof.

 The Company hereby represents and warrants that any Shares issued upon the exercise of Warrants evidenced by this Warrant
Certificate in accordance with the provisions of Section 3 will be duly and validly authorized and issued, fully paid and nonassessable and free from all taxes, liens and charges (other than liens or charges created by a Warrantholder, income
and franchise taxes incurred in connection with the exercise of the Warrant or taxes in respect of any transfer occurring contemporaneously therewith). The Company agrees that the Shares so issued will be deemed to have been issued to a
Warrantholder as of the close of business on the date on which Warrants evidenced by this Warrant Certificate have been duly exercised, notwithstanding that the stock transfer books of the Company may then be closed or certificates representing such
Shares may not be actually delivered on such date. The Company will at all times until the Expiration Time (or, if such date shall not be a business day, then on the next succeeding business day) reserve and keep available, out of its authorized but
unissued Common Stock, solely for the purpose of providing for the exercise of Warrants evidenced by this Warrant Certificate, the aggregate number of shares of Common Stock then issuable upon exercise hereof at any time. The Company will
(A) procure, at its sole expense, the listing of the Shares issuable upon exercise hereof at any time, subject to issuance or notice of issuance, on all principal stock exchanges on which the Common Stock is then listed or traded and
(B) maintain such listings of such Shares at all times after issuance. The Company will use reasonable best efforts to ensure that the Shares may be issued without violation of any applicable law or regulation or of any requirement of any
securities exchange on which the Shares are listed or traded. 
 5. No Fractional Shares or Scrip. 

No fractional Shares or scrip representing fractional Shares shall be issued upon any exercise of Warrants evidenced by this Warrant
Certificate. In lieu of any fractional Share that would otherwise be issued to a Warrantholder upon the exercise of any Warrants, such Warrantholder shall be entitled to receive a cash payment equal to the Market Price of the Common Stock on the
trading day on which such warrants are exercised representing such fractional Share. The beneficial owners of the Warrants and the Warrantholder, by their 

  
 7 

 
acceptance hereof, expressly waive their right to receive any fraction of a share of Common Stock or a certificate representing a fraction of a share of Common Stock or Warrant Certificate
representing a fractional Warrant upon exercise of any Warrant. 
  

	 	6.	No Rights as Stockholders; Transfer Books. 

 Warrants evidenced by this Warrant Certificate do not entitle the Warrantholder or the owner of any beneficial interest in such Warrants to any voting rights or other rights as a stockholder of the
Company prior to the date of exercise hereof. The Company will at no time close its transfer books against transfer of Warrants in any manner which interferes with the timely exercise hereof. 

 

	 	7.	Charges, Taxes and Expenses. 

 Issuance of Shares in certificated or book-entry form to the Warrantholder upon the exercise of Warrants evidenced by this Warrant Certificate shall be made without charge to the Warrantholder for any
issue or transfer tax or other incidental expense in respect of the issuance of such Shares (other than liens or charges created by a Warrantholder, income and franchise taxes incurred in connection with the exercise of the Warrant or taxes in
respect of any transfer occurring contemporaneously therewith), all of which taxes and expenses shall be paid by the Company. 
  

	 	8.	Transfer/Assignment. 

This Warrant Certificate and all rights hereunder are transferable, in whole or in part, upon the books of the Company (or an agent duly
appointed by the Company) by the registered holder hereof in person or by duly authorized attorney, and one or more new Warrant Certificates shall be made and delivered by the Company, of the same tenor and date as this Warrant Certificate but
registered in the name of one or more transferees, upon surrender of this Warrant Certificate, duly endorsed, to the office or agency of the Company described in Section 3; provided that if this Warrant Certificate is a Global Warrant
registered in the name of the Depositary, transfers of such Global Warrant may only be made as a whole, and not in part, and only by (i) the Depositary to a nominee of the Depositary, (ii) a nominee of the Depositary to the Depositary or
another nominee of the Depositary or (iii) the Depositary or any such nominee to a successor Depositary or its nominee. All expenses (other than stock transfer taxes) and other charges payable in connection with the preparation, execution and
delivery of the new Warrant Certificates pursuant to this Section 8 shall be paid by the Company. 
 If this Warrant
Certificate is a Global Warrant, then so long as the Global Warrant is registered in the name of the Depositary, the holders of beneficial interests in the Warrants evidenced thereby shall have no rights under this Warrant Certificate with respect
to the Global Warrant held on their behalf by the Depositary or the Warrant Agent as its custodian, and the Depositary may be treated by the Company, the Warrant Agent and any agent of the Company or the Warrant Agent as the absolute owner of the
Global Warrant for all purposes whatsoever except to the extent set forth herein. Accordingly, any such owner’s beneficial interest in the Global Warrant will be shown only on, and the transfer of such interest shall be effected only through,
records maintained by the Depositary or the Agent Members, and neither the Company 

  
 8 

 
nor the Warrant Agent shall have any responsibility with respect to such records maintained by the Depositary or the Agent Members. Notwithstanding the foregoing, nothing herein shall
(i) prevent the Company, the Warrant Agent or any agent of the Company or the Warrant Agent from giving effect to any written certification, proxy or other authorization furnished by the Depositary or (ii) impair, as between the Depositary
and the Agent Members, the operation of customary practices governing the exercise of the rights of a holder of a beneficial interest in any Warrant. Except as may otherwise be provided in this Warrant Certificate or the Warrant Agreement, the
rights of beneficial owners in a Global Warrant shall be exercised through the Depositary subject to the applicable procedures of the Depositary. Any holder of the Global Warrant shall, by acceptance of the Global Warrant, agree that transfers of
beneficial interests in the Global Warrant may be effected only through a book-entry system maintained by the Depositary, and that ownership of a beneficial interest in the Warrants represented thereby shall be required to be reflected in book-entry
form. 
 A Global Warrant shall be exchanged for Definitive Warrants, and Definitive Warrants may be transferred or exchanged
for a beneficial interest in a Global Warrant, only at such times and in the manner specified in the Warrant Agreement. Subject to the provisions of the Warrant Agreement, the holder of a Global Warrant may grant proxies and otherwise authorize any
person, including Agent Members and persons that may hold beneficial interests in such Global Warrant through Agent Members, to take any action that a Warrantholder is entitled to take under a Warrant or the Warrant Agreement. 

 

	 	9.	Exchange and Registry of Warrants. 

 This Warrant Certificate is exchangeable, upon the surrender hereof by the Warrantholder to the Company, for a new Warrant Certificate or Warrant Certificates of like tenor and representing the same
aggregate number of Warrants. The Company or an agent duly appointed by the Company (which initially shall be the Warrant Agent) shall maintain a Registry showing the name and address of the Warrantholder as the registered holder of this Warrant
Certificate. This Warrant Certificate may be surrendered for exchange or exercise in accordance with its terms, at the office of the Company or any such agent, and the Company shall be entitled to rely in all respects, prior to written notice to the
contrary, upon such Registry. 
  

	 	10.	Loss, Theft, Destruction or Mutilation of Warrant Certificate. 

 Upon receipt by the Company of proof reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant Certificate, and in the case of any such loss, theft or destruction, upon
receipt of a bond, indemnity or security reasonably satisfactory to the Company and the Warrant Agent, or, in the case of any such mutilation, upon surrender and cancellation of this Warrant Certificate, the Company shall make and deliver, in lieu
of such lost, stolen, destroyed or mutilated Warrant Certificate, a new Warrant Certificate of like tenor and representing the same aggregate number of Warrants as provided for in such lost, stolen, destroyed or mutilated Warrant Certificate.

  
 9 

	 	11.	Saturdays, Sundays, Holidays, etc. 

 If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a business day, then such action may be taken or such right may be
exercised on the next succeeding day that is a business day. 
  

	 	12.	Adjustments and Other Rights. 

 The Exercise Price and the Warrant Share Number shall be subject to adjustment from time to time as follows; provided that if more than one subsection of this Section 12 is applicable to a
single event, the subsection shall be applied that produces the largest adjustment and no single event shall cause an adjustment under more than one subsection of this Section 12 so as to result in duplication: 

 

	 	(A)	Stock Splits, Subdivisions, Reclassifications or Combinations. 

 If the Company shall (i) declare and pay a dividend or make a distribution on its Common Stock in shares of Common Stock, (ii) subdivide or reclassify the outstanding shares of Common Stock into
a greater number of shares, or (iii) combine or reclassify the outstanding shares of Common Stock into a smaller number of shares, the Warrant Share Number at the time of the record date for such dividend or distribution or the effective date
of such subdivision, combination or reclassification shall be proportionately adjusted so that the holder of a Warrant after such date shall be entitled to purchase the number of shares of Common Stock which such holder would have owned or been
entitled to receive in respect of the Warrant Share Number had such Warrant been exercised immediately prior to such date. In such event, the Exercise Price in effect immediately prior to the record date for such dividend or distribution or the
effective date of such subdivision, combination or reclassification shall be adjusted by multiplying such Exercise Price by the quotient of (x) the Warrant Share Number immediately prior to such adjustment divided by (y) the new Warrant
Share Number determined pursuant to the immediately preceding sentence. 
  

	 	(B)	Other Distributions. 

 In
case the Company shall fix a record date for the making of a distribution to all holders of shares of its Common Stock of securities, evidences of indebtedness, assets, cash, rights or warrants (excluding Ordinary Cash Dividends, dividends of its
Common Stock and other dividends or distributions referred to in Section 12(A)), in each such case, the Exercise Price in effect prior to such record date shall be reduced immediately thereafter to the price determined by multiplying the
Exercise Price in effect immediately prior to the reduction by the quotient of (x) the Market Price of the Common Stock on the last trading day preceding the first date on which the Common Stock trades regular way on the principal national
securities exchange on which the Common Stock is listed or admitted to trading without the right to receive such distribution, minus the amount of cash and/or the Fair Market Value of the securities, evidences of indebtedness, assets, rights or
warrants to be so distributed in respect of one share of Common Stock (such subtracted amount and/or Fair Market Value, the “Per Share Fair Market Value”) divided by (y) such Market Price on such date specified in clause (x);
such adjustment shall be made successively whenever such a record date is fixed. In such event, the Warrant Share Number shall be increased to the number obtained by multiplying the Warrant Share Number immediately prior to such adjustment by the
quotient of (x) the Exercise Price in effect 

  
 10 

 
immediately prior to the distribution giving rise to this adjustment divided by (y) the new Exercise Price determined in accordance with the immediately preceding sentence. In the case of
adjustment for a cash dividend that is, or is coincident with, a regular quarterly cash dividend, the Per Share Fair Market Value would be reduced by the per share amount of the portion of the cash dividend that would constitute an Ordinary Cash
Dividend. In the event that such distribution is not so made, the Exercise Price and the Warrant Share Number then in effect shall be readjusted, effective as of the date when the Board of Directors determines not to distribute such shares,
evidences of indebtedness, assets, rights, cash or warrants, as the case may be, to the Exercise Price and the Warrant Share Number that would then be in effect if such record date had not been fixed. 

 

	 	(C)	Certain Repurchases of Common Stock. 

 In case the Company effects a Pro Rata Repurchase of Common Stock, then the Exercise Price shall be reduced to the price determined by multiplying the Exercise Price in effect immediately prior to the
Effective Date of such Pro Rata Repurchase by a fraction of which the numerator shall be (i) the product of (x) the number of shares of Common Stock outstanding immediately before such Pro Rata Repurchase and (y) the Market Price of a
share of Common Stock on the trading day immediately preceding the first public announcement by the Company or any of its Affiliates of the intent to effect such Pro Rata Repurchase, minus (ii) the aggregate purchase price of the Pro Rata
Repurchase, and of which the denominator shall be the product of (i) the number of shares of Common Stock outstanding immediately prior to such Pro Rata Repurchase minus the number of shares of Common Stock so repurchased and (ii) the
Market Price per share of Common Stock on the trading day immediately preceding the first public announcement by the Company or any of its Affiliates of the intent to effect such Pro Rata Repurchase. In such event, the Warrant Share Number shall be
increased to the number obtained by multiplying the Warrant Share Number immediately prior to such adjustment by the quotient of (x) the Exercise Price in effect immediately prior to the Pro Rata Repurchase giving rise to this adjustment
divided by (y) the new Exercise Price determined in accordance with the immediately preceding sentence. For the avoidance of doubt, no increase to the Exercise Price or decrease in the Warrant Share Number shall be made pursuant to this
Section 12(C). 
  

	 	(D)	Business Combinations or Reclassifications of Common Stock. 

 In case of any Business Combination or reclassification of Common Stock (other than a reclassification of Common Stock referred to in Section 12(A)), a Warrantholder’s right to receive Shares
upon exercise of a Warrant shall be converted into the right to exercise such Warrant to acquire the number of shares of stock or other securities or property (including cash) which the Common Stock issuable (at the time of such Business Combination
or reclassification) upon exercise of such Warrant immediately prior to such Business Combination or reclassification would have been entitled to receive upon consummation of such Business Combination or reclassification; and in any such case, if
necessary, the provisions set forth herein with respect to the rights and interests thereafter of the Warrantholder shall be appropriately adjusted so as to be applicable, as nearly as may reasonably be, to such Warrantholder’s right to
exercise a Warrant in exchange for any shares of stock or other securities or property pursuant to this paragraph. In determining the kind and amount of stock, securities or the property receivable upon exercise of a Warrant following the
consummation of such Business Combination, if the holders of Common Stock have the right to elect the kind or amount of consideration receivable upon consummation of 

  
 11 

 
such Business Combination, then the consideration that a Warrantholder shall be entitled to receive upon exercise shall be deemed to be the types and amounts of consideration received by the
majority of all holders of the shares of Common Stock that affirmatively make an election (or of all such holders if none make an election). For purposes of determining any amount to be withheld pursuant to Section 3 from stock, securities or
the property that would otherwise be delivered to a Warrantholder upon exercise of Warrants following any Business Combination, the amount of such stock, securities or property to be withheld shall have a Market Price equal to the aggregate Exercise
Price as to which such Warrants are so exercised, based on the Fair Market Value of such stock, securities or property on the trading day on which such Warrants are exercised and the Notice of Exercise is delivered to the Warrant Agent;
provided that in the case of any property that is not a security, the Market Price of such property shall be deemed to be its Fair Market Value as determined in good faith by the Board of Directors in reliance on an opinion of a nationally
recognized independent investment banking firm retained by the Company for this purpose; and further, provided that if making such determination requires the conversion of any currency other than U.S. dollars into U.S. dollars, such
conversion shall be done in accordance with customary procedures based on the rate for conversion of such currency into U.S. dollars displayed on the relevant page by Bloomberg L.P. (or any successor or replacement service) on or by 4:00 p.m., New
York City time, on such exercise date. 
  

	 	(E)	Rounding of Calculations; Minimum Adjustments. 

 All calculations under this Section 12 shall be made to the nearest one-tenth (1/10th) of a cent or to the nearest one-hundredth (1/100th) of a share, as the case may be. Any provision of
this Section 12 to the contrary notwithstanding, no adjustment in the Exercise Price or the Warrant Share Number shall be made if the amount of such adjustment would be less than $0.01 or one-tenth (1/10th) of a share of Common Stock, but
any such amount shall be carried forward and an adjustment with respect thereto shall be made at the time of and together with any subsequent adjustment which, together with such amount and any other amount or amounts so carried forward, shall
aggregate $0.01 or 1/10th of a share of Common Stock, or more, or on exercise of a Warrant if it shall earlier occur. 
  

	 	(F)	Timing of Issuance of Additional Common Stock Upon Certain Adjustments. 

 In any case in which the provisions of this Section 12 shall require that an adjustment shall become effective immediately after a record date for an event, the Company may defer until the occurrence
of such event (i) issuing to a Warrantholder of Warrants exercised after such record date and before the occurrence of such event the additional shares of Common Stock issuable upon such exercise by reason of the adjustment required by such
event over and above the shares of Common Stock issuable upon such exercise before giving effect to such adjustment and (ii) paying to such Warrantholder any amount of cash in lieu of a fractional share of Common Stock; provided,
however, that the Company upon request shall deliver to such Warrantholder a due bill or other appropriate instrument evidencing such Warrantholder’s right to receive such additional shares, and such cash, upon the occurrence of the
event requiring such adjustment. 

  
 12 

	 	(G)	Other Events. 

 Neither
the Exercise Price nor the Warrant Share Number shall be adjusted in the event of a change in the par value of the Common Stock or a change in the jurisdiction of incorporation of the Company. 

 

	 	(H)	Statement Regarding Adjustments. 

 Whenever the Exercise Price or the Warrant Share Number shall be adjusted as provided in Section 12, the Company shall forthwith file at the principal office of the Company a statement showing in
reasonable detail the facts requiring such adjustment and the Exercise Price that shall be in effect and the Warrant Share Number after such adjustment. The Company shall deliver to the Warrant Agent a copy of such statement and shall cause a copy
of such statement to be sent or communicated to the Warrantholders pursuant to Section 18. 
  

	 	(I)	Notice of Adjustment Event. 

 In the event that the Company shall propose to take any action of the type described in this Section 12 (but only if the action of the type described in this Section 12 would result in an
adjustment in the Exercise Price or the Warrant Share Number or a change in the type of securities or property to be delivered upon exercise of a Warrant), the Company shall deliver to the Warrant Agent a notice and shall cause such notice to be
sent or communicated to the Warrantholders in the manner set forth in Section 18, which notice shall specify the record date, if any, with respect to any such action and the approximate date on which such action is to take place. Such notice
shall also set forth the facts with respect thereto as shall be reasonably necessary to indicate the effect on the Exercise Price and the number, kind or class of shares or other securities or property which shall be deliverable upon exercise of a
Warrant. In the case of any action which would require the fixing of a record date, such notice shall be given at least 10 days prior to the date so fixed, and in case of all other action, such notice shall be given at least 15 days prior to the
taking of such proposed action. Failure to give such notice, or any defect therein, shall not affect the legality or validity of any such action. 
  

	 	(J)	Proceedings Prior to Any Action Requiring Adjustment. 

 As a condition precedent to the taking of any action which would require an adjustment pursuant to this Section 12, the Company shall take any action which may be necessary, including obtaining
regulatory, New York Stock Exchange, NASDAQ Stock Market or other applicable national securities exchange or stockholder approvals or exemptions, in order that the Company may thereafter validly and legally issue as fully paid and nonassessable all
Shares that a Warrantholder is entitled to receive upon exercise of a Warrant pursuant to this Section 12. 
  

	 	(K)	Adjustment Rules. 

 Any
adjustments pursuant to this Section 12 shall be made successively whenever an event referred to herein shall occur. If an adjustment in Exercise Price made hereunder would reduce the Exercise Price to an amount below par value of the Common
Stock, then such adjustment in Exercise Price made hereunder shall reduce the Exercise Price to the par value of the Common Stock. 

  
 13 

 13. No Impairment. 

The Company will not, by amendment of its Charter or through any reorganization, transfer of assets, consolidation, merger, dissolution,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed hereunder by the Company, but will at all times in good faith assist in the carrying out
of all the provisions of this Warrant Certificate and in taking of all such action as may be necessary or appropriate in order to protect the rights of the Warrantholder. 
 14. Governing Law. 
 This Warrant Certificate and the Warrants evidenced
hereby shall be governed by and construed in accordance with the laws of the State of New York applicable to contracts made and to be performed entirely within such State. 
 15. Binding Effect; Countersignature by Warrant Agent. 
 This Warrant
Certificate shall be binding upon any successors or assigns of the Company. This Warrant Certificate shall not be valid until an authorized signatory of the Warrant Agent (as defined below) or its agent as provided in the Warrant Agreement (as
defined below) countersigns this Warrant Certificate. Such signature shall be solely for the purpose of authenticating this Warrant Certificate and shall be conclusive evidence that this Warrant Certificate has been countersigned under the Warrant
Agreement. 
 16. Warrant Agreement; Amendments. 

This Warrant Certificate is issued under and in accordance with a Warrant Agreement dated as of November 29, 2012 (the
“Warrant Agreement”), between the Company and Zions First National Bank (the “Warrant Agent,” which term includes any successor Warrant Agent under the Warrant Agreement), and is subject to the terms and provisions
contained in the Warrant Agreement, to all of which terms and provisions the beneficial owners of the Warrants and the Warrantholders consent by acceptance hereof. The Warrant Agreement is hereby incorporated herein by reference and made a part
hereof. Reference is hereby made to the Warrant Agreement for a statement of the respective rights, limitations of rights, duties and obligations of the Company, the Warrant Agent and the Warrantholders and beneficial owners of the Warrants. A copy
of the Warrant Agreement may be obtained for inspection by the Warrantholders or beneficial owners of the Warrants upon request to the Warrant Agent at the address of the Warrant Agent (or successor warrant agent) set forth in the Warrant Agreement.
The Warrant Agreement and this Warrant Certificate may be amended and the observance of any term of the Warrant Agreement or this Warrant Certificate may be waived only to the extent provided in the Warrant Agreement. 

17. Prohibited Actions. 
 The Company agrees that it will not take any action which would entitle the Warrantholder to an adjustment of the Exercise Price if the total number of shares of Common Stock issuable after such action
upon exercise of the Warrants evidenced by this Warrant 

  
 14 

 
Certificate, together with all shares of Common Stock then outstanding and all shares of Common Stock then issuable upon the exercise of all outstanding options, warrants, conversion and other
rights, would exceed the total number of shares of Common Stock then authorized by its Charter. 
 18. Notices.

 Unless this Warrant Certificate is a Global Warrant, any notice or communication mailed to the Warrantholder shall be mailed
to the Warrantholder at the Warrantholder’s address as it appears in the Registry and shall be sufficiently given if so mailed within the time prescribed. Any notice to holders of a beneficial interest in a Global Warrant shall be distributed
through the Depositary in accordance with the procedures of the Depositary. Communications to such holders shall be deemed to be effective at the time of dispatch to the Depositary. 

[Remainder of page intentionally left blank] 

  
 15 

 IN WITNESS WHEREOF, the Company has caused this Warrant Certificate to be duly executed by a
duly authorized officer. This Warrant Certificate shall not be valid or obligatory for any purpose until it shall have been countersigned by the Warrant Agent. 
 Dated:
                                      
   
  

					
	ZIONS BANCORPORATION
		
	By:	 	 
		 	Name:	 	
		 	Title:	 	

 Countersigned: 
 ZIONS FIRST NATIONAL BANK, 
 as Warrant Agent 

 

			
	By:	 	 
		 	Authorized Signatory

  
 16 

 Schedule A to Global Warrant 

The initial number of Warrants represented by the Global Warrant is 5,789,909. 

The following decreases in the number of Warrants represented by this Global Warrant have been made as a result of the exercise of
certain Warrants represented by this Global Warrant: 
  

							
	 Date of Exercise

of Warrants
	 	 Number of Warrants Exercised
	 	 Total Number of Warrants
Represented
Hereby Following Such
Exercise
	 	 Notation Made
by Warrant Agent

  
 1 

 Form of Notice of Exercise 

(to be executed only upon exercise of Warrants) 
 Date:                              

TO:     Zions Bancorporation (the “Company”) 
 RE:     Election to Purchase Common Stock 
 The undersigned
registered holder of [                ] Warrants irrevocably elects to exercise the number of Warrants set forth below represented by the Global Warrant (or, in
the case of a Definitive Warrant, the Warrant Certificate enclosed herewith), and surrenders all right, title and interest in the number of Warrants exercised hereby to the Company, and directs that the shares of Common Stock or other securities or
property delivered upon exercise of such Warrants, and any interests in the Global Warrant or Definitive Warrant representing unexercised Warrants, be registered or placed in the name and at the address specified below and delivered thereto.

  

					
	Number of Warrants	  	 	  	

  

					
	Holder:	 	 	 	 
	By:	 	 	 	
	Name:	 	 	 	
	Title:	 	 	 	

 Signature guaranteed by (if a guarantee is required): 

 

							
	 	  		  		  	

  
 1 

 Securities and/or check to be issued to: 
 If in book-entry form through the Depositary: 
  

									
		 	 Depositary Account Number:
	  		  	 	  	

  

									
		 	Name of Agent Member:	  		  	 	  	

 If in definitive form: 
  

									
		 	 Social Security Number

or Other Identifying Number:
	  		  	 	  	
					
		 	Name:	  		  	 	  	
					
		 	Street Address:	  		  	 	  	
					
		 	City, State and Zip Code:	  		  	 	  	

 Any unexercised Warrants evidenced by the exercising Warrantholder’s interest in the Global Warrant or Definitive
Warrant, as the case may be, to be issued to: 
 If in book-entry form through the Depositary: 

 

									
		 	 Depositary Account Number:
	  		  	 	  	

  

									
		 	Name of Agent Member:	  		  	 	  	

 If in definitive form: 
  

									
		 	 Social Security Number

or Other Identifying Number:
	  		  	 	  	
					
		 	Name:	  		  	 	  	
					
		 	Street Address:	  		  	 	  	
					
		 	City, State and Zip Code:	  		  	 	  	

  
 2 

 Form of Assignment 

For value received, the undersigned registered Warrantholder of the within Warrant Certificate hereby sells, assigns and transfers unto
the Assignee(s) named below (including the undersigned with respect to any Warrants constituting a part of the Warrants evidenced by the within Warrant Certificate not being assigned hereby) all of the right, title and interest of the undersigned
under the within Warrant Certificate with respect to the number of Warrants set forth below. 
  

							
	 
Name of Assignees
	 	 
Address
	 	 
Number of Warrants
	 	 Social Security Number

or other Identifying
 Number

 and does irrevocably constitute and appoint
[                ], the undersigned’s attorney, to make such transfer on the books of the Company maintained for the purpose, with full power of substitution
in the premises. 
 Dated: 
  

			
		
	Holder:	 	 

 
			
	By:	 	 
	Name:	 	 
	Title:	 	 

 Signature guaranteed by (if a guarantee is required): 

 

									
	 	 		 		 		  	

  
 3Exhibit 10.1 Purchase Agreement dated November 28, 2012

 Exhibit 10.1 
 EXECUTION VERSION 
 Alere Inc. 

$450,000,000 7.250% Senior Notes due 2018 
 PURCHASE AGREEMENT 
 November 28, 2012 

JEFFERIES & COMPANY, INC. 
 GOLDMAN,
SACHS & CO. 
 CREDIT SUISSE SECURITIES (USA) LLC 
 As Representatives of the several Initial Purchasers 
 c/o 520 Madison Avenue 

New York, New York, 10022 
 Ladies and
Gentlemen: 
 Introductory. Alere Inc., a Delaware corporation (the “Company”), proposes to issue and
sell to the several initial purchasers named in Schedule A (the “Initial Purchasers”) $450,000,000 aggregate principal amount of its 7.250% senior unsecured notes due 2018 (the “Original Notes”). The
Company’s obligations under the Original Notes and the Indenture (as defined below) will be, jointly and severally, unconditionally guaranteed (the “Guarantees”), on a senior unsecured basis, by each of the Subsidiaries (as
defined below) listed on the signature pages hereto (collectively, the “Guarantors,” and, together with the Company, the “Issuers”). The Original Notes and the Guarantees are referred to herein as the
“Securities.” The respective principal amounts of the Original Notes to be so purchased by the several Initial Purchasers are set forth opposite their names in Schedule A hereto. The Original Notes are to be issued under an
indenture dated as of August 11, 2009 (the “Base Indenture”) as supplemented by a fifteenth supplemental indenture (the “Supplemental Indenture” and, together with the Base Indenture, the
“Indenture”) to be dated as of the Closing Date (as defined below), by and between the Issuers and The Bank of New York Mellon Trust Company, N.A., as Trustee (the “Trustee”). 

Jefferies & Company, Inc. (“Jefferies”), Goldman, Sachs & Co. (“GS”) and Credit
Suisse Securities (USA) LLC (“CS”) have agreed to act as representatives of the several Initial Purchasers (in such capacity, the “Representatives”) in connection with the offering and sale of the Securities.

 The Securities will be offered and sold to the Initial Purchasers pursuant to an exemption from the registration requirements
under the Securities Act of 1933, as amended (the “Securities Act”). The Issuers have prepared a preliminary offering memorandum, dated as of November 27, 2012 (the “Preliminary Offering Memorandum”), and a
pricing supplement thereto dated the date hereof (the “Pricing Supplement”). The Preliminary Offering Memorandum and the Pricing Supplement are herein referred to as the “Pricing Disclosure Package.” Promptly after
the execution of this Purchase Agreement (this “Agreement”), the Issuers will prepare a final offering memorandum dated the date hereof (the “Final Offering Memorandum”). As used herein, “Applicable
Time” is 3:47 p.m. (New York time) on November 28, 2012. Unless stated to the contrary, any references herein to the terms “Pricing Disclosure Package” and “Final Offering Memorandum” shall be deemed to refer to and
include any information filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), prior to the Applicable Time and incorporated by reference therein, and any references herein to the terms “amend,”
“amendment” or “supplement” with respect to the Final Offering Memorandum shall be deemed to refer to and include any information filed under the Exchange Act subsequent to the Applicable Time that is incorporated by reference
therein. All references in this Agreement to financial statements and schedules 

 
and other information which are “contained,” “included” or “stated” (or other references of like import) in the Pricing Disclosure Package (including the Preliminary
Offering Memorandum) or Final Offering Memorandum shall be deemed to mean and include all such financial statements and schedules and other information which are or are deemed to be incorporated by reference in the Pricing Disclosure Package or
Final Offering Memorandum, as the case may be. 
 The Initial Purchasers have advised the Issuers that the Initial Purchasers
intend, as soon as they deem practicable after this Agreement has been executed and delivered, to resell (the “Exempt Resales”) the Securities in private sales exempt from registration under the Securities Act on the terms set forth
in the Pricing Disclosure Package, solely to (i) persons whom the Initial Purchasers reasonably believe to be “qualified institutional buyers” (“QIBs”), as defined in Rule 144A under the Securities Act (“Rule
144A”), in accordance with Rule 144A and (ii) other eligible purchasers pursuant to offers and sales that occur outside the United States within the meaning of Regulation S under the Securities Act (“Regulation S”) in
accordance with Regulations S (the persons specified in clauses (i) and (ii), the “Eligible Purchasers”). 

Holders (including subsequent transferees) of the Securities will have the registration rights under the registration rights agreement
(the “Registration Rights Agreement”), among the Issuers and the Initial Purchasers, to be dated the Closing Date and in form and substance mutually satisfactory to the Initial Purchasers and the Company, substantially in the form
of the Issuers’ registration rights agreement dated as of September 15, 2010 with such changes as are necessary due to current law and to substantively match the disclosure regarding the Registration Rights Agreement in the Pricing
Disclosure Package. Under the Registration Rights Agreement, the Issuers will agree to (i) file with the Securities and Exchange Commission (the “Commission”) a registration statement under the Securities Act (the
“Exchange Offer Registration Statement”) relating to a new issue of debt securities, the “Exchange Notes” and, together with the Original Notes, the “Notes”), guaranteed by the guarantors under the
Indenture, to be offered in exchange for the Original Notes and the Guarantees thereof (the “Exchange Offer”) and issued under the Indenture or an indenture substantially identical to the Indenture (including the Supplemental
Indenture), (ii) use their commercially reasonable efforts to cause the Exchange Offer Registration Statement to become effective and (iii) use their commercially reasonable efforts to consummate the Exchange Offer, all within the time
periods specified in the Registration Rights Agreement. 
 This Agreement, the Notes, the Guarantees, the Indenture and the
Registration Rights Agreement are hereinafter sometimes referred to collectively as the “Note Documents.” The issuance and sale of the Securities are referred to as the “Transactions.” 

The Issuers hereby confirm their respective agreements with the Initial Purchasers as follows: 

Section 1 Representations and Warranties. (i) The Issuers hereby represent and warrant to each Initial Purchaser, as of
the date of this Agreement and as of the Closing Date (as hereinafter defined) and jointly and severally covenant with each Initial Purchaser (references in this Section 1 to the “Offering Memorandum” are to (x) the
Pricing Disclosure Package in the case of representations and warranties made as of the date hereof and (y) the Final Offering Memorandum in the case of representations and warranties made as of the Closing Date), as follows: 

(a) Accuracy of Notes Documents. Neither the Pricing Disclosure Package, as of the date hereof or as of the Closing Date, nor the
Final Offering Memorandum, as of its date or (as amended or supplemented in accordance with Section 3(c), if applicable) as of the Closing Date, contains any untrue 

  
 -2-

 
statement of a material fact or omits to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;
provided, however, that the Issuers make no representation or warranty with respect to information relating to the Initial Purchasers contained in or omitted from the Pricing Disclosure Package, the Final Offering Memorandum or any amendment
or supplement thereto in reliance upon and in conformity with information furnished to the Company in writing by or on behalf of any Initial Purchaser through the Representatives expressly for inclusion in the Pricing Disclosure Package, the Final
Offering Memorandum or any amendment or supplement thereto, as the case may be. No order preventing the use of the Preliminary Offering Memorandum, the Pricing Supplement or the Final Offering Memorandum, or any amendment or supplement thereto, or
any order asserting that any of the transactions contemplated by this Agreement are subject to the registration requirements of the Securities Act, has been issued or, to the Company’s knowledge, has been threatened. 

(b) Distribution of Note Documents. The Company (including its agents and representatives, other than the Initial Purchasers in
their capacity as such) has not prepared, made, used, authorized, approved or referred to and will not prepare, make, use, authorize, approve or refer to any written communication that constitutes an offer to sell or solicitation of an offer to buy
the Securities (each such communication by the Company or its agents and representatives an “Issuer Written Communication”) other than (i) the Pricing Disclosure Package and (ii) the Final Offering Memorandum. Each such
Issuer Written Communication, when taken together with the Pricing Disclosure Package, did not, and at the Closing Date will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were made, not misleading. 
 (c) Class of
Securities. There are no securities of the Issuers that are listed on a national securities exchange registered under Section 6 of the Exchange Act or that are quoted in a United States automated interdealer quotation system that are of the
same class, within the meaning of Rule 144A as the Securities. 
 (d) The Purchase Agreement. This Agreement has been
duly and validly authorized, executed and delivered by, and is a valid and binding agreement of, each Issuer, enforceable against it in accordance with its terms, except as rights to indemnification hereunder may be limited by applicable law and
except as the enforcement hereof may be limited by bankruptcy, insolvency, reorganization, fraudulent conveyance, moratorium or similar laws affecting the enforcement of creditors’ rights generally and by general principles of equity and the
discretion of the court before which any proceeding therefor may be brought (all such exceptions collectively, the “Enforceability Exceptions”). This Agreement conforms in all material respects to the description thereof in the
Pricing Disclosure Package. 
 (e) Authorization of the Indenture. The Indenture has been duly and validly authorized by
each Issuer and, when duly executed and delivered by the Issuers (assuming the due authorization, execution and delivery thereof by the Trustee), will be a legally binding and valid obligation of each such Issuer, enforceable against it in
accordance with its terms, except as the enforcement thereof may be limited by Enforceability Exceptions. The Indenture, when executed and delivered, will conform in all material respects to the description thereof in the Pricing Disclosure Package.
The Base Indenture has been duly qualified under the Trust Indenture Act of 1939, as amended (the “Trust Indenture Act”). 
 (f) Authorization of the Notes. The Original Notes have been duly and validly authorized for issuance and sale to the Initial Purchasers by the Company and, when issued, authenticated by the
Trustee, and delivered by or on behalf of the Company against payment therefor by the Initial 

  
 -3-

 
Purchasers in accordance with the terms of this Agreement and the Indenture, the Original Notes will be legally binding and valid obligations of the Company, entitled to the benefits of the
Indenture and enforceable against the Company in accordance with their terms, except as the enforcement thereof may be limited by the Enforceability Exceptions. The Original Notes, when issued, authenticated by the Trustee and delivered by or on
behalf of the Company, will conform in all material respects to the description thereof in the Offering Memorandum. The Exchange Notes have been, or on or before the Closing Date will be, duly and validly authorized for issuance by the Company, and
when issued, authenticated by the Trustee and delivered by or on behalf of the Company in accordance with the terms of the Registration Rights Agreement, the Exchange Offer and the applicable indenture, the Exchange Notes will be legally binding and
valid obligations of the Company, entitled to the benefits of the Indenture and enforceable against the Company in accordance with their terms, except as the enforcement thereof may be limited by the Enforceability Exceptions. 

(g) Authorization of the Guarantees. Each Guarantee has been duly and validly authorized by the applicable Guarantor and, when the
Original Notes are issued and delivered by or on behalf of the Company and authenticated by the Trustee against payment therefor by the Initial Purchasers in accordance with the terms of this Agreement and the Indenture, will be legally binding and
valid obligations of such Guarantor, enforceable against such Guarantor in accordance with its terms, except that enforceability thereof may be limited by the Enforceability Exceptions. Each Guarantee, when the Original Notes are issued,
authenticated by the Trustee and delivered by or on behalf of the Company, will conform in all material respects to the description thereof in the Offering Memorandum. Each guarantee of the Exchange Notes has been duly and validly authorized by the
applicable Guarantor and, when the Exchange Notes are issued, authenticated by the Trustee and delivered by or on behalf of the Company in accordance with the terms of the Registration Rights Agreement, the Exchange Offer and the applicable
indenture, will be legally binding and valid obligations of such Guarantor, enforceable against it in accordance with its terms, except as the enforceability thereof may be limited by the Enforceability Exceptions. 

(h) Authorization of the Registration Rights Agreement. The Registration Rights Agreement has been duly and validly authorized by
each Issuer and, when duly executed and delivered by the Issuers (assuming the due authorization, execution and delivery thereof by the Initial Purchasers), will constitute a valid and legally binding obligation of each such Issuer, enforceable
against it in accordance with its terms, except that (A) the enforcement thereof may be limited by the Enforceability Exceptions and (B) any rights to indemnity or contribution thereunder may be limited by federal and state securities laws
and public policy considerations. The Registration Rights Agreement, when executed and delivered, will conform in all material respects to the description thereof in the Offering Memorandum. 

(i) No Material Adverse Change. Except as otherwise disclosed in the Pricing Disclosure Package, subsequent to the respective
dates as of which information is given in Pricing Disclosure Package: (i) there has been no material adverse change, or any development that could reasonably be expected to result in a material adverse change, in the condition, financial or
otherwise, or in the earnings, business, operations or prospects, whether or not arising from transactions in the ordinary course of business, of the Company and its subsidiaries, considered as one entity (any such change is called a
“Material Adverse Change”); (ii) the Company and its subsidiaries, considered as one entity, have not incurred any material liability or obligation, indirect, direct or contingent, not in the ordinary course of business nor
entered into any material transaction or agreement not in the ordinary course of business; and (iii) there has been no dividend or distribution of any kind (other than regular quarterly dividends on the Company’s Series B Convertible
Perpetual Preferred Stock) declared, paid or made by the Company or, except for dividends paid to the Company or other subsidiaries, any of its subsidiaries on any class of capital stock or repurchase or redemption by the Company or any of its
subsidiaries of any class of capital stock. 

  
 -4-

 (j) Independent Accountants. To the Company’s knowledge, BDO USA, LLP and
PricewaterhouseCoopers LLP, who have expressed their opinions with respect to the financial statements (which term as used in this Agreement includes the related notes thereto) and supporting schedules included and incorporated by reference in the
Offering Memorandum, are (i) independent public or certified public accountants as required by the Securities Act and the Exchange Act, (ii) in compliance with the applicable requirements relating to the qualification of accountants under
Rule 2-01 of Regulation S-X and (iii) a registered public accounting firm as defined by the Public Company Accounting Oversight Board (the “PCAOB”) whose registration has not been suspended or revoked and who has not requested
such registration to be withdrawn. 
 (k) Preparation of the Financial Statements. The financial statements and
supporting schedules included and incorporated by reference in the Offering Memorandum present fairly the consolidated financial position of the Company and its subsidiaries (or its applicable subsidiaries) as of and at the dates indicated and the
results of their operations and cash flows for the periods specified. Such financial statements and supporting schedules have been prepared in conformity with generally accepted accounting principles as applied in the United States applied on a
consistent basis throughout the periods involved, except as may be expressly stated in the related notes thereto. The financial data set forth in the Offering Memorandum under the caption “Summary Consolidated Financial Information” fairly
present the information set forth therein on a basis consistent with that of the audited financial statements included and incorporated by reference in the Offering Memorandum. To the Company’s knowledge, no person who has been suspended or
barred from being associated with a registered public accounting firm, or who has failed to comply with any sanction pursuant to Rule 5300 promulgated by the PCAOB, has participated in or otherwise aided the preparation of, or audited, the financial
statements, supporting schedules or other financial data included and incorporated by reference in the Offering Memorandum. 

(l) Company’s Accounting System. The Company makes and keeps accurate books and records and maintains a system of internal
accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorization; (ii) transactions are recorded as necessary to permit preparation of
financial statements in conformity with generally accepted accounting principles as applied in the United States and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management’s general or
specific authorization; and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences. 

(m) Incorporation and Good Standing of the Company and its Subsidiaries. Each of the Company and its subsidiaries has been duly
incorporated or organized, as the case may be, and is validly existing as a corporation, partnership or limited liability company, as applicable, in good standing under the laws of the jurisdiction of its incorporation or organization and has the
power and authority (corporate or other) to own, lease and operate its properties and to conduct its business as described in the Offering Memorandum and, in the case of each Issuer, to enter into and perform its obligations under this Agreement.
Each of the Company and the subsidiaries of the Company set forth on Schedule B attached hereto (each a “Subsidiary” and, collectively, the “Subsidiaries”) is duly qualified as a foreign corporation,
partnership or limited liability company, as applicable, to transact business and is in good standing in each other jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of
business, except where the failure to be so qualified and in good standing would not, individually or in the aggregate, result in a Material Adverse Change. Each “significant subsidiary” (as such term is defined in Rule 1-02 of Regulation
S-X) of the Company is 

  
 -5-

 
set forth on Schedule B attached hereto. All of the issued and outstanding capital stock or other equity or ownership interests of each Subsidiary wholly owned by the Company or any other
Subsidiary have been duly authorized and validly issued, are (in the case of capital stock) fully paid and non-assessable and are owned by the Company, directly or through subsidiaries, free and clear of any security interest, mortgage, pledge,
lien, encumbrance or adverse claim other than (A) the security interests created by that certain Credit Agreement, dated as of June 30, 2011 among, inter alia, the Company, the lenders party thereto and General Electric Capital Corporation
as administrative agent, including any notes, guarantees, collateral and security documents, instruments and agreements executed in connection therewith (the “Senior Credit Documents”) and (B) any other liens or security
interests permitted by the Senior Credit Documents. The Company does not own or control, directly or indirectly, any corporation, association or other entity other than (i) the subsidiaries listed in Exhibit 21.1 to the Company’s Annual
Report on Form 10-K/A for the fiscal year ended December 31, 2011 and the subsidiaries listed in Schedule B attached hereto and (ii) such other entities omitted from Exhibit 21.1 to the Company’s Annual Report on Form 10-K/A
for the fiscal year ended December 31, 2011 or Schedule B attached hereto which, when such omitted entities are considered in the aggregate as a single subsidiary, would not constitute a “significant subsidiary” within the
meaning of Rule 1-02(w) of Regulation S-X. All subsidiaries of the Company that are guarantors of the Senior Credit Documents and organized under the laws of a state of the United States are Guarantors, other than SPDH, Inc. 

(n) Capitalization and Other Capital Stock Matters. The authorized, issued and outstanding capital stock of the Company is as set
forth in the Offering Memorandum in the Company’s balance sheet as of September 30, 2012 (other than for subsequent issuances, if any, pursuant to employee benefit plans described in the Offering Memorandum or upon the exercise of
outstanding options or warrants described in the Offering Memorandum). All of the issued and outstanding shares of capital stock of the Company have been duly authorized and validly issued, are fully paid and non-assessable and have been issued in
compliance with federal and state securities laws. None of the outstanding equity interests of the Company was issued in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities of
the Company. All outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any capital stock of the Company are as set
forth and accurately and fairly described, in all material respects, in the Offering Memorandum. The description of the Company’s stock option, stock bonus and other stock plans or arrangements, and the options or other rights granted
thereunder, set forth in the Offering Memorandum accurately and fairly presents, in all material respects, the information required to be shown with respect to such plans, arrangements, options and rights. 

(o) Non-Contravention of Existing Instruments; No Further Authorizations or Approvals Required. Neither the Company nor any of its
subsidiaries is in violation of its charter or by-laws, partnership agreement or operating agreement or similar organizational document, as applicable, or is in default (or, with the giving of notice or lapse of time, would be in default)
(“Default”) under any indenture, mortgage, loan or credit agreement, note, contract, franchise, lease or other instrument to which the Company or any of its subsidiaries is a party or by which it or any of them may be bound
(including, without limitation, any credit agreement, indenture, pledge agreement, security agreement or other instrument or agreement evidencing, guaranteeing, securing or relating to indebtedness of the Company or any of its subsidiaries), or to
which any of the property or assets of the Company or any of its subsidiaries is subject (each, an “Existing Instrument”), except for such Defaults as would not, individually or in the aggregate, result in a Material Adverse Change.
The Issuers’ execution, delivery and performance of this Agreement, the Indenture and the Registration Rights Agreement, the consummation by the Issuers of the Transactions contemplated hereby and by the Offering Memorandum and the issuance and
sale of the Securities to be sold by the Issuers (i) have been duly authorized by all 

  
 -6-

 
necessary corporate or other organizational action and will not result in any violation of the provisions of the charter or by-laws, partnership agreement or operating agreement or similar
organizational document of the Company or any subsidiary, as applicable, (ii) will not conflict with or constitute a breach of, or Default or a Debt Repayment Triggering Event (as defined below) under, or result in the creation or imposition of
any lien, charge or encumbrance upon any property or assets of the Company or any of its subsidiaries pursuant to, or require the consent of any other party to, any Existing Instrument (other than requiring the consent of General Electric Capital
Corporation as administrative agent under the respective Senior Credit Documents) and (iii) will not result in any violation of any law, administrative regulation or administrative or court decree applicable to the Company or any subsidiary,
except, with respect to clauses (ii) and (iii), for such conflicts, breaches, Defaults, Debt Repayment Triggering Events, liens, charges, encumbrances or violations as would not, individually or in the aggregate, result in a Material Adverse
Change. No consent, approval, authorization or other order of, or registration or filing with, any court or other governmental or regulatory authority or agency, is required for the Issuers’ execution, delivery and performance of this Agreement
and the consummation by the Issuers of the Transactions contemplated hereby and by the Offering Memorandum, except (1) such as have been obtained or made by the Company or the Trustee and are in full force and effect under the Securities Act or
the Trust Indenture Act, (2) such as may be required under applicable state securities or blue sky laws, (3) such as may be required from the Financial Industry Regulatory Authority (“FINRA”) and (4) as contemplated
by the Registration Rights Agreement with respect to the Exchange Offer. As used herein, a “Debt Repayment Triggering Event” means any event or condition which gives, or with the giving of notice or lapse of time would give, the
holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder’s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company or any of its
subsidiaries. 
 (p) No Material Actions or Proceedings. Except as otherwise disclosed in the Offering Memorandum, there
are no legal or governmental actions, suits or proceedings pending or, to the Company’s knowledge, threatened (i) against or affecting the Company or any of its subsidiaries, (ii) which have as the subject thereof any officer or
director of, or property owned or leased by, the Company or any of its subsidiaries or (iii) relating to environmental or discrimination matters, where in any such case (A) any such action, suit or proceeding, if determined adversely to
the Company, such subsidiary or such officer or director, would reasonably be expected to result in a Material Adverse Change or, individually or in the aggregate, adversely affect the consummation of the transactions contemplated by this Agreement
or (B) any such action, suit or proceeding is or would be material in the context of the sale of Securities. No material labor dispute with the employees of the Company or any of its Subsidiaries exists or, to the Company’s knowledge, is
threatened or imminent. 
 (q) Intellectual Property Rights. To the Company’s knowledge, the Company owns, possesses
or can acquire on reasonable terms sufficient trademarks, servicemarks, trade names, patents, copyrights, and any registrations and applications for any of the foregoing, domain names, licenses, approvals, trade secrets, know-how, inventions,
technology and other similar rights (collectively, “Intellectual Property Rights”) reasonably necessary to conduct its business as now conducted and as proposed to be conducted as set forth in the Offering Memorandum (the
“Business”). The operation of the Business by the Company, together with the Company’s use of the Intellectual Property Rights purported to be owned by, or exclusively licensed to, the Company and used by the Company in the
Business (collectively, “Company Intellectual Property Rights”), does not infringe, misappropriate or otherwise violate the Intellectual Property Rights of any third party, other than the rights of any third party under any
patent, and to the Company’s knowledge, the operation of the Business, together with the Company’s use of any Company Intellectual Property Rights, does not infringe or otherwise violate the rights of any third party under any patent.
Except as disclosed in the Offering Memorandum, no actions, suits, claims or proceedings have been asserted or, to the knowledge of the Company, threatened against 

  
 -7-

 
the Company alleging any of the forgoing or seeking to challenge, deny or restrict the operation of the Business by the Company, except for such actions, suits, claims or proceedings as would
not, individually or in the aggregate, result in a Material Adverse Change. The Company has not received any written notice of a claim of infringement, misappropriation or conflict with Intellectual Property Rights of others, except for such claims,
individually or in the aggregate, as would not result in a Material Adverse Change. Except as disclosed in the Offering Memorandum or except as would not, individually or in the aggregate, be reasonably expected to result in a Material Adverse
Change, no court, administrative body or arbitral body has issued any order, judgment, decree or injunction restricting the operation of the Business by the Company. 
 Except as disclosed in the Offering Memorandum or except as would not, individually or in the aggregate, be reasonably expected to result in a Material Adverse Change, the Company Intellectual Property
Rights owned by the Company and, to the knowledge of the Company, any Intellectual Property Rights exclusively licensed to the Company have not been adjudged invalid or unenforceable, in whole or in part, and, except as aforesaid, there is no
pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others challenging the validity or scope of any such Intellectual Property Rights. Except as disclosed in the Offering Memorandum or except as would not,
individually or in the aggregate, be reasonably expected to result in a Material Adverse Change, there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others challenging the Company’s right in
or to any Company Intellectual Property Rights. Except as otherwise disclosed in the Offering Memorandum, the Company is not a party to or bound by any agreements with respect to the Intellectual Property Rights of any other person or entity that
are required to be set forth in the Offering Memorandum. None of the technology or intellectual property included in, or that is the subject matter of, the Company Intellectual Property Rights has been obtained or is being used by the Company in
violation of any contractual obligation binding on the Company or, to the Company’s knowledge, any of its officers, directors or employees. 
 Other than the patent applications acquired by the Company from a third party (the “Acquired Patent Applications”), the Company has duly filed or caused to be filed with the U.S. Patent
and Trademark Office (the “PTO”) or foreign and international patent authorities all patent applications disclosed in the Offering Memorandum as owned by the Company (the “Company Patent Applications”). The Company
has complied with the PTO’s duty of candor and disclosure for the Company Patent Applications and has made no material misrepresentation during prosecution of the Company Patent Applications and the Acquired Patent Applications. To the
Company’s knowledge, the Company Patent Applications disclose patentable subject matters and correctly name the inventors of the claimed subject matter. With respect to the Company Patent Applications, the Company has not been notified of any
inventorship challenges nor has any interference been declared. 
 The Company has used reasonable security measures, but in no
event less than those efforts that would accord with normal industry practice, to maintain the confidentiality of the trade secrets and other confidential information included in the Company Intellectual Property Rights. To the knowledge of the
Company, all material trade secrets included in the Company Intellectual Property Rights are valid and protectible. Furthermore, to the knowledge of the Company, (i) there has been no misappropriation of any material trade secrets included in
the Company Intellectual Property Rights by any other person, (ii) no employee, independent contractor or agent of the Company has misappropriated any trade secrets of any other person in the course of performance as an employee, independent
contractor or agent of the Company, and (iii) no employee, independent contractor or agent of the Company is in material default or breach of any term of any employment agreement, nondisclosure agreement, assignment of invention agreement or
similar agreement or contract relating in any way to the protection, ownership, development, use or transfer of Company Intellectual Property Rights owned by the Company. 

  
 -8-

 (r) All Necessary Permits, etc. The Company and each subsidiary possess such valid
and current certificates, authorizations or permits issued by the appropriate state, federal or foreign regulatory agencies or bodies necessary to conduct their respective businesses, and neither the Company nor any subsidiary has received, or has
any reason to believe that it will receive, any notice of proceedings relating to the revocation or modification of, or noncompliance with, any such certificate, authorization or permit which, individually or in the aggregate, if the subject of an
unfavorable decision, ruling or finding, could result in a Material Adverse Change. 
 (s) Title to Properties. Except as
otherwise disclosed in the Offering Memorandum, each of the Company and its subsidiaries has good and marketable title to all of the real and personal property and other assets reflected as owned in the financial statements referred to in Section
l(i)(k) above (or elsewhere in the Offering Memorandum), in each case free and clear of any security interests, mortgages, liens, encumbrances, equities, adverse claims and other defects, except such as do not materially and adversely affect the
value of such property and do not materially interfere with the use made or proposed to be made of such property by the Company or such subsidiary and except for (A) the security interests created by the Senior Credit Documents and (B) any
other liens or security interests permitted by the Senior Credit Documents. The real property, improvements, equipment and personal property held under lease by the Company or any subsidiary are held under valid and enforceable leases, with such
exceptions as are not material and do not materially interfere with the use made or proposed to be made of such real property, improvements, equipment or personal property by the Company or such subsidiary. 

(t) Tax Law Compliance. The Company and its subsidiaries have filed all necessary federal, state and foreign income and franchise
tax returns and have paid all taxes required to be paid by any of them and, if due and payable, any related or similar assessment, fine or penalty levied against any of them, except for such failure to file or pay as would not, individually or in
the aggregate, result in a Material Adverse Change. The Company has made adequate charges, accruals and reserves in the applicable financial statements referred to in Section 1(i)(k) above in respect of all federal, state and foreign income and
franchise taxes for all periods as to which the tax liability of the Company or any of its consolidated subsidiaries has not been finally determined. 
 (u) Each Issuer Not an “Investment Company”. Each Issuer has been advised of the rules and requirements under the Investment Company Act of 1940, as amended (the “Investment
Company Act”). Each Issuer is not, and will not be, either after receipt of payment for the Securities or after the application of the proceeds therefrom as described under “Use of Proceeds” in the Offering Memorandum, an
“investment company” within the meaning of the Investment Company Act. 
 (v) Insurance. The Company and
its subsidiaries are insured by recognized institutions with policies in such amounts and with such deductibles and covering such risks as are generally deemed adequate and customary for their businesses including, but not limited to, policies
covering real and personal property owned or leased by the Company and its subsidiaries against theft, damage, destruction, acts of vandalism and earthquakes and policies covering the Company and its subsidiaries for product liability claims and
clinical trial liability claims. The Company has no reason to believe that it or any subsidiary will not be able (i) to renew its existing insurance coverage as and when such policies expire or (ii) to obtain comparable coverage from
similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not, individually or in the aggregate, result in a Material Adverse Change. Neither the Company nor any subsidiary has been
denied any insurance coverage which it has sought or for which it has applied. 

  
 -9-

 (w) No Price Stabilization or Manipulation; Compliance with Regulation M. No Issuer
has taken, directly or indirectly, any action designed to or that might be reasonably expected to cause or result in stabilization or manipulation of the price of the Securities or any other “reference security” (as defined in Rule 100 of
Regulation M under the Exchange Act (“Regulation M”)) whether to facilitate the sale or resale of the Securities or otherwise, or has taken any action which would directly or indirectly violate Regulation M. 

(x) Related-Party Transactions. There are no business relationships or related-party transactions involving the Company or any of
its subsidiaries or any other person required to be described in the Offering Memorandum which have not been described as required. 
 (y) Exchange Act Compliance. The documents incorporated or deemed to be incorporated by reference in the Offering Memorandum, at the time they were or hereafter are filed with the Commission,
complied and will comply in all material respects with the requirements of the Exchange Act, and, when read together with the other information in the Offering Memorandum, at the Closing Date will not contain an untrue statement of a material fact
or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. 

(z) Statistical and Market-Related Data. The statistical, demographic and market-related data included in the Offering Memorandum
are based on or derived from sources that the Company believes to be reliable and accurate or represent the Company’s good faith estimates that are made on the basis of data derived from such sources. 

(aa) No Unlawful Contributions or Other Payments. Neither the Company nor any of its subsidiaries nor, to the Company’s
knowledge, any employee or agent of the Company or any subsidiary, has made any contribution or other payment to any official of, or candidate for, any federal, state or foreign office in violation of any law or of the character required to be
disclosed in the Offering Memorandum. 
 (bb) Disclosure Controls and Procedures; Deficiencies in or Changes to Internal
Control Over Financial Reporting. The Company has established and maintains disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)), which (i) are designed to ensure that material information relating
to the Company, including its consolidated subsidiaries, is made known to the Company’s principal executive officer and its principal financial officer by others within those entities, particularly during the periods in which the periodic
reports required under the Exchange Act are being prepared; (ii) have been evaluated by management of the Company for effectiveness as of a date within 90 days prior to the earlier of the date that the Company filed its most recent annual or
quarterly report with the Commission and the date of the Pricing Disclosure Package; and (iii) are effective in all material respects to perform the functions for which they were established. There has not been and is no material weakness in
the Company’s internal control over financial reporting since January 1, 2011, and since December 31, 2011, there has been no change in the Company’s internal control over financial reporting that has materially affected, or is
reasonably likely to materially affect, the Company’s internal control over financial reporting. The Company is not aware of any fraud, whether or not material, that involves management or other employees who have a significant role in the
Company’s internal control over financial reporting. The principal executive officers (or their equivalents) and principal financial officers (or their equivalents) of the Company have made all certifications required by the Sarbanes-Oxley Act
of 2002 (the “Sarbanes-Oxley Act”) and any related rules and regulations promulgated by the Commission. 

  
 -10-

 (cc) Compliance with Environmental Laws. Except as described in the Offering
Memorandum and except as would not, individually or in the aggregate, result in a Material Adverse Change, (i) neither the Company nor any of its subsidiaries is in violation of any federal, state, local or foreign statute, law, rule,
regulation, ordinance, code, policy or rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the
environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened release of chemicals,
pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products (collectively, “Hazardous Materials”) or to the manufacture, processing, distribution, use, treatment, storage, disposal,
transport or handling of Hazardous Materials (collectively, “Environmental Laws”), (ii) the Company and its subsidiaries have all permits, authorizations and approvals required under any applicable Environmental Laws and are
each in compliance with their requirements, (iii) there are no pending or, to the Company’s knowledge, threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or
violation, investigation or proceedings relating to any Environmental Law against the Company or any of its subsidiaries and (iv) there are no events or circumstances that might reasonably be expected to form the basis of an order for clean-up
or remediation, or an action, suit or proceeding by any private party or governmental body or agency, against or affecting the Company or any of its subsidiaries relating to Hazardous Materials or any Environmental Laws. 

(dd) ERISA Compliance. The Company and its subsidiaries and any “employee benefit plan” (as defined under the
Employee Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, “ERISA”)) established or maintained by the Company, its subsidiaries or their “ERISA
Affiliates” (as defined below) are in compliance in all material respects with ERISA. “ERISA Affiliate” means, with respect to the Company or a subsidiary, any member of any group of organizations described in Sections 414(b),
(c), (m) or (o) of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder (the “Code”) of which the Company or such subsidiary is a member. No “reportable
event” (as defined under ERISA) has occurred or is reasonably expected to occur with respect to any “employee benefit plan” established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates. No
“employee benefit plan” established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates, if such “employee benefit plan” were terminated, would have any “amount of unfunded benefit
liabilities” (as defined under ERISA). Neither the Company, its subsidiaries nor any of their ERISA Affiliates has incurred or reasonably expects to incur any liability under (i) Title IV of ERISA with respect to termination of, or
withdrawal from, any “employee benefit plan” or (ii) Sections 412, 4971, 4975 or 4980B of the Code. Each “employee benefit plan” established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates
that is intended to be qualified under Section 401(a) of the Code is so qualified and nothing has occurred, whether by action or failure to act, which would cause the loss of such qualification. 

(ee) Broker. Except as described in the section entitled “Plan of Distribution” in the Offering Memorandum, there are no
contracts, agreements or understandings between the Issuer or any Subsidiary and any other person other than the Initial Purchasers pursuant to this Agreement that would give rise to a valid claim against the Issuer, any such Subsidiary or any
Initial Purchaser for a brokerage commission, finder’s fee or like payment in connection with the issuance, purchase and sale of the Original Notes. 

  
 -11-

 (ff) Regulation S Compliance. None of the Issuers nor, to the Company’s
knowledge, any of their affiliates, or any person acting on behalf of any of the foregoing persons (other than any Initial Purchaser, as to whom the Issuers make no representation), is engaged in any directed selling effort with respect to the
Securities, and each of the Issuers and, to the Company’s knowledge, their affiliates and persons acting on behalf of the foregoing persons, if any, has complied with the offering restrictions requirement of Regulation S under the Securities
Act. Terms used in this paragraph have the meaning given to them by Regulation S. 
 (gg) Affiliates of the Issuer. None
of the Issuers nor, to the Company’s knowledge, any of their affiliates (as defined in Regulation D under the Securities Act) has, directly or through any agent (other than the Initial Purchasers or any affiliate of the Initial Purchasers, as
to which no representation is made), sold, offered for sale, contracted to sell, pledged, solicited offers to buy or otherwise disposed of or negotiated in respect of, any security (as defined in the Securities Act) that is currently or will be
integrated with the sale of the Securities in a manner that would require the registration of the Original Notes under the Securities Act. 
 (hh) General Solicitation. No form of general solicitation or general advertising (prohibited by the Securities Act in connection with offers or sales such as the Exempt Resales) was used by the
Issuers or, to the Company’s knowledge, any of their representatives (other than any Initial Purchaser, as to whom the Issuers make no representation) in connection with the offer and sale of any of the Original Notes or in connection with
Exempt Resales, including, but not limited to, articles, notices or other communications published in any newspaper, magazine or similar medium or broadcast over television or radio or the Internet, or any seminar or meeting whose attendees have
been invited by any general solicitation or general advertising within the meaning of Regulation D under the Securities Act. None of the Issuers nor, to the Company’s knowledge, any of their affiliates has entered into, and none of the Issuers
nor, to the Company’s knowledge, any of their affiliates will enter into, any contractual arrangement with respect to the distribution of the Securities except for this Agreement. 

(ii) No Outstanding Loans or Other Extensions of Credit. Since the adoption of Section 13(k) of the Exchange Act, neither the
Company nor any of its subsidiaries has extended or maintained credit, arranged for the extension of credit, or renewed any extension of credit, in the form of a personal loan, to or for any director or executive officer (or equivalent thereof) of
the Company and/or such subsidiary except for such extensions of credit as are expressly permitted by Section 13(k) of the Exchange Act. 
 (jj) Compliance with Laws. The Company and each of its subsidiaries are conducting business in compliance with all applicable laws, rules and regulations of the jurisdictions in which it is
conducting business, except where failure to be so in compliance would not, individually or in the aggregate, result in a Material Adverse Change. The Company, its subsidiaries and, to the Company’s knowledge, the Company’s directors and
officers are each in compliance in all material respects with all applicable effective provisions of the Sarbanes-Oxley Act and the rules and regulations of the Commission and the New York Stock Exchange promulgated thereunder. 

(kk) Dividend Restrictions. Except as otherwise described in the Offering Memorandum and except as set forth in the Senior Credit
Documents, and except for any prohibitions or restrictions under applicable law, no subsidiary of the Company is prohibited or restricted, directly or indirectly, from paying dividends to the Company, or from making any other distribution with
respect to such subsidiary’s equity securities or from repaying to the Company or any other subsidiary of the Company any amounts that may from time to time become due under any loans or advances to such subsidiary from the Company or from
transferring any property or assets to the Company or to any other subsidiary. 

  
 -12-

 (ll) Foreign Corrupt Practices Act. Neither the Company nor any of its subsidiaries
nor, to the knowledge of the Company, any director, officer, agent, employee, affiliate or other person acting on behalf of the Company or any of its subsidiaries is aware of, or has taken any action, directly or indirectly, that has resulted or
would result in, a violation of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the “FCPA”) in any material respect, including, without limitation, making use of the mails or any
means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of any money, or other property, gift, promise to give, or authorization of the giving of anything of value
to any “foreign official” (as such term is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office, in contravention of the FCPA in any material respect; and the Company
and its subsidiaries and, to the knowledge of the Company, the Company’s affiliates have conducted their respective businesses in compliance with the FCPA in all material respects and have instituted and maintain policies and procedures
designed to ensure, and which are reasonably intended to continue to ensure, continued compliance therewith. 
 (mm) Money
Laundering Laws. The operations of the Company and its subsidiaries are, and have been conducted at all times, in compliance in all material respects with applicable financial recordkeeping and reporting requirements of the Currency and Foreign
Transactions Reporting Act of 1970, as amended, the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or similar applicable rules, regulations or guidelines, issued, administered or
enforced by any governmental agency (collectively, the “Money Laundering Laws”), and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of
its subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened. 
 (nn)
OFAC. Neither the Company nor any of its subsidiaries nor, to the knowledge of the Company, any director, officer, agent, employee, affiliate or person acting on behalf of the Company or any of its subsidiaries is currently subject to any
U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”); and the Company will not directly or indirectly use the proceeds of this offering, or lend, contribute or otherwise make
available such proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing the activities of any person currently subject to any U.S. sanctions administered by OFAC. 

(oo) Summaries of Certain Sections. The statements under the headings “Material United States Federal Income Tax
Consequences” and “Description of Notes” and under the subheadings “Risk Factors—Risks Relating to Our Business—If we are unable to obtain required clearances or approvals for the commercialization of our products in
the United States, we would not be able to sell those products in the United States”;—”We are subject to regulatory approval requirements of the foreign countries in which we sell our products, and these requirements may prevent or
delay us from marketing our products in those countries”;—”Our business is subject to substantial regulatory oversight and our failure to comply with applicable regulations may result in significant costs or, in certain circumstances,
the suspension or withdrawal of previously obtained clearances and approvals”;—”We are subject to healthcare fraud and abuse regulations that could result in significant liability, require us to change our business practices and
restrict our operations in the future”; and—”Healthcare reform legislation could adversely affect our revenue and financial condition” in the Offering Memorandum, under the subheading “Business—Government
Regulation” and under the heading “Item 3. Legal Proceedings” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 

  
 -13-

 
2011 and under the heading “Item 1. Legal Proceedings” in the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2012, fairly summarize the
matters therein described in all material respects. 
 (pp) Regulation T, U and X. Neither the issuance, sale and
delivery of the Securities nor the application of the proceeds thereof by the Company as described in the Offering Memorandum will violate Regulation T, U or X of the Board of Governors of the Federal Reserve System or any other regulation of such
Board of Governors. 
 (qq) Forward-Looking Statements. No forward-looking statement (within the meaning of
Section 27 A of the Securities Act or Section 21E of the Exchange Act) contained in the Offering Memorandum has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith. 

(rr) Solvency. As of the date hereof and as of the Closing Date, immediately prior to and immediately following the consummation
of the issuance of the Securities, the Issuers and their Restricted Subsidiaries (as defined in the Indenture) are and will be Solvent on a consolidated basis. As used herein, “Solvent” shall mean, for any person on a particular
date, that on such date (A) the fair value of the property of such person is greater than the total amount of liabilities, including, without limitation, contingent liabilities, of such person, (B) the present fair salable value of the
assets of such person is not less than the amount that will be required to pay the probable liability of such person on its debts as they become absolute and matured, (C) such person does not intend to, and does not believe that it will, incur
debts and liabilities beyond such person’s ability to pay as such debts and liabilities mature, (D) such person is not engaged in a business or a transaction, and is not about to engage in a business or a transaction, for which such
person’s property would constitute an unreasonably small capital and (E) such person is able to pay its debts as they become due and payable. 
 The Issuers understand that the Initial Purchasers and, for purposes of the opinions to be delivered to the Initial Purchasers pursuant to Section 5 hereof, counsel to the Issuers and counsel to the
Initial Purchasers will rely upon the accuracy and truth of the foregoing representations, and each Issuer hereby consents to such reliance. 
 Any certificate signed by any officer of the Company or any of its subsidiaries and delivered to the Representatives or to counsel for the Initial Purchasers shall be deemed a representation and warranty
by the Company to each Initial Purchaser as to the matters covered thereby. 
 (ii) Each Initial Purchaser represents that it is
a QIB and acknowledges that it is purchasing the Securities pursuant to a private sale exemption from registration under the Securities Act, and that the Securities have not been registered under the Securities Act and may not be offered or sold
within the United States or to, or for the account or benefit of, U.S. persons except pursuant to an exemption from the registration requirements of the Securities Act. Each Initial Purchaser, severally and not jointly, represents, warrants and
covenants to the Issuers that: 
 (a) Neither it, nor any person acting on its behalf, has solicited or will solicit offers for,
or has offered or sold or will offer or sell, the Securities by any form of general solicitation or general advertising (as those terms are used in Regulation D under the Securities Act) or in any manner involving a public offering within the
meaning of Section 4(a)(2) of the Securities Act, and it has solicited and will solicit offers for the Securities only from, and will offer and sell the Securities only to, (1) persons whom such Initial Purchaser reasonably believes to be
QIBs or, if any such person is buying for one or more institutional accounts for which such person is acting as fiduciary or agent, only when such person has 

  
 -14-

 
represented to such Initial Purchaser that each such account is a QIB to whom notice has been given that such sale or delivery is being made in reliance on Rule 144A, and, in each case, in
reliance on the exemption from the registration requirements of the Securities Act pursuant to Rule 144A, or (2) persons who are not U.S. persons and who are outside the United States in reliance on, and in compliance with, the exemption from
the registration requirements of the Securities Act provided by Regulation S. 
 (b) With respect to offers and sales outside
the United States, such Initial Purchaser has offered the Securities and will offer and sell the Securities (1) as part of its distribution at any time and (2) otherwise until 40 days after the later of the commencement of the offering of
the Securities and the Closing Date, only in accordance with Rule 903 of Regulation S or another exemption from the registration requirements of the Securities Act. Accordingly, neither such Initial Purchasers nor any person acting on their behalf
has engaged or will engage in any directed selling efforts (within the meaning of Regulation S) with respect to the Securities, and any such persons have complied and will comply with the offering restrictions requirements of Regulation S. Terms
used in this Section l(ii)(b) have the meanings given to them by Regulation S. 
 (c) Each Initial Purchaser severally agrees
that, at or prior to confirmation of a sale of Securities pursuant to Regulation S it will have sent to each distributor, dealer or person receiving a selling concession, fee or other remuneration that purchases Securities from it or through it
during the restricted period a confirmation or notice to substantially the following effect: 
 “The
Securities covered hereby have not been registered under the United States Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States or to or for the account or benefit of, U.S.
persons (i) as part of their distribution at any time and (ii) otherwise until forty days after the later of the date upon which the offering of the Securities commenced and the date of closing, except in either case in accordance with
Regulation S or Rule 144A under the Securities Act. Terms used above have the meanings given to them by Regulation S.” 

The Initial Purchasers understand that the Issuers and, for purposes of the opinions to be delivered to the Initial Purchasers pursuant
to Section 5 hereof, counsel to the Issuers and counsel to the Initial Purchasers will rely upon the accuracy and truth of the foregoing representations, and each Initial Purchaser hereby consents to such reliance. 

Section 2 Purchase, Sale and Delivery of the Securities. 

(a) Agreements to Sell and Purchase the Securities. On the basis of the representations, warranties and covenants contained in
this Agreement, the Issuers agree to issue and sell to the several Initial Purchasers, and on the basis of the representations, warranties and covenants herein contained, and upon the terms but subject to the conditions herein set forth, the Initial
Purchasers agree, severally and not jointly, to purchase from the Issuers the respective number of Securities set forth opposite their names on Schedule A. The purchase price for the Original Notes shall be 98.500% of their aggregate
principal amount. 
 (b) Delivery and Payment. Delivery of the Securities to be purchased by the Initial Purchasers and
payment therefor shall be made at the offices of White & Case LLP, 1155 Avenue of the Americas, New York, New York (or such other place as may be agreed to by the Company and the Representatives) at 10:00 a.m. New York time, on
December 11, 2012, or such other time and date not later than 1:30 p.m. New York time on December 31, 2012 as the Representatives shall designate by notice to the Company (the time and date of such closing are called the “Closing
Date”). 

  
 -15-

 (c) Payment for the Securities. Payment for the Securities to be sold by the Issuers
shall be made at the Closing Date by wire transfer of immediately available funds to the order of the Company. 
 It is
understood that the Representatives have been authorized, for their own accounts and the accounts of the several Initial Purchasers, to accept delivery of and receipt for, and make payment of the purchase price for, the Securities. Jefferies, GS and
CS individually and not as a Representative of the Initial Purchasers, may (but shall not be obligated to) make payment for any Securities to be purchased by any Initial Purchaser whose funds shall not have been received by the Representatives by
the Closing Date for the account of such Initial Purchaser, but any such payment shall not relieve such Initial Purchaser from any of its obligations under this Agreement. 
 (d) Delivery of the Securities. The Securities shall be delivered by the Issuers to the Initial Purchasers (or as the Initial Purchasers direct) through the facilities of The Depository Trust
Company against payment by the Initial Purchasers of the purchase price therefor. The Securities shall be evidenced by one or more certificates in global form registered in such names as the Initial Purchasers may request upon at least one business
day’s notice prior to the Closing Date and having an aggregate principal amount corresponding to the aggregate principal amount of the Securities. 
 Section 3 Additional Covenants of the Issuers. The Issuers jointly and severally further covenant and agree with each Initial Purchaser as follows: 

(a) Delivery of the Preliminary Offering Memorandum, Pricing Supplement, any Issuer Written Communication and Final Offering
Memorandum. The Issuers shall furnish the Initial Purchasers and those persons identified by the Initial Purchasers, without charge, with as many copies of the Preliminary Offering Memorandum, Pricing Supplement, any Issuer Written Communication
and the Final Offering Memorandum, and any amendments or supplements thereto, as the Initial Purchasers may reasonably request. The Issuers consent to the use, in accordance with the provisions of the Securities Act and securities or “blue
sky” laws of the jurisdictions in which the Original Notes are offered, of the Preliminary Offering Memorandum, Pricing Supplement and the Final Offering Memorandum, and any amendments and supplements thereto required pursuant to this
Agreement, by the Initial Purchasers in connection with Exempt Resales. 
 (b) Representatives’ Review of Proposed
Amendments and Supplements. As promptly as practicable following the execution and delivery of this Agreement and in any event not later than the second business day following the date hereof, the Issuers shall prepare and deliver to the Initial
Purchasers the Final Offering Memorandum, which shall consist of the Preliminary Offering Memorandum as modified only to reflect the information contained in the Pricing Supplement. Prior to amending or supplementing the Preliminary Offering
Memorandum, the Pricing Supplement or the Final Offering Memorandum (including any amendment or supplement through incorporation by reference of any report filed under the Exchange Act), the Issuers shall furnish to the Representatives for review, a
reasonable amount of time prior to the proposed time of use thereof, a copy of each such proposed amendment or supplement, and the Issuers shall not use any such proposed amendment or supplement without the Representatives’ consent. 

(c) Amendments to the Final Offering Memorandum. From the date hereof and until the later of the Closing Date and the date that
the Initial Purchasers have completed their distribution of 

  
 -16-

 
the Securities (but in no event after the consummation of the Exchange Offer), if any event shall occur that, in the judgment of the Issuers or in the judgment of counsel to the Initial
Purchasers, makes any statement of a material fact in the Final Offering Memorandum, as then amended or supplemented, untrue or that requires the making of any additions to or changes in the Final Offering Memorandum in order to make the statements
in the Final Offering Memorandum, as then amended or supplemented, in the light of the circumstances under which they are made, not misleading, or if it is necessary to amend or supplement the Final Offering Memorandum to comply with all applicable
laws, the Issuer shall promptly notify the Initial Purchasers of such event and (subject to Section 3(b)) prepare an appropriate amendment or supplement to the Final Offering Memorandum so that (i) the statements in the Final Offering
Memorandum, as amended or supplemented, will, in the light of the circumstances at the time that the Final Offering Memorandum is delivered to prospective Eligible Purchasers, not be misleading and (ii) the Final Offering Memorandum will comply
with all applicable laws. 
 (d) Pricing Supplement. The Issuers will prepare for use by the Initial Purchasers a Pricing
Supplement in the form of Exhibit B hereto reflecting the final terms of the Securities (and containing such other information as the Issuers shall deem necessary in order that the Pricing Disclosure Package shall not contain an untrue
statement of a material fact or omit to state a material fact necessary to make the statements in the Pricing Disclosure Package, in the light of the circumstances under which they were made, not misleading), in form and substance reasonably
satisfactory to the Representatives. The Pricing Supplement shall constitute an Issuer Written Communication. The Issuers shall provide the Representatives with copies of the Pricing Supplement a reasonable amount of time prior to such proposed use
and will not use any Pricing Supplement to which the Representatives or counsel to the Initial Purchasers shall reasonably object. 
 (e) Securities Act Compliance. After the date of this Agreement, through the time the Exchange Offer is consummated, the Issuers shall promptly advise the Representatives in writing of the receipt
of any comments of, or requests for additional or supplemental information from, the Commission, with respect to any registration statement or report filed by such Issuers with the Commission. 

(f) Notification upon Suspension. The Issuers shall advise the Initial Purchasers promptly and, if requested by the Initial
Purchasers, to confirm such advice in writing, of the issuance by any securities commission of any stop order suspending the qualification or exemption from qualification of any of the Original Notes for offering or sale in any jurisdiction, or the
initiation of any proceeding for such purpose by any securities commission or other regulatory authority. The Issuers shall use their commercially reasonable efforts to prevent the issuance of any stop order or order suspending the qualification or
exemption from qualification of any of the Original Notes under any securities laws, and if at any time any securities commission or other regulatory authority shall issue an order suspending the qualification or exemption from qualification of any
of the Original Notes under any securities laws, the Issuers shall use their commercially reasonable efforts to obtain the withdrawal or lifting of such order at the earliest possible time. 

(g) Use of Proceeds. The Company shall apply the net proceeds from the sale of the Original Notes sold by it in the manner
described under the caption “Use of Proceeds” in the Preliminary Offering Memorandum and the Final Offering Memorandum. 
 (h) Trustee. The Issuers shall engage and maintain, at the Company’s expense, a trustee for the Securities. 

  
 -17-

 (i) Investment Limitation. The Company shall not invest, or otherwise use the
proceeds received by the Company from its sale of the Securities in such a manner as would require the Issuers or any of their subsidiaries to register as an investment company under the Investment Company Act. 

(j) No Stabilization or Manipulation; Compliance with Regulation M. The Issuers will not take, directly or indirectly, any action
designed to or that might be reasonably expected to cause or result in stabilization or manipulation of the price of the Securities or any other reference security, whether to facilitate the sale or resale of the Securities or otherwise, and the
Issuers will, and shall cause each of their affiliates to, comply with all applicable provisions of Regulation M. If the limitations of Rule 102 of Regulation M (“Rule 102”) do not apply with respect to the Securities or any other
reference security pursuant to any exception set forth in section (d) of Rule 102, then promptly upon notice from the Representatives (or, if later, at the time stated in the notice), the Issuers will, and shall cause each of their affiliates
to, comply with Rule 102 as though such exception were not available but the other provisions of Rule 102 (as interpreted by the Commission) did apply. 
 (k) Conditions Precedent. The Issuers will do and perform all things required to be done and performed under this Agreement by them prior to the Closing Date in order to satisfy all conditions
precedent on their part to the delivery of the Securities. 
 (l) DTC Book-Entry. The Issuers will comply with their
obligations under the letter of representations to DTC relating to the approval of the Securities by DTC for “book-entry” transfer and to use their best efforts to obtain approval of the Securities by DTC for “book-entry”
transfer. 
 (m) Financial Statements. Prior to the Closing Date, the Company will furnish without charge to the Initial
Purchasers, (i) as soon as they have been prepared by the Company, a copy of any regularly prepared internal financial statements of the Company and the Subsidiaries for any period subsequent to the period covered by the financial statements
appearing in the Pricing Disclosure Package and the Final Offering Memorandum, (ii) all other reports and other communications (financial or otherwise) that the Company mails or otherwise makes available to its security holders and
(iii) such other information as the Initial Purchasers shall reasonably request. 
 (n) No Integration. The Issuers
will not, and will not permit any of their subsidiaries to, sell, offer for sale or solicit offers to buy any security (as defined in the Securities Act) that would be integrated with the sale of the Securities in a manner that would require the
registration under the Securities Act of the sale of the Securities to the Initial Purchasers or any Eligible Purchasers. 
 (o)
No Resales. The Issuers will not, and will not permit any of their subsidiaries to, and will use their commercially reasonable efforts to cause their other affiliates (as defined in Rule 144 under the Securities Act) not to, resell any of the
Securities that have been reacquired by any of them. 
 (p) No General Solicitation. The Issuers will not engage, and
will not allow any of their subsidiaries to engage, and will use their commercially reasonable efforts to cause their other affiliates and any person acting on their behalf (other than, in any case, the Initial Purchasers and any of their
affiliates, as to whom the Issuers make no covenant) not to engage, in any form of general solicitation or general advertising (within the meaning of Regulation D under the Securities Act) in connection with any offer or sale of the Securities in
the United States prior to the effectiveness of a registration statement with respect to the Exchange Notes. 

  
 -18-

 (q) No Directed Selling Efforts. The Issuers will not engage, and will not allow any
of their subsidiaries to engage, and will use their commercially reasonable efforts to cause their other affiliates and any person acting on their behalf (other than, in any case, the Initial Purchasers and any of their affiliates, as to whom the
Issuers make no covenant) not to engage, in any directed selling effort with respect to the Securities, and to comply with the offering restrictions requirement of Regulation S under the Securities Act. Terms used in this paragraph have the meanings
given to them by Regulation S. 
 (r) Compliance with Regulation S. The Issuers will not register any transfer of the
Securities not made in accordance with the provisions of Regulation S (unless otherwise in compliance with the Securities Act) and not, except in accordance with the provisions of Regulation S, if applicable, issue any such Securities in the form of
definitive securities in connection with the Securities offered and sold in an offshore transaction (as defined in Regulation S). 
 (s) Rule 144A Disclosure. From and after the Closing Date, for so long as any of the Original Notes remain outstanding and are “restricted securities” within the meaning of Rule 144(a)(3)
under the Securities Act and during any period in which the Issuer is not subject to Section 13 or 15(d) of the Exchange Act, the Issuers will make available upon request the information required by Rule 144A(d)(4) under the Securities Act to
(i) any holder or beneficial owner of Notes in connection with any sale of such Notes and (ii) any prospective purchaser of such Notes from any such holder or beneficial owner designated by the holder or beneficial owner. The Issuers will
pay the expenses of preparing, printing and distributing such documents. 
 (t) Compliance with Registration Rights
Agreement. The Issuers will comply with all of their agreements set forth in the Registration Rights Agreement. 
 (u) No
Distribution of Offering Materials. The Issuers will not, and will use their commercially reasonable efforts to cause their affiliates or anyone acting on their or their affiliates’ behalf (other than the Initial Purchasers and their
affiliates, as to whom the Issuers make no covenant) not to, distribute prior to the Closing Date any offering material in connection with the offer and sale of the Securities other than the Preliminary Offering Memorandum, the Pricing Supplement
and the Final Offering Memorandum. Before communicating any Issuer Written Communication to any person other than the Initial Purchasers and their counsel, the Company will furnish to the Representatives and counsel for the Initial Purchasers a copy
of such written communication for review and will not communicate to any such third party any such written communication to which the Representative reasonably objects. 
 (v) No Registration under the Investment Company Act. During the period of one year after the Closing Date or, if earlier, until such time as the Securities are no longer restricted securities (as
defined in Rule 144 under the Securities Act), the Issuers will not be or become a closed-end investment company required to be registered, but not registered, under the Investment Company Act of 1940, as amended. 

(w) No Manipulation. In connection with the offering of the Original Notes, until the Representatives shall have notified the
Issuers of the completion of the distribution of the Original Notes, the Issuers will not, and will use their commercially reasonable efforts to cause their affiliates (as such term is defined in Rule 501(b) of Regulation D under the Securities Act)
not to, either alone or with one or more other persons, bid for or purchase for any account in which they or any of their affiliates have a beneficial interest, and none of the Issuers will, and the Issuers shall use their commercially reasonable
efforts to cause their affiliates not to, make bids or purchases for the purpose of creating actual or apparent active trading in, or raising the price of, the Original Notes. 

  
 -19-

 The Representatives, on behalf of the Initial Purchasers, may, in their sole discretion,
waive in writing the performance by the Company of any one or more of the foregoing covenants or extend the time for their performance. 
 Section 4 Payment of Expenses. The Issuers agree to pay all costs, fees and expenses incurred in connection with the performance of their obligations hereunder and in connection with the
transactions contemplated hereby, including without limitation (i) all expenses incident to the issuance and delivery of the Securities (including all printing and engraving costs), (ii) all fees and expenses of the Trustee, including fees
and expenses of counsel for the Trustee, (iii) all necessary issue, transfer and other stamp taxes in connection with the issuance and sale of the Securities to the Initial Purchasers, (iv) all fees and expenses of the Company’s
counsel, independent public or certified public accountants and other advisors, (v) all costs and expenses incurred in connection with the preparation, printing, shipping and distribution of the Preliminary Offering Memorandum, the Pricing
Supplement, the Final Offering Memorandum, the Registration Rights Agreement, any Issuer Written Communication prepared by or on behalf of, used by, or referred to by the Company, and any amendments and supplements thereto, and this Agreement,
(vi) upon receipt of such evidentiary documentation as the Company shall reasonably request, reasonable attorneys’ fees and expenses incurred by the Company or the Initial Purchasers in connection with qualifying or registering (or
obtaining exemptions from the qualification or registration of) all or any part of the Securities for offer and sale under the state securities or blue sky laws or the provincial securities laws of Canada, and, if requested by the Representatives,
preparing and printing a “Blue Sky Survey” or memorandum and a Canadian wrapper and any supplements thereto, advising the Initial Purchasers of such qualifications, registrations and exemptions, which fees and expenses shall not exceed
$20,000, (vii) the filing fees incident to, and the reasonable fees and expenses of counsel for the Initial Purchasers in connection with, the FINRA’s review, if any, and approval of the Initial Purchasers’ participation in the
offering and distribution of the Securities, (viii) 50% of the costs and expenses of the Company relating to investor presentations on any “road show” undertaken in connection with the marketing of the offering of the Securities,
including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in
connection with the road show presentations with the prior approval of the Company, travel and lodging expenses of the representatives, employees and officers of the Company and of the Representatives and any such consultants, and the cost of any
aircraft chartered in connection with the road show, (ix) the inclusion of the Securities in the book-entry system of The Depository Trust Company, (x) the rating of the Securities by rating agencies and (xi) the performance by the
Company of its other obligations under the Note Documents. Upon the consummation of the Transactions contemplated hereby to be consummated on or by the Closing Date, the Initial Purchasers shall pay to the Company either by wire transfer of
immediately available funds, by direct payment to vendors or by credit against other monies owed to the Initial Purchasers, such method to be selected by the Initial Purchasers in their sole discretion, an amount equal to the expenses described in
Section 4(viii). Except as provided in this Section 4, Section 6, Section 7 and Section 8 hereof, the Initial Purchasers shall pay their own expenses, including the fees and disbursements of their counsel. 

  
 -20-

 Section 5 Conditions of the Obligations of the Initial Purchasers. The
obligations of the several Initial Purchasers to purchase and pay for the Securities as provided herein on the Closing Date shall be subject to the accuracy of the representations and warranties on the part of the Issuers set forth in
Section 1(i) hereof as of the date hereof and as of the Closing Date as though then made, to the timely performance by the Issuers of their covenants and other obligations hereunder, and to each of the following additional conditions:

 (a) Accountants’ Comfort Letter. 

(i) Prior to the Applicable Time, the Representatives shall have received from BDO USA, LLP, former independent public or
certified public accountants for the Company, a letter dated the date hereof addressed to the Initial Purchasers, in form and substance satisfactory to the Representatives (i) containing statements and information of the type ordinarily
included in accountants’ “comfort letters” to initial purchasers, delivered according to Statement of Auditing Standards No. 72 (or any successor bulletin), with respect to the audited and unaudited financial statements of the
Company as of dates and for periods ended on or before March 31, 2010 and certain financial information of the Company contained in the Pricing Disclosure Package as of such dates and for such periods or as otherwise agreed (and the
Representatives shall have received an additional five conformed copies of such accountants’ letter for each of the several Initial Purchasers), and (ii) confirming that they are (A) independent public or certified public accountants
with respect to the Company as required by the Securities Act and the Exchange Act and (B) in compliance with the applicable requirements relating to the qualification of accountants under Rule 2-01 of Regulation S-X. 

(ii) Prior to the Applicable Time, the Representatives shall have received from PricewaterhouseCoopers LLP, independent
public or certified public accountants for the Company, a letter dated the date hereof addressed to the Initial Purchasers, in form and substance satisfactory to the Representatives (i) containing statements and information of the type
ordinarily included in accountants’ “comfort letters” to initial purchasers, delivered according to Statement of Auditing Standards No. 72 (or any successor bulletin), with respect to the unaudited financial statements of the
Company as of dates and for periods after March 31, 2010 and certain financial information of the Company contained in the Pricing Disclosure Package as of such dates and for such periods (and the Representatives shall have received an
additional five conformed copies of such accountants’ letter for each of the several Initial Purchasers), and (ii) confirming that they are (A) independent public or certified public accountants with respect to the Company as required
by the Securities Act and the Exchange Act and (B) in compliance with the applicable requirements relating to the qualification of accountants under Rule 2-01 of Regulation S-X. 

(b) No Material Adverse Change or Ratings Agency Change. For the period from and after the date of this Agreement through and
including the Closing Date: 
 (i) in the judgment of the Representatives there shall not have occurred any
Material Adverse Change; and 
 (ii) there shall not have occurred any downgrading, nor shall any notice have
been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any
“nationally recognized statistical rating organization” as such term is defined for purposes of Rule 436(g)(2) under the Securities Act. 
 (c) Opinion of Counsel for the Company. On the Closing Date the Representatives shall have received the opinion of Foley Hoag LLP, counsel for the Company, substantially in the form attached hereto
as Exhibit A, dated as of such Closing Date, in form and substance satisfactory to the Representatives and counsel to the Initial Purchasers (and the Representatives shall have received an additional five signed copies of such counsel’s
legal opinion for each of the several Initial Purchasers). 

  
 -21-

 
On the Closing Date the Representatives shall have received the opinion of local counsel in the jurisdiction of organization of each Issuer not organized under the laws of Massachusetts, Delaware
or New York, dated as of such Closing Date, in form and substance satisfactory to the Representatives and counsel to the Initial Purchasers (and the Representatives shall have received an additional five signed copies of each such counsel’s
legal opinion for each of the several Initial Purchasers). 
 (d) Opinion of Counsel for the Initial Purchasers. On the
Closing Date, the Representatives shall have received the opinion of White & Case LLP, counsel for the Initial Purchasers, in form and substance satisfactory to the Initial Purchasers, dated as of such Closing Date. 

(e) Officers’ Certificate. On the Closing Date, the Representatives shall have received a written certificate executed by the
Chief Executive Officer or President of the Company and the Chief Financial Officer of the Company, dated as of the Closing Date, to the effect set forth in subsection (b)(ii) of this Section 5, and further to the effect that: 

(i) for the period from and including the date of this Agreement and through and including the Closing Date, there has not
occurred any Material Adverse Change; 
 (ii) the representations, warranties and covenants of the Issuers set
forth in Section 1(i) of this Agreement are true and correct with the same force and effect as though expressly made on and as of the Closing Date; 
 (iii) (A) at October 31, 2012, there was no change in the capital stock, increase in long term debt, or decrease in consolidated net current assets or stockholders’ equity of the Company and its
subsidiaries on a consolidated basis as compared with amounts shown in the September 30, 2012 unaudited condensed consolidated balance sheet incorporated by reference in the Pricing Disclosure Package, or (B) for the period from
October 1, 2012 to October 31, 2012, there were no decreases, as compared to the corresponding period in the preceding year, in consolidated net sales, except in all instances under the foregoing clauses (A) and (B) for changes,
increases, or decreases that the Pricing Disclosure Package disclosed have occurred or may occur; and 
 (iv) the
Issuers have complied with all the agreements hereunder and satisfied all the conditions on their part to be performed or satisfied hereunder at or prior to the Closing Date. 
 (f) Bring-down Comfort Letters. On the Closing Date, the Representatives shall have received from each of (i) BDO USA, LLP, former independent public or certified public accountants for the
Company and (ii) PricewaterhouseCoopers LLP, independent public or certified public accountants for the Company, a letter dated such date, in form and substance satisfactory to the Representatives, to the effect that they reaffirm the
statements made in the letter furnished by them pursuant to subsection (a) of this Section 5 but related to the Final Offering Memorandum, except that the specified date referred to therein for the carrying out of procedures shall be no
more than three business days prior to the Closing Date (and the Representatives shall have received an additional five conformed copies of such accountants’ letter for each of the several Initial Purchasers). 

(g) Additional Documents. The Issuers and the Trustee shall have executed and delivered the Indenture and the Securities and the
Initial Purchasers shall have received copies thereof. The Issuers shall have executed and delivered the Registration Rights Agreement and the Initial Purchasers shall have received copies thereof. On or before the Closing Date, the Representatives
and 

  
 -22-

 
counsel for the Initial Purchasers shall have received such information, documents and opinions as they may reasonably request for the purposes of enabling them to pass upon the issuance and sale
of the Securities as contemplated herein, or the satisfaction of any of the conditions or agreements herein contained; and all proceedings taken by the Issuers in connection with the issuance and sale of the Securities as contemplated herein and in
connection with the other transactions contemplated by this Agreement shall be reasonably satisfactory in form and substance to the Representatives and counsel for the Initial Purchasers. 

If any condition specified in this Section 5 is not satisfied when and as required to be satisfied, this Agreement may be terminated
by the Representatives by notice to the Company at any time on or prior to the Closing Date, which termination shall be without liability on the part of any party to any other party, except that Section 4, Section 6, Section 7 and
Section 8 shall at all times be effective and shall survive such termination. 
 Section 6 Reimbursement of Initial
Purchasers’ Expenses. If this Agreement is terminated by the Representatives pursuant to Section 5 or Section 10, or if the sale to the Initial Purchasers of the Securities on the Closing Date is not consummated because of any
refusal, inability or failure on the part of the Company to perform any agreement herein or to comply with any provision hereof, the Company agrees to reimburse the Representatives and the other Initial Purchasers (or such Initial Purchasers as have
terminated this Agreement with respect to themselves), severally, upon demand for all out-of-pocket expenses that shall have been reasonably incurred by the Representatives and the Initial Purchasers in connection with the proposed purchase and the
offering and sale of the Securities, including but not limited to fees and disbursements of counsel, printing expenses, travel expenses, postage, facsimile and telephone charges. 

Section 7 Indemnification. 
 (a) Indemnification of the Initial Purchasers. The Issuers jointly and severally agree to indemnify and hold harmless each Initial Purchaser, its officers and employees, and each person, if any,
who controls any Initial Purchaser within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or expense, as incurred, to which such Initial Purchaser or such officer, employee or controlling person may
become subject, under the Securities Act, the Exchange Act, other federal or state statutory law or regulation, or at common law or otherwise (including in settlement of any litigation), insofar as such loss, claim, damage, liability or expense (or
actions in respect thereof as contemplated below) arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in the Pricing Disclosure Package, any Road Show (as defined below), any Issuer
Written Communication that the Issuers have used or referred to or the Final Offering Memorandum (or any amendment or supplement thereto), or the omission or alleged omission therefrom of a material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading; or (ii) any act or failure to act or any alleged act or failure to act by any Initial Purchaser in connection with, or relating in any manner to, the
Securities or the offering contemplated hereby, and which is included as part of or referred to in any loss, claim, damage, liability or action arising out of or based upon any matter covered by clause (i) above, provided that the Issuers shall
not be liable under this clause (ii) to any Initial Purchaser, to the extent that a court of competent jurisdiction shall have determined by a final judgment that such loss, claim, damage, liability or action resulted directly from any such
acts or failures to act undertaken or omitted to be taken by such Initial Purchaser through its bad faith or willful misconduct and to reimburse each Initial Purchaser and each such officer, employee and controlling person for any and all expenses
(including the fees and disbursements of counsel chosen by the Representatives) as such expenses are reasonably incurred by such Initial Purchaser or such officer, employee or controlling person in connection with investigating,

  
 -23-

 
defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action; provided, however, that the foregoing indemnity agreement shall not apply to any loss,
claim, damage, liability or expense to the extent, but only to the extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with written information
furnished to the Issuers by the Representatives expressly for use in the Pricing Disclosure Package, any Issuer Written Communication (including, but not limited to, any Road Show) or the Final Offering Memorandum (or any amendment or supplement
thereto), it being understood and agreed that the only such information furnished by the Representatives to the Issuers consists of the information described in subsection (b) below. The indemnity agreement set forth in this Section 7(a)
shall be in addition to any liabilities that the Issuers may otherwise have. “Road Show” means each “road show” (as defined in Rule 433 under the Securities Act), if any, related to the offering of the Securities
contemplated hereby that is a “written communication” (as defined in Rule 405 under the Securities Act) as if this offering were a registered offering. 
 (b) Indemnification of the Issuers and their Directors and Officers. Each Initial Purchaser agrees, severally and not jointly, to indemnify and hold harmless the Issuers, each of their directors
(as defined in Rule 405 under the Securities Act), each of their officers (as defined in Rule 405 under the Securities Act) and each person, if any, who controls any Issuer within the meaning of the Securities Act or the Exchange Act, against any
loss, claim, damage, liability or expense, as incurred, to which any Issuer, or any such director, officer, manager, member, partner, other person having similar positions or controlling person may become subject, under the Securities Act, the
Exchange Act, or other federal or state statutory law or regulation, or at common law or otherwise (including in settlement of any litigation), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated
below) arises out of or is based upon any untrue statement or alleged untrue statement of a material fact contained in the Pricing Disclosure Package, any Issuer Written Communication (including, but not limited to, any Road Show) that the Issuers
have used or referred to or the Final Offering Memorandum (or any amendment or supplement thereto), or arises out of or is based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to
make the statements therein (in the case of the Pricing Disclosure Package, any such Issuer Written Communication, or the Final Offering Memorandum, in the light of the circumstances under which they were made) not misleading, in each case to the
extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in the Pricing Disclosure Package, such Issuer Written Communication that the Issuers have used or referred to, or the
Final Offering Memorandum (or such amendment or supplement thereto), in reliance upon and in conformity with written information furnished to the Issuers by the Representatives expressly for use therein; and to reimburse the Issuers, or any such
director, officer, manager, member, partner, other person having similar positions or controlling person for any and all expenses (including the fees and disbursements of counsel chosen by them) as such expenses are reasonably incurred by any
Issuer, or any such director, officer, manager, member, partner, other person having similar positions or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability,
expense or action. The Issuers hereby acknowledge that the only information that the Representatives and the Initial Purchasers have furnished to the Issuers expressly for use in the Pricing Disclosure Package, any Issuer Written Communication
(including, but not limited to, any Road Show) or the Final Offering Memorandum (or any amendment or supplement thereto) are the statements set forth in the first sentence of the fourth paragraph, the first sentence of the sixth paragraph, the fifth
sentence of the seventh paragraph, the first sentence of the eighth paragraph, the fourth sentence of the ninth paragraph, the twelfth paragraph and the first sentence of the thirteenth paragraph under the caption “Plan of Distribution” in
the Pricing Disclosure Package and the Final Offering Memorandum. The indemnity agreement set forth in this Section 7(b) shall be in addition to any liabilities that each Initial Purchaser may otherwise have. 

  
 -24-

 (c) Notifications and Other Indemnification Procedures. Promptly after receipt by an
indemnified party under Section 7(a) or (b) of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under Section 7(a) or (b), notify the
indemnifying party in writing of the commencement thereof, but the omission so to notify the indemnifying party will not relieve the indemnifying party from any liability which it may have to any indemnified party for contribution under
Section 8 below or otherwise under the indemnity agreement contained in Section 7(a) or (b), except to the extent such indemnifying party is materially prejudiced as a proximate result of such failure. In case any such action is brought
against any indemnified party and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and, to the extent that it shall elect, jointly with all other
indemnifying parties similarly notified, by written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume the defense thereof with counsel reasonably satisfactory to such
indemnified party; provided, however, if the defendants in any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that a conflict may arise between the positions of the
indemnifying party and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it and/or other indemnified parties which are different from or additional to those available to the
indemnifying party, the indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise participate in the defense of such action on behalf of such indemnified party or parties. Upon
receipt of notice from the indemnifying party to such indemnified party of such indemnifying party’s election so to assume the defense of such action and approval by the indemnified party of counsel (which shall not be unreasonably withheld,
delayed or conditioned), the indemnifying party or parties will not be liable to such indemnified party under Section 7(a) or (b) for any legal or other expenses subsequently incurred by such indemnified party in connection with the
defense thereof unless (i) the indemnified party shall have employed separate counsel in accordance with the proviso to the preceding sentence (it being understood, however, that the indemnifying party shall not be liable for the fees and
expenses of more than one separate firm of attorneys (together with local counsel), representing the indemnified parties who are parties to such action), which counsel (together with any local counsel) for the indemnified parties shall be selected
by the Representatives (in the case of counsel for the indemnified parties referred to in Section 7(a) above) or by the Company (in the case of counsel for the indemnified parties referred to in Section 7(b) above)), (ii) the
indemnifying party shall not have employed counsel reasonably satisfactory to the indemnified party to represent the indemnified party within a reasonable time after notice of commencement of the action or (iii) the indemnifying party
authorizes the indemnified party to employ separate counsel at the indemnifying party’s expense, in each of which cases the reasonable fees and expenses of counsel shall be at the expense of the indemnifying party and shall be paid as they are
incurred. 
 (d) Settlements. The indemnifying party under this Section 7 shall not be liable for any settlement of
any proceeding effected without its written consent (such consent not to be unreasonably withheld, delayed or conditioned), but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to
indemnify the indemnified party against any loss, claim, damage, liability or expense (to the extent provided in this Section 7) by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an indemnified
party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated by Section 7(c) hereof, the indemnifying party agrees that it shall be liable (to the extent provided in this
Section 7) for any settlement of any proceeding effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by such indemnifying party of the aforesaid request (including documentation of
such fees and expenses reasonably satisfactory to the indemnifying party) and (ii) such indemnifying party shall not have reimbursed the indemnified party in accordance with such request (to the extent required by this Section 7) prior to
the date of such settlement. No 

  
 -25-

 
indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened action,
suit or proceeding in respect of which any indemnified party is or could have been a party and indemnity was or could have been sought hereunder by such indemnified party, unless such settlement, compromise or consent includes an unconditional
release of such indemnified party from all liability on claims that are the subject matter of such action, suit or proceeding and does not include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of any
indemnified party. 
 Section 8 Contribution. If the indemnification provided for in Section 7 is for any
reason held to be unavailable to or otherwise insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each indemnifying party shall contribute to the aggregate
amount paid or payable by such indemnified party, as incurred, as a result of any losses, claims, damages, liabilities or expenses referred to therein (i) in such proportion as is appropriate to reflect the relative benefits received by the
Issuers, on the one hand, and the Initial Purchasers, on the other hand, from the offering of the Securities pursuant to this Agreement or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such
proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the Issuers, on the one hand, and the Initial Purchasers, on the other hand, in connection with the statements
or omissions which resulted in such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative benefits received by the Issuers, on the one hand, and the Initial Purchasers, on the other
hand, in connection with the offering of the Securities pursuant to this Agreement shall be deemed to be in the same respective proportions as the total net proceeds from the offering of the Securities pursuant to this Agreement (before deducting
expenses) received by the Issuers, and the total initial purchasers’ discounts and commissions received by the Initial Purchasers hereunder. The relative fault of the Issuers, on the one hand, and the Initial Purchasers, on the other hand,
shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Issuers, on the one hand,
or the Initial Purchasers, on the other hand, and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. 

The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be
deemed to include, subject to the limitations set forth in Section 7(c), any legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending any action or claim. The provisions set forth in
Section 7(c) with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this Section 8; provided, however, that no additional notice shall be required with respect to any action for
which notice has been given under Section 7(c) for purposes of indemnification. 
 The Issuers and the Initial Purchasers
agree that it would not be just and equitable if contribution pursuant to this Section 8 were determined by pro rata allocation (even if the Initial Purchasers were treated as one entity for such purpose) or by any other method of allocation
which does not take account of the equitable considerations referred to in this Section 8. 
 Notwithstanding the
provisions of this Section 8, no Initial Purchaser shall be required to contribute any amount in excess of the initial purchasers’ discounts and commissions received by such Initial Purchaser in connection with the Securities purchased by
it. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Initial
Purchasers’ obligations to contribute pursuant to this Section 8 are several, and not joint, in proportion to 

  
 -26-

 
their respective purchase commitments as set forth opposite their respective names on Schedule A. For purposes of this Section 8, each officer and employee of an Initial Purchaser and
each person, if any, who controls an Initial Purchaser within the meaning of the Securities Act or the Exchange Act shall have the same rights to contribution as such Initial Purchaser, and each director of the Issuers, each officer of the Issuers,
and each person, if any, who controls the Issuers with the meaning of the Securities Act and the Exchange Act shall have the same rights to contribution as the Issuers. 
 Section 9 Default of One or More of the Several Initial Purchasers. If, on the Closing Date, any one or more of the several Initial Purchasers shall fail or refuse to purchase Securities that
it or they have agreed to purchase hereunder on such date, and the aggregate principal amount of Securities which such defaulting Initial Purchaser or Initial Purchasers agreed but failed or refused to purchase does not exceed 10% of the aggregate
principal amount of the Securities to be purchased on such date, the Representatives may make arrangements satisfactory to the Issuers for the purchase of such Securities by other persons, including any of the Initial Purchasers, but if no such
arrangements are made by the Closing Date, the other Initial Purchasers shall be obligated, severally and not jointly, in the proportions that the principal amount of Securities set forth opposite their respective names on Schedule A bears to
the aggregate principal amount of Securities set forth opposite the names of all such non-defaulting Initial Purchasers, or in such other proportions as may be specified by the Representatives with the consent of the non-defaulting Initial
Purchasers, to purchase the Securities which such defaulting Initial Purchaser or Initial Purchasers agreed but failed or refused to purchase on such date. If, on the Closing Date, any one or more of the Initial Purchasers shall fail or refuse to
purchase Securities and the aggregate principal amount of Securities with respect to which such default occurs exceeds 10% of the aggregate principal amount of Securities to be purchased on such date, and arrangements satisfactory to the
Representatives and the Issuers for the purchase of such Securities are not made within 48 hours after such default, this Agreement shall terminate without liability of any party to any other party except that the provisions of Section 4,
Section 7 and Section 8 shall at all times be effective and shall survive such termination. In any such case either the Representatives or the Issuers shall have the right to postpone the Closing Date, but in no event for longer than seven
days in order that the required changes, if any, to the Final Offering Memorandum or any other documents or arrangements may be effected. 
 As used in this Agreement, the term “Initial Purchaser” shall be deemed to include any person substituted for a defaulting Initial Purchaser under this Section 9. Any action taken under
this Section 9 shall not relieve any defaulting Initial Purchaser from liability in respect of any default of such Initial Purchaser under this Agreement. 
 Section 10 Termination of this Agreement. Prior to the purchase of the Securities by the Initial Purchasers on the Closing Date this Agreement may be terminated by the Representatives by
notice given to the Company if at any time (i) trading or quotation in any of the Company’s securities shall have been suspended or limited by the Commission or by any exchange, or trading in securities generally on any exchange shall have
been suspended or limited, the settlement of such trading shall have been materially disrupted or minimum or maximum prices shall have been generally established on any of such stock exchanges by such exchange, the Commission or the FINRA;
(ii) a general banking moratorium shall have been declared by any of federal, New York, or Delaware authorities; (iii) there shall have occurred any outbreak or escalation of national or international hostilities or any crisis or calamity,
or any change in the United States or international financial markets, or any substantial change or development involving a prospective substantial change in United States’ or international political, financial or economic conditions, as in the
judgment of the Representatives is material and adverse and makes it impracticable to market the Securities in the manner and on the terms described in the Pricing Disclosure Package and the Final Offering Memorandum or to enforce contracts for the
sale of securities; (iv) in the judgment of the Representatives there shall have occurred any Material Adverse Change; or (v) the 

  
 -27-

 
Company shall have sustained a loss by strike, fire, flood, earthquake, accident or other calamity of such character as in the judgment of the Representatives may interfere materially with the
conduct of the business and operations of the Company regardless of whether or not such loss shall have been insured. Any termination pursuant to this Section 10 shall be without liability on the part of (a) the Issuers to any Initial
Purchaser, except that the Issuers shall be obligated to reimburse the expenses of the Representatives and the Initial Purchasers pursuant to Sections 4 and 6 hereof, (b) any Initial Purchaser to the Issuers, or (c) of any party hereto to
any other party except as aforesaid and except that the provisions of Section 7 and Section 8 shall at all times be effective and shall survive such termination. 
 Section 11 No Advisory or Fiduciary Relationship. Each of the Issuers acknowledges and agrees that (a) the purchase and sale of the Securities sold by such party pursuant to this
Agreement, including the determination of the public offering price of the Securities and any related discounts and commissions, are an arm’s-length commercial transaction between such party, on the one hand, and the several Initial Purchasers,
on the other hand, (b) in connection with the offering contemplated hereby and the process leading to such transaction each Initial Purchaser is and has been acting solely as a principal and is not the agent or fiduciary of such party, or its
stockholders, creditors or employees, as applicable, or any other party, (c) no Initial Purchaser has assumed or will assume an advisory or fiduciary responsibility in favor of such party with respect to the offering contemplated hereby or the
process leading thereto (irrespective of whether such Initial Purchaser has advised or is currently advising any Issuer on other matters) and no Initial Purchaser has any obligation to such party with respect to the offering contemplated hereby
except the obligations expressly set forth in this Agreement, (d) the Initial Purchasers and their respective affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Issuers, and
(e) the Initial Purchasers have not provided any legal, accounting, regulatory or tax advice with respect to the offering contemplated hereby and such party has consulted its own legal, accounting, regulatory and tax advisors to the extent it
deemed appropriate. 
 Section 12 Certain Acknowledgments. The Issuers understand that each of the Initial
Purchasers is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity
securities of the companies that may be the subject of the transactions contemplated by this Agreement. 
 Each Initial
Purchaser, severally and not jointly, represents and warrants to and agrees with the Issuers that: 
 (a) in relation to each
member state of the European Economic Area which has implemented the Prospectus Directive (each, a “Relevant Member State”), with effect from and including the date on which the Prospectus Directive is implemented in that Relevant
Member State (the “Relevant Implementation Date”), no offer of any notes which are the subject of the offering contemplated by this offering memorandum has been or will be made to the public in that Relevant Member State other than
any offer where a prospectus has been or will be published in relation to such notes that has been approved by the competent authority in that Relevant Member State or, where appropriate, approved in another Relevant Member State and notified to the
relevant competent authority in that Relevant Member State in accordance with the Prospectus Directive, except that with effect from and including the Relevant Implementation Date, an offer of such securities may be made to the public in that
Relevant Member State: 
 (i) to any legal entity which is a “qualified investor” as defined in the
Prospectus Directive; 

  
 -28-

 (ii) to fewer than 100 or, if the Relevant Member State has implemented the
relevant provision of the 2010 PD Amending Directive, 150, natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the
representatives of the underwriters for any such offer; or 
 (iii) in any other circumstances falling within
Article 3(2) of the Prospectus Directive, 
 provided that no such offer of securities shall require the Company or any of the underwriters to
publish a prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive. 
 For the purposes of this provision, the expression an “offer to the public” in relation to any of the notes in any Relevant Member State means the communication in any form and by any
means of sufficient information on the terms of the offer and the notes to be offered so as to enable an investor to decide to purchase or subscribe to the notes, as the same may be varied in that Relevant Member State by any measure implementing
the Prospectus Directive in that Relevant Member State and the expression “Prospectus Directive” means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the Relevant
Member State), and includes any relevant implementing measure in the Relevant Member State and the expression “2010 PD Amending Directive” means Directive 2010/73/EU; 

(b) it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or
inducement to engage in investment activity (within the meaning of Section 21 of the Financial Services and Markets Act 2000 (the “FSMA”)) received by it in connection with the issue or sale of the notes in circumstances in
which Section 21(1) of the FSMA does not apply to the Issuers; 
 (c) it has complied and will comply with all applicable
provisions of the FSMA with respect to anything done by it in relation to the notes in, from or otherwise involving the United Kingdom; and 
 (d) it intends to comply with all applicable laws and regulations in each jurisdiction in which it acquires, offers, sells or delivers the Notes or has in its possession or distributes the Pricing
Disclosure Package and the Final Offering Memorandum. 
 Section 13 Representations and Indemnities to Survive
Delivery. The respective indemnities, contribution obligations, agreements, representations, warranties and other statements of the Issuers, of their officers and of the several Initial Purchasers set forth in or made pursuant to this Agreement
will remain in full force and effect, regardless of any investigation made by or on behalf of any Initial Purchaser or the Issuers or any of their partners, officers or directors or any controlling person, as the case may be, and, anything herein to
the contrary notwithstanding, will survive delivery of and payment for the Securities sold hereunder and any termination of this Agreement. 

  
 -29-

 Section 14 Notices. All communications hereunder shall be in writing and shall
be mailed, hand delivered or telecopied and confirmed to the parties hereto as follows: 
 If to the Representatives: 

Jefferies & Company, Inc. 

520 Madison Avenue 
 New York, New York 10022 
 Facsimile: (212) 284-2280

 Attention: General Counsel 
 If to the Company: 
 Alere Inc. 

51 Sawyer Road, Suite 200 
 Waltham, Massachusetts 02453 
 Facsimile: (781) 647-3939

 Attention: Chief Executive Officer 
 with a copy to: 
 Foley Hoag LLP 

155 Seaport Boulevard 
 Boston, Massachusetts 02210 
 Facsimile: (617) 832-7000

 Attention: John D. Hancock, Esq. 
 Any party hereto may change the address for receipt of communications by giving written notice to the others. 
 Section 15 Successors. This Agreement will inure to the benefit of and be binding upon the parties hereto, including any substitute Initial Purchasers pursuant to Section 9 hereof, and to
the benefit of the employees, officers, directors and controlling persons referred to in Section 7 and Section 8, and in each case their respective successors, and no other person will have any right or obligation hereunder. The term
“successors” shall not include any purchaser of the Securities as such from any of the Initial Purchasers merely by reason of such purchase. 
 Section 16 Partial Unenforceability. The invalidity or unenforceability of any Section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other
Section, paragraph or provision hereof. If any Section, paragraph or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are
necessary to make it valid and enforceable. 
 Section 17 Governing Law Provisions. This Agreement shall be governed
by and construed in accordance with the internal laws of the State of New York applicable to agreements made and to be performed in such state. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions
contemplated hereby (“Related Proceedings”) may be instituted in the federal courts of the United States of America located in the Borough of Manhattan in the City of New York or the courts of the State of New York in each case
located in the Borough of Manhattan in the City of New York and the appellate courts thereof (collectively, the “Specified Courts”), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted
in regard to the enforcement of a judgment of any such court (a “Related Judgment”), as to which such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding. Service of any process, summons, notice or
document by mail to such party’s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and

  
 -30-

 
unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or
claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum. 
 With respect to any Related Proceeding, each party irrevocably waives, to the fullest extent permitted by applicable law, all immunity (whether on the basis of sovereignty or otherwise) from jurisdiction,
service of process, attachment (both before and after judgment) and execution to which it might otherwise be entitled in the Specified Courts, and with respect to any Related Judgment, each party waives any such immunity in the Specified Courts or
any other court of competent jurisdiction, and will not raise or claim or cause to be pleaded any such immunity at or in respect of any such Related Proceeding or Related Judgment, including, without limitation, any immunity pursuant to the United
States Foreign Sovereign Immunities Act of 1976, as amended. 
 Section 18 USA Patriot Act. In accordance with the
requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)), the Initial Purchasers are required to obtain, verify and record information that identifies their respective clients, including the Company,
which information may include the name and address of their respective clients, as well as other information that will allow the Initial Purchasers to properly identify their respective clients. 

Section 19 General Provisions. This Agreement constitutes the entire agreement of the parties to this Agreement and
supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This Agreement may be executed in two or more counterparts, each one of which shall be an
original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein (express or implied) may be
waived unless waived in writing by each party whom the condition is meant to benefit. The Section headings herein are for the convenience of the parties only and shall not affect the construction or interpretation of this Agreement. 

Each of the parties hereto acknowledges that it is a sophisticated business person who was adequately represented by counsel during
negotiations regarding the provisions hereof, including, without limitation, the indemnification provisions of Section 7 and the contribution provisions of Section 8, and is fully informed regarding said provisions. Each of the parties
hereto further acknowledges that the provisions of Sections 7 and 8 hereto fairly allocate the risks in light of the ability of the parties to investigate the Issuers, their affairs and their business in order to assure that adequate disclosure has
been made in the Pricing Disclosure Package, any Issuer Written Communication (including, but not limited to, any Road Show) and the Final Offering Memorandum (and any amendments and supplements thereto), as required by the Securities Act and the
Exchange Act. 

  
 -31-

 If the foregoing is in accordance with your understanding of our agreement, kindly sign and
return to the Company the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms. 

 

					
	Very truly yours,
	
	ALERE INC.
		
	BY:	 	 /s/ David A. Teitel

		 	Name:	 	David A. Teitel
		 	Title:	 	Chief Financial Officer,
		 		 	Vice President and Treasurer

 

					
	AS Guarantors:
	
	 ALERE GENETICS, INC.

ALERE HEALTH IMPROVEMENT COMPANY
 ALERE HEALTH,
LLC

	 ALERE HEALTHCARE OF ILLINOIS, INC.
 ALERE HOME MONITORING, INC.
 ALERE INTERNATIONAL HOLDING CORP.

	 ALERE OF NEW YORK, INC.
 ALERE NEWCO, INC.
 ALERE NEWCO II, INC.

	 ALERE NORTH AMERICA, INC.
 ALERE SAN DIEGO, INC.
 ALERE SCARBOROUGH, INC.

	ALERE US HOLDINGS, LLC
	ALERE WELLBEING, INC.
	 ALERE WELLOLOGY INC.

ALERE WOMEN’S AND CHILDREN’S HEALTH, LLC

AMEDITECH INC.

	BINAX, INC.

 

					
	BY:	 	 /s/ David A. Teitel

		 	Name: David A. Teitel
		 	Title (respectively): Vice President and Treasurer; Vice President and Treasurer; Vice President and Treasurer; Vice President, Finance; Vice President, Finance;
President; Vice President, Finance; President; President; Vice President, Finance; Vice President, Finance; Vice President, Finance; President; Vice President, Finance and Treasurer; Vice President, Finance; Vice President, Finance; Chief Financial
Officer; Vice President, Finance

 
					
	AS Guarantors:
	
	BIOSITE INCORPORATED
	 FIRST CHECK DIAGNOSTICS CORP.
 FIRST CHECK ECOM, INC.

	INNOVACON, INC.
	 INSTANT TECHNOLOGIES, INC.
 INVERNESS MEDICAL, LLC
 IVC INDUSTRIES, INC.

	 QUALITY ASSURED SERVICES, INC.
 REDWOOD TOXICOLOGY LABORATORY, INC.
 RMD NETWORKS, INC.

	 RTL HOLDINGS, INC.

SELFCARE TECHNOLOGY, INC.
 ZYCARE,
INC.

		
	BY:	 	 /s/ David A. Teitel

		 	Name: David A. Teitel
		 	Title (respectively): Vice President, Finance; Vice President, Finance; Vice President; Vice President, Finance; Vice President, Finance; Vice President, Finance;
President; Vice President, Finance; Vice President, Finance; Vice President, Finance and Treasurer; Vice President, Finance; Vice President, Finance; Chief Financial Officer and Treasurer

 
					
	AS Guarantors:
	
	ALERE TOXICOLOGY SERVICES, INC.
	LABORATORY SPECIALISTS OF AMERICA, INC.
		
	BY:	 	 /s/ Ellen V. Chiniara

		 	Name: Ellen V. Chiniara
		 	Title (respectively): Secretary; Assistant Secretary

 
	
	The foregoing Purchase Agreement is hereby confirmed
and accepted by the Representatives
in New York, New York
as of the date first above
written.

  

					
	JEFFERIES & COMPANY, INC.
	GOLDMAN, SACHS & CO.
	CREDIT SUISSE SECURITIES (USA) LLC
	
	 Acting as Representatives of the
 several Initial Purchasers named in
 the attached Schedule A.

	
	JEFFERIES & COMPANY, INC.
		
	By:	 	 /s/ Craig Zaph

		 	Name:	 	Craig Zaph
		 	Title:	 	Managing Director
	
	GOLDMAN, SACHS & CO.
		
	By:	 	 /s/ Michael Hickey

		 	(Goldman, Sachs & Co.)
	
	CREDIT SUISSE SECURITIES (USA) LLC
		
	By:	 	 /s/ Colin Bathgate

		 	Name:	 	Colin Bathgate
		 	Title:	 	Director

 [Purchase Agreement Signature Page] 

 SCHEDULE A 

 

					
	 Initial Purchasers
	  	Principal
Amount of
Notes to be Sold	 
		
	 Jefferies & Company, Inc.
	  	$	180,000,000	  
	 Goldman, Sachs & Co.
	  	$	135,000,000	  
	 Credit Suisse Securities (USA) LLC
	  	$	45,000,000	  
	 DNB Markets, Inc.
	  	$	30,000,000	  
	 RBC Capital Markets, LLC.
	  	$	30,000,000	  
	 SunTrust Robinson Humphrey, Inc.
	  	$	30,000,000	  
		  	  
	  
	 
	 Total
	  	$	450,000,000	  

 SCHEDULE B 
 Guarantors 
  

	1.	Alere Genetics, Inc. 

	2.	Alere Health Improvement Company 

	3.	Alere Health, LLC 

	4.	Alere Healthcare of Illinois, Inc. 

	5.	Alere Home Monitoring, Inc. 

	6.	Alere International Holding Corp 

	7.	Alere NewCo, Inc. 

	8.	Alere NewCo II, Inc. 

	9.	Alere North America, Inc. 

	10.	Alere of New York, Inc. 

	11.	Alere San Diego, Inc. 

	12.	Alere Scarborough, Inc. 

	13.	Alere Toxicology Services, Inc. 

	14.	Alere US Holdings, LLC 

	15.	Alere Wellbeing, Inc. 

	16.	Alere Wellology, Inc. 

	17.	Alere Women’s and Children’s Health, LLC 

	18.	Ameditech Inc. 

	19.	Binax, Inc. 

	20.	Biosite Incorporated 

	21.	First Check Diagnostics Corp. 

	22.	First Check Ecom, Inc. 

	23.	Innovacon, Inc. 

	24.	Instant Technologies, Inc. 

	25.	Inverness Medical, LLC 

	26.	IVC Industries, Inc. 

	27.	Laboratory Specialists of America, Inc. 

	28.	Quality Assured Services, Inc. 

	29.	Redwood Toxicology Laboratory, Inc. 

	30.	RMD Networks, Inc. 

	31.	RTL Holdings, Inc. 

	32.	Selfcare Technology, Inc. 

	33.	Zycare, Inc. 

 Non-Guarantor Subsidiaries

  

	1.	Alere Switzerland GmbH (f/k/a Inverness Medical Switzerland GmbH) 

	2.	Alere Holding GmbH (f/k/a IMG Holding GmbH) 

	3.	Alere Technologies GmbH (f/k/a CLONDIAG GmbH) 

	4.	Alere UK Holdings Ltd. (f/k/a Inverness Medical (UK) Holdings Limited) 

	5.	Unipath Limited 

	6.	Alere Medical Co., Ltd. (f/k/a Inverness Medical Japan Co., Ltd.) 

	7.	ABON Biopharm (Hangzhou) Co., Ltd. 

	8.	Alere Spain, S.L. (f/k/a Inverness Medical Spain, S.L.) 

	9.	BBI Holdings Limited (f/k/a BBI Holdings PLC) 

  
 -2-

	10.	Alere Toxicology plc (f/k/a Concateno PLC) 

	11.	Standard Diagnostics, Inc. 

  
 -3-

 EXHIBIT A 
 FORM OF NEGATIVE ASSURANCE LETTER OF FOLEY HOAG LLP 
 As counsel to
the Company, we reviewed the Pricing Disclosure Package and the Final Offering Memorandum, and participated in discussions with your representatives, those of counsel for the several Initial Purchasers (the “Initial Purchasers”),
and those of the Company and its independent public accountants, at which the contents of the Pricing Disclosure Package and the Final Offering Memorandum were discussed. Between the Applicable Time and the time of the delivery of this letter, we
participated in further discussions with your representatives, those of counsel for the Initial Purchasers, and those of the Company and its accountants, and we reviewed certain certificates of officers of the Company and public officials and
letters from the Company’s independent public accountants delivered to you today. 
 The purpose of our engagement was not
to establish or to confirm factual matters set forth in the Pricing Disclosure Package or the Final Offering Memorandum, and we have not undertaken any obligation to verify independently any of the factual matters set forth in the Pricing Disclosure
Package or the Final Offering Memorandum (except as set forth below). Moreover, many of the determinations required to be made in the preparation of the Pricing Disclosure Package and the Final Offering Memorandum involve matters of a non-legal
nature. 
 Subject to the foregoing, and although we are not passing upon and do not assume any responsibility for the accuracy,
completeness or fairness of the statements contained in the Pricing Disclosure Package or the Final Offering Memorandum, except to the extent expressly set forth in numbered paragraph 20 of our opinion letter to you of even date herewith, we confirm
to you that: (i) on the basis of the information that we gained in the course of performing the services referred to above, nothing came to our attention that caused us to believe that (a) the Pricing Disclosure Package, at the Applicable
Time, contained an untrue statement of a material fact or omitted to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading or (b) the Final Offering
Memorandum, as of its date, contained any untrue statement of a material fact or omitted to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, and
(ii) nothing came to our attention in the course of the procedures described in the second sentence of the first paragraph of this letter that caused us to believe that the Final Offering Memorandum, as of the date and time of delivery of this
letter, contains any untrue statement of a material fact or omits to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided, however, that we do not
express any belief as to the financial statements and related notes, financial statement schedules or financial or accounting data and information, contained in or omitted from the Pricing Disclosure Package or the Final Offering Memorandum. In the
first sentence of this paragraph, “attention” refers to the conscious awareness of each of the lawyers of our firm who actively participated in the preparation of the Pricing Disclosure Package and the Final Offering Memorandum. In
addition, we express no opinion or belief as to the conveyance of the Pricing Disclosure Package or the information contained therein to investors. 
 Further, we confirm to you that each Incorporated Document (in each case as the same may have been amended prior to the Applicable Time), at the time such document was filed with the Commission or at the
time such document became effective, as applicable, appears to us on its face to respond in all material respects to the requirements of the form on which the Incorporated Document was filed, except that the foregoing statement does not address any
requirement relating to financial statements and related notes, financial statement schedules or financial or accounting data and information contained in or omitted from any Incorporated Document. 

  
 A-1

 FORM OF LEGAL OPINION OF FOLEY HOAG LLP 

[For purposes of this opinion, the term “Covered Guarantor” shall mean each Guarantor organized under the laws of Delaware, New York or
Massachusetts, and “Identified Contracts” shall mean contracts included or incorporated by reference in the Pricing Disclosure Package and the Final Offering Memorandum. Local counsel will give opinions 2, 4, 5, 7, 10 (first
clause), and 17 (only as to local law and charter documents) as to other Guarantors.] 
 1. The Company is validly existing
as a corporation in good standing under the Delaware General Corporation Law. The Company has the corporate power to own its properties and conduct its business as described in the Pricing Disclosure Package and the Final Offering Memorandum. The
Company is duly qualified to do business and in good standing as a foreign corporation pursuant to the Massachusetts Business Corporation Act. 
 2. Each Covered Guarantor is validly existing as a corporation or limited liability company (as applicable) in good standing under the laws of the state of its incorporation or formation. Each Covered
Guarantor has the corporate or limited liability company (as applicable) power to own its properties and conduct its business as described in the Pricing Disclosure Package and the Final Offering Memorandum. 

3. The Company has the corporate power to execute and deliver the Purchase Agreement, the Base Indenture, the Supplemental Indenture, the
Registration Rights Agreement and the Original Notes and to perform its obligations thereunder. 
 4. Each Covered Guarantor has
the corporate or limited liability company (as applicable) power to execute and deliver the Purchase Agreement, the Supplemental Indenture, the Registration Rights Agreement and to perform its obligations thereunder, including its Guarantee.

 5. The Purchase Agreement has been duly authorized, executed and delivered by the Company and each Covered Guarantor.

 6. Each of the Base Indenture and the Supplemental Indenture has been duly authorized, executed and delivered by the Company.

 7. The Supplemental Indenture and each Guarantee of a Covered Guarantor have been duly authorized by the applicable Covered
Guarantor, and the Supplemental Indenture has been duly executed and delivered by each Covered Guarantor. 
 8. The Base
Indenture is a valid and legally binding obligation of the Company, enforceable against the Company in accordance with its terms, subject to the Enforceability Exceptions. 
 9. The Supplemental Indenture is a valid and legally binding obligation of each Issuer, enforceable against such Issuer in accordance with its terms, subject to the Enforceability Exceptions. 

10. The Registration Rights Agreement has been duly authorized, executed and delivered by the Company and each Covered Guarantor, and the
Registration Rights Agreement constitutes a valid and legally binding obligation of the Company, enforceable against the Company in accordance with its terms, subject to the Enforceability Exceptions. 

  
 A-2

 11. The Original Notes have been duly authorized and executed by the Company. 

12. When the Original Notes are duly authenticated by the Trustee and delivered by or on behalf of the Company against payment therefor
by the Initial Purchasers in accordance with the terms of the Purchase Agreement and the Indenture, the Original Notes will be valid and legally binding obligations of the Company, entitled to the benefits of the Indenture and enforceable against
the Company in accordance with their terms, subject to the Enforceability Exceptions. 
 13. When the Original Notes are duly
authenticated by the Trustee and delivered by or on behalf of the Company against payment therefor by the Initial Purchasers in accordance with the terms of the Purchase Agreement and the Indenture, each Guarantee will be a valid and legally binding
obligation of the applicable Guarantor, enforceable against such Guarantor in accordance with its terms, subject to the Enforceability Exceptions. 
 14. The execution and delivery by the Company of the Purchase Agreement, the Indenture, the Registration Rights Agreement and the Original Notes, and the performance by the Company of its obligations
under the Purchase Agreement, the Indenture, the Registration Rights Agreement and the Original Notes, including the issuance and sale by the Company of the Original Notes, will not result in a breach of, or constitute a default (or an event that
with notice or the lapse of time, or both, would constitute a default) under, any Identified Contract. 
 15. The execution and
delivery by the Company of the Purchase Agreement, the Indenture, the Registration Rights Agreement and the Original Notes, and the performance by the Company of its obligations under the Purchase Agreement, the Indenture, the Registration Rights
Agreement and the Original Notes, including the issuance and sale by the Company of the Original Notes, will not (a) except as contemplated by the Registration Rights Agreement, require any consent, approval, license, or exemption by, or order
or authorization of, or filing, recording or registration by the Company with, any Massachusetts or United States federal governmental authority or pursuant to the Delaware General Corporation Law, except for filings pursuant to the Securities Act,
the Exchange Act and the Trust Indenture Act that have been made and are available on EDGAR and except for filings that may be required under Section 13(a) or 15 of the Exchange Act regarding disclosure of the terms of the Purchase Agreement,
the Indenture, the Registration Rights Agreement, the Original Notes, the Guarantees and the transactions contemplated thereby, (b) violate the Certificate of Incorporation or By-laws of the Company, or (c) violate the Delaware General
Corporation Law or any Massachusetts or federal statute, rule or regulation, except that we express no opinion with respect to the anti-fraud provisions of federal securities laws or with respect to state securities or Blue Sky laws. 

16. The execution and delivery by each Guarantor of the Purchase Agreement, the Supplemental Indenture and the Registration Rights
Agreement, and the performance by each Guarantor of its obligations under the Purchase Agreement, the Supplemental Indenture, the Registration Rights Agreement and its Guarantee, including the issuance by each Guarantor of its Guarantee, will not
result in a breach of, or constitute a default (or an event that with notice or the lapse of time, or both, would constitute a default) under, any Identified Contract. 
 17. The execution and delivery by each Guarantor of the Purchase Agreement, the Supplemental Indenture and the Registration Rights Agreement, and the performance by each Guarantor of its obligations under
the Purchase Agreement, the Supplemental Indenture, the Registration Rights Agreement and its Guarantee, including the issuance by each Guarantor of its Guarantee, will not (a) except as contemplated by the Registration Rights Agreement,
require any consent, approval, license, or exemption by, or order or authorization of, or filing, recording or registration by such Guarantor with, 

  
 A-3

 
any Massachusetts or United States federal governmental authority or (in the case of Covered Guarantors organized under the Delaware General Corporation Law, the Delaware Limited Liability
Company Act or the New York Business Corporation Law) any Delaware, Delaware or New York governmental authority, respectively, pursuant to the Delaware General Corporation Law, the Delaware Limited Liability Company Act or the New York Business
Corporation Law, respectively, except for filings pursuant to the Securities Act, the Exchange Act and the Trust Indenture Act that have been made and are available on EDGAR and except for filings that may be required under Section 13(a) or 15
of the Exchange Act regarding disclosure of the terms of the Purchase Agreement, the Indenture, the Registration Rights Agreement, the Original Notes, the Guarantees and the transactions contemplated thereby, (b) violate the certificate of
incorporation or by-laws of any Covered Guarantor that is a corporation organized under the Delaware General Corporation Law, the articles of organization or by-laws of any Covered Guarantor that is a corporation organized under the Massachusetts
Business Corporation Act, the certificate of incorporation or by-laws of any Covered Guarantor that is a corporation organized under the New York Business Corporation Law or the certificate of formation or operating agreement of any Covered
Guarantor that is a limited liability company organized under the Delaware Limited Liability Company Act, or (c) violate any Massachusetts or federal statute, rule or regulation or (in the case of Covered Guarantors organized under the Delaware
General Corporation Law, the Delaware Limited Liability Company Act or the New York Business Corporation Law) the Delaware General Corporation Law, the Delaware Limited Liability Company Act or the New York Business Corporation Law, respectively,
except that we express no opinion with respect to the anti-fraud provisions of federal securities laws or with respect to state securities or Blue Sky laws. 
 18. Neither the issuance, sale and delivery of the Original Notes and the Guarantees nor the application of the proceeds thereof by the Company as described in the Final Offering Memorandum will violate
Regulation T, U or X of the Board of Governors of the Federal Reserve System. 
 19. The Purchase Agreement, the Indenture, the
Registration Rights Agreement, the Original Notes and the Guarantees conform in all material respects to the descriptions thereof in the Pricing Disclosure Package and the Final Offering Memorandum. 

20. The statements in the Pricing Disclosure Package and the Final Offering Memorandum under the headings “Material United States
Federal Income Tax Consequences” and “Description of Notes,” insofar as such statements contain descriptions of Massachusetts or federal laws, rules or regulations or of legal proceedings, and insofar as they describe the terms of
agreements, are correct in all material respects. 
 21. Neither the Company nor any Guarantor is or, after giving effect to the
issuance of the Original Notes and the Guarantees and the application of the proceeds thereof by the Company as described in the Final Offering Memorandum, will be, required to register as an “investment company,” as that term is defined
in the Investment Company Act of 1940, as amended. 
 22. No registration under the Securities Act of the Securities or
qualification of the Indenture under the Trust Indenture Act is required for the sale of the Securities to the Initial Purchasers as contemplated by the Purchase Agreement or for the Exempt Resales, assuming in each case (a) that the purchasers
who buy the Securities in the Exempt Resales are Eligible Purchasers and (b) the accuracy of and compliance with the Initial Purchasers’ representations, warranties and covenants contained in the Purchase Agreement. 

23. We are not representing the Company or any Guarantor in any pending litigation in which the Company or any Guarantor is a named
defendant that challenges the validity or enforceability of, or seeks to enjoin the performance of, the Purchase Agreement, the Indenture, the Registration Rights Agreement, the Original Notes or any Guarantee. 

  
 A-4

 EXHIBIT B 
 PRICING SUPPLEMENT 

					
	SUMMARY OF FINAL TERMS	  		  	
	  
 November 28, 2012
	  	$450,000,000	  	CONFIDENTIAL
		  	  
 

	  	
		  	  
 7.250% Senior Notes due 2018
	  	

  
  

 This summary pricing sheet relates only to the securities described below and should be read together
with the Preliminary Offering Memorandum, subject to completion, dated November 27, 2012, relating to these securities and supersedes the information in the Preliminary Offering Memorandum to the extent inconsistent with the information in the
Preliminary Offering Memorandum. This pricing term sheet is qualified in its entirety by reference to the Preliminary Offering Memorandum. Capitalized terms not defined herein have the meanings assigned to them in the Preliminary Offering
Memorandum. 
  

							
	 Issuer
	  	Alere Inc.	  		  	
		
	 Security Description
	  	7.250% Senior Notes due 2018.
	 Distribution
	  	144A / Regulation S – with Registration Rights.
		
	 Aggregate Principal Amount
	  	$450,000,000.
	 Gross Proceeds
	  	$450,000,000.
				
	 Coupon
	  	7.250%.	  		  	
	 Maturity Date
	  	July 1, 2018.	  		  	
				
	 Offering Price
	  	100.000%.	  		  	
	 Yield to Maturity
	  	7.250%.	  		  	
				
	 Ratings (Moody’s / S&P)1
	  	B3 / B-.	  		  	
		
	 Interest Payment Dates
	  	June 15 and December 15, commencing June 15, 2013.
	 Coupon Record Dates
	  	June 1 and December 1.	  	
		
	 Optional Redemption
	  	Make-whole at T+50 prior to December 15, 2015. Callable thereafter at the following prices:
				
	 	  	 For the period below
	  	 Percentage
	  	 
		  	On or after December 15, 2015	  	103.625%	  	
		  	On or after December 15, 2016	  	101.813%	  	
		  	On or after June 15, 2017	  	100.000%	  	
		
	Equity Clawback	  	35% at 107.25% (prior to December 15, 2015).
		
	Change of Control Offer	  	101%.
	Asset Sale Offer	  	100%.
		
	Trade Date	  	Wednesday, November 28, 2012.
	Settlement Date	  	Tuesday, December 11, 2012 (T+9).
				
	 	  	 144A
	  	 Regulation S
	  	 
	CUSIP Numbers	  	01449J AF2	  	U01457 AB3	  	

  

	1 	 A securities rating is not a recommendation to buy, sell or hold securities and should be evaluated independently of any other rating. The rating is
subject to revision or withdrawal at any time by the assigning rating organization. 

  
  

 

					
		  	Page 1 of 3	  	

					
	SUMMARY OF FINAL TERMS	  		  	
	  
 November 28, 2012
	  	$450,000,000	  	CONFIDENTIAL
		  	  
 

	  	
		  	  
 7.250% Senior Notes due 2018
	  	

  
  

			
	 Joint Book-Running Managers
	  	 Jefferies & Company, Inc.
 Goldman, Sachs & Co.
 Credit Suisse Securities (USA) LLC

	  
	  
		
	 Co-Managers
	  	 DNB Markets, Inc.
 RBC
Capital Markets, LLC
 SunTrust Robinson Humphrey, Inc.

		
	Changes to Preliminary Offering Memorandum	  	The following changes will be made to the Preliminary Offering Memorandum, as well as additional conforming changes consistent with the changes described
herein.
	  
		
	Description of Notes—Certain Covenants—Limitations on Additional Indebtedness (p. 47)	  	Clause (1) of the second paragraph under the heading “Limitations on Additional Indebtedness” is amended in its entirety to read as follows:
		
		  	“(1) Indebtedness of the Issuer or any Restricted Subsidiary under any Credit Facility (including any Credit Agreement) (including the issuance or creation of letters of
credit and bankers’ acceptances thereunder) so long as the aggregate amount of all Indebtedness of the Issuer and its Restricted Subsidiaries (without duplication) at any time outstanding under all Credit Facilities (including all Credit
Agreements) (excluding Hedging Obligations related to the Indebtedness thereunder) does not exceed the greater of (x) $2.8 billion, less the aggregate amount of Net Available Proceeds applied to repayments under any Credit Facility (including
any Credit Agreement) in accordance with the covenant described under “—Limitations on Asset Sales,” and (y) 85% of the book value of the accounts receivable of the Issuer and the Restricted Subsidiaries plus 65% of the book
value of inventory of the Issuer and the Restricted Subsidiaries, in each case calculated on a consolidated basis and in accordance with GAAP as of the last day of the last full fiscal quarter for which financial statements are
available;”

  
  

 

					
		  	Page 2 of 3	  	

					
	SUMMARY OF FINAL TERMS	  		  	
	  
 November 28, 2012
	  	$450,000,000	  	CONFIDENTIAL
		  	  
 

	  	
		  	  
 7.250% Senior Notes due 2018
	  	

  
  

			
		  	 Clause (3) of the second paragraph under the heading “Limitations on Additional Indebtedness” is amended in its entirety to
read as follows:
  
 “(3) Indebtedness of the Issuer and the Restricted
Subsidiaries to the extent outstanding on the Issue Date (other than Indebtedness referred to in clauses (1) and (2) above);”
  

The first sentence of the third paragraph under the heading “Limitations on Additional Indebtedness” is amended in its entirety to read as
follows:
  
 “For purposes of determining compliance with this covenant,
in the event that an item of Indebtedness meets the criteria of more than one of the categories of Permitted Indebtedness described in clauses (1) through (16) above or is entitled to be incurred pursuant to the Coverage Ratio Exception, the Issuer
shall, in its sole discretion, classify such item of Indebtedness and may divide and classify (and may later redivide and reclassify) such Indebtedness in more than one of the types of Indebtedness described in this covenant in any manner that
complies with this covenant, except that Indebtedness incurred under the Credit Agreement on the Issue Date shall be deemed to have been incurred under clause (1) above.”

 THE NOTES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR
ANY STATE SECURITIES LAWS. UNLESS THEY ARE REGISTERED, THE NOTES MAY BE OFFERED ONLY IN TRANSACTIONS EXEMPT FROM OR NOT SUBJECT TO REGISTRATION UNDER THE SECURITIES ACT, OR ANY STATE SECURITIES LAWS. ACCORDINGLY, THE NOTES HAVE BEEN OFFERED ONLY TO
QUALIFIED INSTITUTIONAL BUYERS AS DEFINED IN RULE 144A UNDER THE SECURITIES ACT OR TO NON-U.S. PERSONS OUTSIDE THE UNITED STATES UNDER REGULATION S UNDER THE SECURITIES ACT. 
 TO ENSURE COMPLIANCE WITH INTERNAL REVENUE SERVICE CIRCULAR 230, YOU ARE HEREBY NOTIFIED THAT ANY DISCUSSION OF FEDERAL TAX MATTERS SET FORTH IN THIS SUMMARY WAS WRITTEN IN CONNECTION WITH THE
PROMOTION OR MARKETING OF THE TRANSACTIONS OR MATTERS ADDRESSED HEREIN AND WAS NOT INTENDED OR WRITTEN TO BE USED, AND CANNOT BE USED, BY YOU, OR ANY NOTE HOLDER, FOR THE PURPOSE OF AVOIDING TAX-RELATED PENALTIES UNDER FEDERAL TAX LAW. YOU, OR ANY
NOTE HOLDER, SHOULD SEEK ADVICE BASED ON YOUR, OR THE HOLDER’S, PARTICULAR CIRCUMSTANCES FROM AN INDEPENDENT TAX ADVISOR. 
 THIS
COMMUNICATION DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY ANY SECURITIES IN ANY JURISDICTION TO ANY PERSON TO WHOM IT IS UNLAWFUL TO MAKE SUCH OFFER OR SOLICITATION IN SUCH JURISDICTION. 

A copy of the offering memorandum relating to this offering may be obtained by contacting Jefferies & Company, Inc. at 888-708-5831. 

Any disclaimers or other notices that may appear below are not applicable to this communication and should be disregarded. Such disclaimers were
automatically generated as a result of this communication being sent via Bloomberg or another email system. 

  
  

 

					
		  	Page 3 of 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00210-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00210-of-00352.parquet"}]]